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Abstract 
 
Methadone is acknowledged as an effective pharmacological substitution treatment for heroin 
dependence. However, patients presenting to addiction treatment services usually have 
multiple substance use, mental and physical health and social problems. Excessive alcohol 
use in individuals receiving methadone substitute maintenance treatment is a well-established 
clinical problem, which creates a treatment challenge. The research addressing the 
management of this group of patients is limited. 
There were three key studies in this thesis. The first study investigated the measurement of 
methadone and EDDP in the urine samples of 60 patients, calculated the EDDP:methadone 
ratio, and explored whether it could be used effectively as an index of methadone metabolism 
among clients receiving methadone substitution treatment. The results indicated a correlation 
between methadone and EDDP concentrations and methadone dose; however, 
EDDP:methadone ratio exhibited a high inter- and intra-individual variability, which 
hindered the possibility of using it as a sensitive objective biomarker for monitoring 
compliance among patients receiving methadone. Part of the study examines whether this 
ratio is altered by the consumption of alcohol in a problematic manner by this group of 
patients. A small study also examined three patients during methadone induction, and 
examined EDDP and methadone ratio.  
A further study explored the effectiveness of using the alcohol biomarkers ethyl glucoronide 
(EtG) and ethyl sulphate (EtS) to screen for recent alcohol consumption in 60 patients (138 
urine samples) collecting their daily methadone dose. The results indicated that the EtG and 
EtS were sensitive biomarkers to detect alcohol use in the past 24 hours or more and 
therefore it would be a useful tool to incorporate during methadone treatment especially 
   II 
coupled with knowledge of patients’ co-dependence. The final study investigated the use of 
the breathalyser test in 23 patients who were screened for alcohol use before the prescription 
of methadone. Results found that breathalysers were successful in detecting alcohol use but 
for a much shorter timeframe than new recent alcohol biomarkers, which could offer a more 
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Chapter 1 LITERATURE REVIEW 
1.1  Methadone Biochemistry and Biological Markers 
1.1.1 Introduction  
The reduction of illicit drug use, the reduction of crime, and the improvement of health, 
including the control of the spread of blood-borne viruses, are important outcomes defining 
effective methadone treatment (Ward et al., 1999). Important factors during methadone 
maintenance have been addressed in the research and include methadone dose, treatment 
modality and level of service provision (Ball & Ross, 1991). Achieving and accurately 
measuring compliance remains a challenge for clinicians, as monitoring depends largely on 
self-report (Weiss et al., 2004; Wolff et al., 1999). However, the use of more objective 
measurements, such as biological markers, may provide an effective alternative or 
supplemental approach to assessing compliance. This research examined the potential 
usefulness of several such biological tools in connection with methadone maintenance 
treatment (MMT) in an outpatient facility.  
1.1.2 Background  
Illicit drug use affects users, their families, and society. It is a multi-dimensional problem that 
is estimated to cost the UK government over £15 billion in annual social, economic, health, 
and crime-related expenses (House of Commons Committee of Public Accounts, 2010). 
Currently, the government is estimated to spend £800 million annually on community-based 
drug treatment services, of which 30% is supplied by Primary Care Trusts (PCTs), which also 
provide over £200 million for alcohol treatment (National Treatment Agency for Substance 
Misuse, 2009; National Audit Office, 2008).  
   2 
In the UK, almost one-third of the population admits to consuming illicit drugs at some stage 
in their lives; however, only a small percentage develops a so-called drug problem (NTA, 
2009). For the period 2009-2010, there were an estimated 264,072 users of opiates and 
42,078 users of crack cocaine in England, putting the former at roughly 7.7 per 1,000 of the 
population (Hay et al., 2013). The total number of users in both categories (306,150) had thus 
declined from the peak estimate of 332,090 in 2005-2006 – a claim that is supported by the 
decline in the number of heroin users seeking treatment for the first time from 2005-2006 
(47,709) to 2011-2012 (9,249) (NTA, 2013). Nonetheless, the National Drug Treatment 
Monitoring System (NDTMS) reported in November 2013 that 193,575 drug users had been 
in contact with a drug service treatment in the previous year 2012-13. Of these, 80% were 
reported to be opiate users (NDTMS, 2013).  
Heroin users are at risk of dying prematurely due to overdose. In fact, an overall pooled crude 
mortality rate among persons using heroin and other opioids in studies published between 
1990 and 2008 was 2.09 deaths per 100 person-years, and was noted to be higher in males 
compared to females (Degenhardt et al., 2011). In 2012, 1,496 drug-related deaths were 
reported for England and Wales, of which 414 were linked to methadone (Office for National 
Statistics, 2013). The occurrence of any such deaths contributes to concern about the use of 
substitution therapy. However, it is understood that recognising risk factors can help prevent 
methadone related deaths. These risk factors include tolerance reduction, route of 
administration, gender, and history of non-fatal overdoses (Best et al., 2000; Bird & 
Robertson, 2011; Bird, Robertson, & Strang, 2010). 
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1.1.2.1 Methadone Treatment  
Structured methadone maintenance treatment was first described in the United States by Dole 
and Nyswander (1965), who considered the pharmacological properties of methadone as an 
opioid receptor agonist to be highly useful in reducing illicit opiate (heroin) use (Dole & 
Nyswander, 1967).  With the appropriate dosing to account for cross-tolerance with heroin, 
methadone would work by curbing withdrawal symptoms. This would assist clients to reduce 
their illicit drug use and engage with treatment (Kreek et al., 1973). 
Initially, diamorphine was more heavily prescribed as a replacement opioid in the UK. 
However, the opening of a number of new drug treatment clinics in the late 1960s coincided 
with a shift to prescribing methadone to new clients, and by the 1970s most clinics were 
prescribing oral methadone as dispensed in the United States (Strang et al., 1994). 
Nonetheless, the number of opiate users increased steadily and was associated with a rise in 
crime over the next decade or so. As a result, in the 1980s the Advisory Council on the 
Misuse of Drugs (ACMD) recommended the expansion of community-based treatment and 
the development of Community Drug Treatment facilities (CDTs), the first of which was 
established in 1983 (Strang & Clement, 1994). Although there was a move toward short-term 
treatment owing to concerns about the spread of HIV among drug dependents using 
intravenous route, CDTs were encouraged to retain clients in long-term treatment (NTA, 
2004). Indeed, the retention of clients in treatment was emphasized as a positive outcome for 
the better part of forty years, with general practitioners (GPs) responsible for a large share of 
methadone prescriptions (40% during the 1990s). However, in 2010 a new strategy was 
introduced that shifted the focus away from individual oriented care to the goal of achieving a 
drug-free life. The new recovery strategy emphasises sustained employment, improvement of 
mental health, and promoting good relationships with family and friends (Home Office, 
2010). 
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Unlike Australia, Canada, France, the Netherlands, and Thailand, the approach to methadone 
treatment in the UK has depended on retail pharmacies to dispense prescribed doses of 
methadone (Gossop & Grant, 1991). The following section reviews dispensing practices in 
the UK, with a focus on issues surrounding supervised consumption.  
1.1.2.2 Supervised methadone consumption in the UK  
As noted above, obtaining a prescription to be dispensed in a retail pharmacy is a 
characteristic of the British methadone maintenance treatment system. However, concerns 
about methadone diversion and a reported increase of fatal methadone overdoses led to a 
global change in dispensing regulations in the 1990s (Cairns et al., 1996: Bell et al., 2010), 
and, in the UK, clinical practice turned to supervised methadone consumption in response to 
reports that the number of methadone-related deaths had begun to level with heroin deaths 
(Hickman et al., 2003; Strang & Clement, 1994). This trend began in Glasgow, but 
supervised methadone consumption began to appear in England in 1996 and, between 1999 
and 2005, spread across the country (Lovell et al., 1999). During this period the Department 
of Health issued prescribing guidelines that recommended that clients should be dispensed 
methadone for consumption under supervision for the first three months in treatment (‘Drug 
Misuse and Dependence: UK Guidelines on Clinical Management’, 2007). In 2000 the 
ACMD recommended that supervised consumption be continued for the first six months of 
treatment (ACMD, 2000). In addition, supervised consumption is recommended whenever 
there is a break in treatment or when patients are considered difficult to contain or are 
perceived as ‘chaotic’ (Bell et al., 2010). Supervised consumption may be eased after a 
period of time or when a specified indicator of ‘patient compliance’ has been established – 
e.g., abstinence from illicit drug use (Robles et al., 2011). The community pharmacies remain 
the main dispensing body where supervised consumption takes place, and they engage in 
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more than 14 million face-to-face contacts with drug users every year (Matheson et al., 2007; 
NTA, 2006).  
Strang et al. (2010) examined the impact of the introduction of supervised consumption on 
the rates of death due to methadone overdose in Scotland and England between 1993 and 
2008. The authors found that deaths related to overdose of methadone peaked in the mid-
1990s in both Scotland and England and subsequently declined. However, a slight increase 
was reported after 2000 in Scotland and in 2004 in England (Strang et al.).   
1.1.3 Methadone pharmacology 
1.1.3.1 Structure and chemistry 
Methadone is a synthetic, long-acting pharmaceutical opioid that has been used as a 
substitution treatment in the management of heroin dependence since the 1960s (Beck et al., 
2010).  The U.S. Food and Drug Administration (FDA) approved methadone as a treatment 
for opiate dependence in 1972 (Kreek et al., 2010). The optimal dose of methadone can vary 
highly across patients, but it is nonetheless important to establish optimal dose to facilitate 
successful methadone maintenance treatment (MMT) (Lehotay et al., 2005).  
Methadone is a weak basic drug with a molecular weight of 309.4. It has a pKa value of 9.2, 
making it a highly lipid soluble drug (Fredheim et al., 2008). Methadone’s chemical structure 
of 6-dimethylamino-4,4-diphenyl-3-heptanone has a chiral centre that allows it to exist in two 
forms: l(R) and d(S) enantiomers (see Figure 1-1). Therapeutically, methadone is usually 
administered orally as a 50:50 racemic mixture. However, R-methadone is pharmacologically 
more active than S-methadone (Ferrari et al., 2004; Lehotay et al., 2005). 
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Figure 1-1 Methadone: chemical structure with asterisk indicating the chiral carbon 
 
1.1.3.2 Stereoselectivity  
The stereoselectivity of methadone influences its pharmacokinetic and pharmacodynamic 
properties. Essentially, the two isomers behave as separate substances and have their own 
kinetic profiles (Rentsch et al., 2002). However, these stereoselectivity differences have not 
been found to negatively impact therapeutic outcomes (Foster et al., 2000; Foster et al. 2004). 
In fact, studies have indicated the importance of stereoselectivity disposition in explaining the 
drug-drug interaction and concentration effects observed in studies of racemic methadone. 
For example, Eap et al. (1990) investigated protein binding and observed that R-methadone 
had lower plasma protein binding to alpha-1-acid glycoprotein than S-methadone, which 
could explain the various concentrations of plasma level and their importance when 
measuring methadone concentration levels (Eap et al., 1999). Eap and colleagues conducted a 
series of studies addressing the inter-individual variability of the plasma level of both R and S 
ratios of methadone. In 2000, Eap et al. looked at the plasma concentrations of the 
enantiomers of methadone and at the therapeutic responses of 180 MMT patients. The results 
indicated a large inter-individual variability in R-methadone concentration-to-dose-to-weight 
ratio, with doses of racemic methadone prescribed in a 70-kg patient varying from 55 mg/day 
to 921 mg/day. In an earlier study, Eap et al. (1996) looked at 22 patients receiving R-
methadone maintenance treatment who were then switched to a double dose of R, S-
methadone and observed a small amplitude decrease (16%). Finally, in a 1998 study, 
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methadone concentrations were found to vary over a sevenfold range in daily doses corrected 
for the body weight of patients receiving MMT (Eap et al., 1998). 
Table 1-1 Parameter Values (Mean) Describing the Kinetics of (R)-, (S)-, and (rac)- 
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59 (Steady State) 
 
112 (S)-methadone 39 (S)-methadone 2.02 (S)-methadone 
94 (R)-methadone 31 (R)-methadone 1.98 (R)-methadone 
145 (rac)-methadone 51 (rac)-methadone 1.98 (rac)-methadone 
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methadone 4.95 (S)-methadone 
0.95r 78 (R)-methadone 43r 22 
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(R)-methadone 
Wolff et al., 
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19 (Steady State) 200 (rac)-methadone 32 (rac)-methadone 2.41 (rac)-methadone 
7 (Trough Plasma) 38 (rac)-methadone 45 (rac)-methadone 0.97 (rac)-methadone 
*Vd= apparent volume of distribution; t ½ =elimination half life; CL/F=total oral clearance  
Although previous studies indicated the importance of stereoselectivity in the 
pharmacokinetics of methadone, Foster et al. (1999) found that the metabolism of methadone 
via N-demethylation is not dependent on methadone’s stereoselectivity. Instead, it is 
dependent on the CYP3A4 enzyme, and hence the inter-individual variability of methadone’s 
pharmacokinetics could be related directly to the expression of CYP enzymes in individuals 
(Foster et al., 1999). However, in 2004 Foster et al. demonstrated that R-methadone has a 
greater elimination half-life and volume of distribution compared to S-methadone (Foster et 
al., 2004). 
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Wolff et al. (1997) observed an absorption lag time for methadone, S-methadone, and R-
methadone in participants receiving higher doses, in addition to the difference due to 
stereoselectivity in the absorption process. The combined effects of this longer lag time and 
slower absorption rate meant that the time to reach peak concentration was 20 minutes longer 
for R-methadone than for S-methadone, while R-methadone’s maximum concentration 
(Cmax) was on average 84% that of S-methadone. Furthermore, plasma binding studies 
found that S-methadone binds more readily to AAG protein than does R-methadone, which 
indicates that plasma protein binding is stereoselective. The methadone half-life is also 
influenced by its stereoselectivity (Wolff et al., 1997). In addition, Boulton et al. (2001) 
found that after a single oral methadone dose the half life of R and S methadone were 42.6 + 
h and 20.4 +- 4.0h, respectively. It is now established that S-methadone has a half-life of 
approximately 16 hours, compared to 36-48 hours for R-methadone (Ferrari et al., 2004). 
Researchers continue to debate the importance of using stereoselective methadone assays to 
determine methadone plasma concentration for methadone enantiomers in patients receiving 
MMT. However, in clinics, methadone is still administered orally in a racemic form instead 
of as R-methadone, which is more expensive to produce, despite the latter having been shown 
to be more active. Therefore, from a clinical practice standpoint, it is important to address the 
effects of methadone as a racemic mixture rather than in an R-methadone form. Nevertheless, 
it is worth noting that R-methadone, which is pharmacologically more active than the S-
methadone compound, has been found to be a less significant factor in MMT outcomes than a 
CYP450 driven metabolism. Table 1-1 summarizes the pharmacokinetic parameters 
influenced by the methadone’s stereoselectivity, including half-life.  
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1.1.4 Methadone pharmacokinetics  
1.1.4.1 Absorption  
Methadone is available in a variety of formulations, including tablets, injectable ampoules, 
and oral solutions (syrup or mixture). In the UK it is usually dispensed as an oral solution 
(1mg/ml) (NICE, 2007). Methadone’s bioavailability varies from 41-76% to 85-95% (Eap et 
al., 1999) but has been described to be almost complete and relatively fast (Eap et al., 2002; 
Meresaar et al., 1981). Methadone is absorbed into the circulatory system and is detectable in 
plasma within 30 minutes, reaching peak plasma concentrations approximately three to four 
hours after acute administration, with concentrations levels maintained for 24 hours (Eap et 
al., 1999; Eap et al., 2002; Wolff et al., 1997).  
Major determinants affecting oral bioavailability are intestinal first pass metabolism and 
extrusion of active methadone by P-glycoprotein (P-gp) (Kharasch et al., 2003). For example, 
Kharasch et al. (2004) investigated the role of hepatic and intestinal cytochrome CYP450, 3A 
and 2B6 in the metabolism, disposition, and meiotic effects of methadone and found that 
methadone had a low intestinal (22%) and hepatic (9%) bioavailability. However, it had a 
high oral bioavailability (70%), which also correlated with intestinal bioavailability. These 
findings confirm earlier studies (Oda et al., 2001; Kharasch et al., 2003) that indicated that 
first-pass intestinal metabolism was a determinant of methadone bioavailability (Kharasch et 
al. 2004).  
1.1.4.2 Distribution 
Methadone disposition is biphasic (i.e., following a bi-exponential curve). The transfer of the 
drug from the central compartment (blood) to the tissues corresponds to the fast alpha-phase. 
It is relatively constant because of the slow release from the hepatic store to the blood 
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(Novick et al., 1981). The high volume of distribution (Vd) has been documented as ranging 
between 0.16 to 6.7 (L/Kg) (Foster et al., 2004). Methadone is highly bound to plasma 
protein (over 90%) and, reportedly, up to 98% reaches the tissues due to high lipid solubility, 
leaving 1-2% of the free drug cycling in the blood. This facilitates the effectiveness of 
prescribing methadone once per day to MMT clients (Inturrisi et al., 1987; Kreek et al., 
1973). Methadone is mainly bound to α1-glycoprotein (AAG), although there is a five- to ten-
fold variation in methadone binding in individuals (Wolff et al., 1991). Garrido et al. (2000) 
observed that patients with signs of withdrawal have shown higher levels of AAG, which 
could indicate that, in these instances, more of the methadone binds to proteins and less of the 
free drug is available to reach opioid receptors.  
Plasma α1-glycoprotein concentration has also been identified as a significant covariant for 
the apparent volume of distribution (Vd) of racemic methadone (Foster et al., 2004), which is 
consistent with its known role in determining the unbound fraction of the drug. Gender and 
α1-glycoprotein concentrations explain over 50% of the variability in apparent Vd of 
methadone, with women reflecting a higher clearance of the drug compared to men (Foster et 
al., 2004). In addition, the binding of methadone is selective for the ORM2A variant (Eap et 
al., 1998) of AAG. Boulton (2001) found that plasma concentrations of the ORM2A variant 
of α1-glycoprotein were a significant predictor of the inter-compartmental transfer rate for R-
methadone. As such, methadone kinetics are characterized by substantial inter-individual 
variability in racemic methadone disposition.  
1.1.4.3 Metabolism  
CYP3A4 is involved in the N-demethylation of methadone to form 2-ethylidene-1,5-
dimethyl-3,3-diphenylpyrrolidine (EDDP). EDDP is further N-demethylated to 2-ethylidene-
1,5-dimethyl-3,3-diphenylpyraline (EMDP). Seven other metabolites have been identified; 
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however, due to the low concentrations that are produced, they are difficult to quantify and 
will not be discussed here. Inter-individual variability has been found related to CYP3A4 
expression (Ferrari et al., 2004; Lugo et al 2005) and to other enzymes that play a less 
significant role than CYP3A4 in methadone metabolism, such as CYP 2B6, CYP 1A2, CYP 
2C19, and CYP2D6. Foster et al. (2004) further reported that the polymorphic CYP3A5 
isoform may also be important in methadone metabolism, as well as that CYP2D6 may be 
involved in the other oxidative pathways, especially for the metabolism of the R-methadone 
isomer (Kreek et al., 1979).  
Although in vitro studies support the role of CYP2B6 in methadone metabolism, researchers 
have had difficulty supporting this finding through in vivo studies. Foster et al. (1999) 
indicated that the large variation in the pharmacokinetics may be due to the expression of 
these enzymes rather than to the stereoselectivity, as well as that CYP2B6 may metabolize S-
methadone more rapidly than R-methadone. This finding led to the conclusion that the 
stereoselectivity of clearance is not due to n-demethylation partial intrinsic clearance. It 
remains unclear whether the pharmacokinetics or the enantiomer-specific metabolism is 
responsible for the clinical importance; together, however, they can help indicate the inter-
individual variability in methadone pharmacokinetics (Totah et al., 2007). 
 
Figure 1-2 Metabolism pathway of methadone 
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1.1.4.4 Elimination and clearance 
Methadone is eliminated by hepatic clearance followed by almost equal renal and faecal 
excretion. Forty-three percent of methadone is metabolised to the primary metabolite 1,5-
dimethyl-3,3- diphenylpyrrolidine (EDDP), and a further 5-10% to 2-ethyl-5-methyl-3,3-
diphenylpyrroline (EMDP) (Bowen et al., 1978; Moffat et al., 1986; Sullivan & Due, 1973). 
The total combined urinary and faecal recovery of methadone and EDDP at steady state 
methadone maintenance accounts for 5-75% of the administered methadone dose, noting that 
elimination is mainly because of metabolic clearance (Nilsson et al., 1982). Although 
methadone metabolism is relatively normal in the presence of mild liver dysfunction, it 
decreases in clients presenting with severe liver disease (Novick et al., 1985). Alteration of 
the pH of urine plays a significant role in the elimination of unmodified methadone. Nilsson 
et al. (1982) found that both the half-life and volume of distribution of methadone increased 
two-fold when the pH of urine was increased. However, urinary pH is unlikely to have a 
clinical impact due to the small amount of methadone eliminated in urine (Anggard et al., 
1975). 
1.1.5 Methadone pharmacokinetic variability 
The sequence of P-glycoprotein and the variability of the CYP enzyme activities probably 
influence the clearance and the plasma half-life inter-individual variability. Studies have 
shown the presence of CYP3A4 in both liver and intestinal mucosa, with a greater degree of 
variability in the former (Ketter, 1995). Studies have also indicated that CYP3A4 and, to a 
lesser degree, CYP2D6 are involved in methadone metabolism (Foster et al., 1999). Other 
enzymes, including CYP1A2 and CYP2C19, are also known to be involved in methadone 
metabolism (Shiran et al, 2009). However, further investigation is needed to determine the 
effects of genetically determined fast and slow metabolisers, which can have a direct effect 
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on the concentration of methadone in the plasma and thus could lead to inter-individual 
variation.  
Studies have reported that there is a relationship between dosage and methadone plasma; 
however, the results are still conflicting. Some studies indicate that there is a linear 
relationship between the methadone dose and the plasma concentration (Wolff & Hay, 1994; 
Wolff et al., 2000). Moreover, although some studies have indicated that the relationship 
between plasma concentration and dose is explained by only 50 to 60% of the variability in 
concentration of methadone (Eap, et al., 2000; Foster, et al., 2000), other studies have 
focused on the inter-individual variability in plasma concentration (Kreek et al, 1973).  
This variability of the methadone dose and plasma concentration is reflected in the difference 
in response within patients. Due to inter-individual variability, studies have shifted to 
investigating optimum methadone blood concentrations. Although 400 µg/L is considered the 
optimum blood level to stabilize maintenance, values vary between 50 and 600 µg/L. 
However, during therapeutic monitoring practice, 400 µg/L is the reference concentration 
used. For example, a study by Eap et al. (2000) investigated the blood concentration of R-
methadone and its association to therapeutic response (defined as the lack of use of illicit 
drugs). The results reported large inter-individual variability in the therapeutic response for 
illicit opiate but not for cocaine. Although methadone is administered as a racemic structure, 
R-methadone is pharmacologically active and could be more important to measure in blood 
compared to S-methadone. In a recent study involving 180 patients receiving MMT, where 
the methadone dose ranged between 5 and 350 mg/day, therapeutic response was measured 
for both R- methadone (250 µg/L) and R, S-methadone (400 µg/L). The study indicated that 
R-methadone reflected a higher specificity threshold compared to R,S-methadone (Eap et al., 
2000) The theoretical dose varied significantly, with between 55 mg/day and 921 mg/day 
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enabling the therapeutic response with levels of 400 ng/ml in a 70-kg patient receiving R,S-
methadone (Eap et al., 2000). 
Methadone elimination half-life can also be useful in evaluating the efficacy of methadone 
treatment. However, it is important to highlight that the methadone half-life is different for 
the first dose of methadone administered or as part of a steady-state dose/chronic methadone 
administration (see Table 1-1). This difference in the half-life is an indicator of a 
phenomenon known as auto-induction and was demonstrated by Wolff et al., (2000), who 
reported that the elimination half-life of methadone decreased from 128 hours at the start of 
treatment to 48 hours when methadone concentration achieved steady state; this was 
explained as due to the increase of the clearance to up to 350% due to CYP3A4 auto-
induction. The change in the elimination half-life over time could be explained as the 
development of tolerance and could be considered an indication of the increase of the 
CYP3A4 metabolism. The increase of CYP3A4 activity has been reported to be highly 
variable: between five and twentyfold among patients (Boulton et al., 2001; Wolff et al.). 
All of these factors indicate the influence of methadone dose and the importance of 
understanding that the variability in methadone pharmacokinetics indicates that some patients 
will require a higher or lower dose to avoid withdrawal symptoms. Indeed, it is clear that 
many factors influence the effectiveness of the daily dose of methadone and that a better 
understanding of these factors will help clinicians to achieve optimum dosage levels. This 
goal may be better achieved on an individual basis, taking into consideration the variability of 
methadone pharmacokinetics, which indicates that some patients will require a higher or 
lower dose to avoid withdrawal symptoms. In this regard, biological indicators, such as the 
methadone/EDDP ratio in urine, could serve as important tools in measuring individual 
metabolism of methadone and hence in assessing treatment compliance and effectiveness. As 
   15 
the present study examined several potential biological indicators and sought to generate 
evidence regarding their potential applications, the remainder of this chapter is devoted to 
providing background on these potential tools.  
1.1.6 Biological tools in methadone treatment  
There are several biological indicators of methadone metabolism in the human body; 
however, quantities of these metabolites of methadone vary widely across the population and 
in response to the treatment received by patients. Moreover, although drugs can be identified 
in various bodily fluids, the identification and utilisation of biological markers of a given 
drug is highly influenced by its pharmacokinetics. 
Blood has been the matrix of choice to give the most accurate measurement of the level of a 
drug in the body; however, urine provides a broad time frame for drug detection (Wolff et al., 
1999) and hence has been the matrix of choice for drug testing to detect the use of illicit 
drugs. Furthermore, urine has been investigated as a matrix to verify patient compliance and 
to assist clinicians in adjusting methadone dosage by measuring its concentration alongside 
its inactive metabolite, EDDP (Goldstein et al., 2003). 
In recent years, there have been efforts to optimise analysis methods for measuring 
methadone and its metabolites in urine, but the application of the relative concentration has 
been limited (El-Beqqali & Abdel-Rehim, 2007; Mandriolini et al., 2011). In urine, 
quantitative studies have documented concentrations of methadone and its main metabolite 
EDDP, and the relationship between the two compounds has been reported as a ratio. 
Although this ratio has been recommended as a potential tool for monitoring patient 
compliance, it is possible that the methadone/EDDP ratio could also indicate a metabolic rate. 
   16 
As of yet, however, no reference range for this ratio has emerged for methadone in urine 
(Leimanis et al., 2012). 
1.1.6.1 Indicators of methadone metabolism 
Thus, urine has been a common matrix for drug testing in methadone treatment; however, its 
use as a means of monitoring compliance and dose adjustment has not been fully 
implemented. The main purpose of routine urine testing in patients receiving methadone 
treatment is to detect the use of heroin and other illicit drugs; however, other information can 
be determined by measuring the concentration of methadone and its main metabolite, EDDP, 
and establishing their ratio (Goldstein et al., 2003). In recent years, due to the limited clinical 
practice of methadone measurements in blood, there have been efforts to optimize analytical 
methods to measure methadone and its metabolites in urine (El-Beqqali & Abdel-Rehim, 
2007; Holm & Linnet, 2012; Mandrioli et al., 2011).  
1.1.6.2 Methadone and EDDP in urine  
As noted, early studies documented urinary methadone and EDDP concentrations but failed 
to establish a reference ratio for EDDP/methadone. Purportedly, this is due to the high inter-
and to some extent intra-individual variability of methadone and EDDP concentrations in 
urine (George & Braithwaite, 1999). In addition to investigating urinary methadone and 
EDDP, at least one early study also addressed the possible link between methadone 
concentrations in plasma and in urine. Using gas chromatography, Kreek (1973) investigated 
the methadone concentration in plasma and urine from nine patients receiving daily oral 
administration of 100 mg of methadone. The mean plasma methadone concentration was 
found to be 0.58 µg/ml, compared to 21.3 µg/ml in urine (Kreek et al.). 
Kell et al. (1994, 1995) investigated the viability of estimating the methadone trough plasma 
   17 
concentration from analysis of urine samples. Although the results were promising, the 
coefficient of variation for plasma concentrations at each prescribed dose was found to be 
large, which could be due to a poor dose response relationship in some cases or to other 
confounding conditions such as renal or hepatic diseases (Kell, 1994, 1995; Kell & Techman, 
1996). Studies that examine methadone and EDDP levels in urine, however, have not been 
standardized compared to studies that have examined blood and plasma.The ratio between 
methadone and EDDP has been studied in various ways. For example, the Leimanis study 
(2012) aimed not only to investigate the metabolic ratio calculated as EDDP/methadone, but 
also to present a different relationship between the concentrations using a ratio calculated as 
methadone/EDDP. 
Leimanis et al. (2012) investigated the relationship between methadone and EDDP in urine in 
order to develop a reference range as a tool for clinicians prescribing methadone for pain 
management. Ninety-five percent of the population had methadone concentrations between 
0.175 and 20.9 mg/g cr, and on average EDDP twice the methadone concentration. Although 
the samples’ methadone doses were not known, an attempt was made to control the variance 
due to different dose exposure by calculating methadone and EDDP from the narrow range of 
the excreted methadone. The study further investigated the relationship between EDDP and 
methadone by calculating the combined total of excreted methadone and EDDP; this enabled 
the calculation of methadone exposure, which is the combination of methadone and EDDP 
molar concentration. Methadone exposure in the inter-participant population ranged from 
0.0832 to 229 mg/g creatinine (antilog –1.08 to 2.36), with median methadone exposure of 
9.40 mg/g creatinine (antilog 0.973). Further investigation of the methadone and EDDP ratio 
was attempted by calculating the metabolic ratio (methadone/EDDP) and relating it to 
methadone exposure. The results indicated no relationship between the two parameters, with 
a 33-fold variability reported in the metabolic ratio (methadone/EDDP ratio) around the 
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median of the methadone exposure concentration (which was calculated in an attempt to 
predict the dose of methadone consumed). Therefore, the study concluded that due to the 
wide range of possible methadone exposure concentrations (which could mean that the urine 
samples analysed were collected from patients on a wide range of methadone doses), the 
metabolic ratio (calculated as methadone/EDDP) could not be reliably predicted (Leimanis et 
al.). Therefore, it is important to have a known methadone dose when analysing urine 
samples in order to reliably predict the methadone/EDDP ratio. Table 1-2 below documents 
the findings of the Leimanis et al. (2012) study. 
Table 1-2 Summary of Study Investigating the Levels of Methadone, EDDP and Other 




Matrix Time of 
Collection 
















Chronic pain patients 
Interparticipant population 
(8,083 participants and 
sample) 
2.64 1.75 4.63 
Intraparticipant (190 
participants) and  (1,270 
samples) 
3.27 1.70 5.55 
*M conc (methadone concentration), E/M ratio (EDDP/methadone ratio), E Conc (EDDP concentration).  
Studies focusing on developing analytical methods to measure methadone and EDDP have 
also documented the relationship between them. However, the purpose of these studies was 
not to establish the metabolic ratio but rather to establish a relationship that was expressed as 
a ratio by calculating methadone/EDDP. Angelo et al. (1999) conducted a study designed to 
develop a high performance liquid chromatography method to analyse methadone and its 
metabolite in urine. The study did not document the doses of methadone in the samples 
collected; however, the mean ratio of EDDP/methadone was 3.2, and the range varied 
between 1.3 and 12.7 in 21 urine samples collected from MMT patients (Angelo et al.). 
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Previously, Lanz & Thormann (1996) examined the EDDP/methadone ratio while 
investigating the capillary electrophoretic assay. The reported mean urinary ratio of 
EDDP/methadone was 0.63, ranging from 0.36 to 2.92 in eight MMT patients. However, no 
information on the doses or the time spent in treatment was referenced in the study. Still 
earlier, a number of researchers documented observations in relation to the ratio, such as 
Verebely et al. (1975), who investigated the EDDP/methadone ratio in 12 patients who were 
just beginning to receive methadone maintenance. The findings indicated that the 
EDDP/methadone ratio increased from 0.6 to 1.8 after 26 days of receiving methadone doses 
every day (Verebely et al.). 
Most recently, Nielsen et al. (2013) investigated the potential of measuring the 
metabolite/drug ratio (EDDP/methadone ratio) in post-mortem blood or urine to indicate 
whether cause of death was due to treatment non-compliance. The study included taking 
measurements of EDDP/methadone in living persons receiving methadone. The median of 
the EDDP/methadone ratio was 1.6 (0.45-5.4). This ratio was not significantly different when 
compared to the ratio in post-mortem samples (Nielsen et al.). 
1.1.6.3 Excretion of methadone and EDDP in urine 
As a basic compound, the elimination of methadone is known to be affected by pH. Nilsson 
et al. (1982) found that both the half-life and the volume of distribution of methadone 
increased two-fold when the urine pH was increased. In terms of the EDDP/methadone ratio, 
when there was an acidic environment, the ratio decreased and the renal clearance of 
methadone was three times greater (Bellward et al., 1977). 
More recently, Bernard et al. (2007) examined the relationship between methadone and 
EDDP and the effect of pH. Urine samples (n=1539) that had tested positive for methadone 
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were provided from the Division of Forensic Toxicology and Drug Abuse (DFTDA). 
However, no records on the dose or the length of time for which methadone was prescribed 
were collected. The results indicated that the median methadone level was 27.3 μmol/L 
(range: 0.7–258.7) and the median concentration of EDDP was 42.6 μmol/L (range: 0–
244.8). The ratio between methadone and EDDP concentrations was calculated and plotted 
against pH to test whether it varied with pH. The results indicated a good relationship 
between the ratio and the pH (Spearman’s ρ = 0.7, P < 0.01), confirming that methadone but 
not EDDP is pH-dependent. The study also indicated that some of the samples with positive 
methadone and negative EDDP may have been spiked, and some results may have been due 
to this adulteration rather than pharmacokinetic reasons and/or inter-individual variation 
(Bernard et al., 2007).   
Larson & Richards (2009) investigated the potential for developing a regression model that 
could predict patients’ drug adherence based on the ratio of EDDP/creatinine levels in urine. 
Urine was collected from a total of 40 patients receiving methadone, either for heroin 
dependence treatment or chronic pain. The doses of methadone consumed by the patients 
varied between 10mg per day and 125mg per day. The levels of creatinine, methadone, and 
EDDP were all measured in urine using GC/MS. Although the results indicated some 
variability in the EDDP concentration levels in urine, correction for creatinine was effective 
in removing the substantial variability. The results indicated that the ratio of EDDP/creatinine 
was found to predict the consumed dosage of methadone (Larson & Richards). 
A number of studies have investigated the importance of understanding the effect of 
metabolism of methadone on the concentration of methadone and its metabolite in plasma 
(Goldberger et al., 1994; Seldén et al., 2012; Verebely et al., 1975). Byrne et al. (1998) 
investigated the use of weekly trough serum levels for optimising methadone dose and found 
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that increasing the dose when concentrations were less than 200 µg/L helped to reduce illicit 
drug use and increased treatment efficacy. These findings indicate the importance of 
methadone level as an indication of treatment efficacy (Byrne et al.).
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Table 1-3 Summary of Studies Investigating Methadone and EDDP in Urine*  








M/E Conc EDDP Conc 
USE ug/L 
George et al. 
(2000) 
GC-MS Random 38 specimens 
from routine drug 
of abuse screening 
Not reported   52 to 515 
ng/mL 
George et al. 
(1999) 
 
GC  14 participants 
during 
detoxification 
30-100 11.8 ng/mL Not reported 17.8 ng/mL 




GC-MS MMT patients, 
3 times a week 
at trough 













27 participants at 





















dose 65 mg 
600 to 300 AU   
*M Conc (Methadone concentration), E/M ratio (EDDP/Methadone ratio), E Conc (EDDP concentration
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A pilot study by George et al. (1999) investigated the application of urinalysis during 
detoxification to measure compliance using methadone to EDDP ratio in urine. The 
study investigated the relationship between the dose of methadone and the 
concentration of methadone and EDDP in urine in patients undergoing methadone 
detoxification. The results indicated that although there was a significant relationship 
between the dose and the concentrations of methadone and EDDP in urine, there was 
high inter-individual variability. Correcting for creatinine concentration did not 
improve the results; however, the authors suggested monitoring the excretion patterns 
of methadone and EDDP in each individual (George et al.) (see Table 1-3). 
It is also important to consider the phase of methadone treatment at which the 
methadone concentration is measured. Nilsson et al. (1982) found that the pH of urine 
was different among patients receiving methadone at induction (1-3 days) and later 
(24-26 days). This change in pH influenced the rate of clearance by 20% and was 
found to increase from (0.095 ± 0.031L.min compared with 0.115 ± 0.036 L.min). 
The authors suggested that this phenomenon could be explained by acidosis, induced 
by methadone due to respiratory depression. Therefore, when choosing urine as the 
matrix for measuring the concentration of methadone, pH has a large impact on inter-
individual variability and needs to be regulated or measured upon analysis of the 
sample.  
Studies have documented the concentrations of methadone and EDDP in urine, and 
recent research has focused on the development of techniques to measure these 
concentrations in various biological matrices. The clinical use of these concentrations 
has also been suggested, including for monitoring compliance. Although some studies 
attempted to investigate the relationship between methadone and EDDP as a ratio, 
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only one study has investigated the development of a reference range for the 
(metabolic) methadone/EDDP ratio in pain patients (see Table 1-2), the results 
indicated a high variability in concentrations of EDDP and methadone and therefore 
in the ratio (methadone/EDDP) as well, which the authors attributed to the lack of 
methadone dose information. Therefore, the present research aimed to investigate the 
methadone/EDDP ratio in relation to known doses and times of sample collection. 
1.2 Alcohol Biochemistry and Biomrkers  
1.2.1 Introduction  
The hazardous and harmful use of alcohol and dependence is a major global 
contributing factor in death, disease, and injury (Rehm et al., 2009). In 2007, the 
World Health Organisation reported that the harmful use of alcohol resulted in 
approximately 2.5 million deaths each year (WHO, 2007). By 2012, the estimate had 
risen to 3.3 million deaths (WHO, 2012). Moreover, as a risk factor for global burden 
of disease (GBD), alcohol is ranked fifth, behind tobacco (Ezzati et al., 2004). Nutt et 
al. (2010), using a multicriteria decision analysis (MCDA) approach to modelling, 
found alcohol to be the most harmful of all the drugs considered. According to data 
cited by Rehm et al., alcohol is implicated in 3.8% of all global deaths and is 
responsible for 4.6% of global disability-adjusted life years (DALYs). This strain on 
global wellness also places a burden on productivity and healthcare costs. In the UK 
alone, the cost of alcohol misuse is estimated at £6.4 billion annually, with £3 billion 
of this cost borne by the National Health Service (NHS) (Ward et al., 2010).  
Faced with the dramatic impact of alcohol misuse on societies, politicians at the 
community and national levels, as well as health authorities worldwide, have pushed 
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for more effective screening and treatment of alcohol use disorders (AUDs). AUDs 
are complex biopsychosocial conditions (Li et al., 2007) that can manifest in a variety 
of ways. For descriptive purposes, however, it is useful to recognize at least the 
following broad categories or levels of abuse: hazardous drinking, harmful use, and 
alcohol dependence. Definitions of these conditions are provided in Table 1-4. 




 A pattern of alcohol use that increases the risk of harmful 
consequences for the user. In contrast to harmful use, hazardous use 
refers to patterns of use that are of public health significance despite 
the absence of any current disorder in the individual user. 
Harmful 
use 
 A pattern of alcohol use that is causing damage to health. The damage 
may be physical or mental. Harmful use commonly, but not invariably, 
has adverse social consequences. 
Alcohol 
dependence 
 A cluster of behavioural, cognitive, and physiological phenomena that 
develop after repeated alcohol use and that typically include a strong 
desire to take alcohol, difficulties in controlling its use, persisting in its 
use despite harmful consequences, a higher priority given to alcohol 
use than to other activities and obligations, increased tolerance, and 
sometimes a physical withdrawal state. 
 
A range of pharmacological and/or behavioural interventions exists for the treatment 
of AUDs (Li et al., 2007). However, the implementation of these treatments – as well 
as the study of these conditions and the identification of individuals misusing alcohol 
– requires reliable screening tools. To screen for current and/or recent alcohol use or 
misuse, most clinical and research settings make use of clinical histories, physical 
examinations and self-reported questionnaires such as the Alcohol Use Disorders 
Identification Test (AUDIT), the CAGE (Ewing, 1984) and the Michigan Alcoholism 
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Screening Test (MAST) (Selzer et al., 1971). However, the accuracy of self-reported 
measures such as these can be affected by under-reporting and/or under-estimation of 
harmful drinking (Del Boca & Darkes, 2003). 
In contrast, bio-physiological markers of the presence or recent presence of alcohol in 
the human organism (i.e., alcohol biomarkers) can provide the basis for a variety of 
objective methods to detect and assess alcohol consumption (Johnson et al., 2008; 
Litten et al., 2005). Although some of these methods still require further research, 
they offer promising options for evaluating the efficacy of treatment and identifying 
individuals who are under the influence and/or at risk of alcohol misuse. Outside of 
clinical or research settings, potential applications for these modalities include the 
screening of motor vehicle operators and workplace drug testing (WDT).  
The current standard for assessing recent alcohol consumption, which involves 
measuring alcohol in the breath, blood, or urine, can only detect consumption within 
the previous 12 hours. Methods involving alcohol biomarkers have the potential to be 
more reliable than standard methods and/or to be reliable over longer periods. Certain 
alcohol biomarkers have been used to measure consumption in excess of 1000g of 
ethanol over periods (detection windows) of more than two weeks (Helander et al., 
2009; Hoiseth et al., 2008). This chapter focuses on the potential use of two 
biomarkers that appear to offer broad detection windows: ethyl glucuronide (EtG) and 
ethyl sulphate (EtS). Following a brief overview of alcohol and alcohol metabolism, 
the chapter addresses some of the research carried out on these and other biomarkers 
to date and discusses the available evidence regarding the potential of EtG and EtS 
for use in screening for alcohol consumption. 
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1.2.2 Problematic alcohol consumption and alcohol dependence 
A better understanding of what distinguishes alcohol dependence from problematic 
alcohol consumption is important in order to effectively treat patients presenting to 
drug treatment facilities, as recognizing the problem early in the treatment can help 
clinicians to develop better intervention measures and thus to avoid escalation of the 
problem. Indeed, management of dependence presents a crucial period in the 
treatment of severely alcohol dependent patients due to the life threatening conditions 
caused by alcohol withdrawal symptoms that can develop when users suddenly 
discontinue or decrease their alcohol consumption (Leggio et al., 2008). However, in 
many cases alcohol problems receive little attention in the treatment of illicit drug 
misusers (Gossop et al., 2005).  
 
The two most prominent classification systems, those of the Diagnostic and Statistical 
Manual (DSM-IV) and the International Classification of Diseases (ICD-10), agree in 
defining ‘alcohol abuse’ and ‘harmful alcohol use’ (their respective terms) as a 
repetitive administration of alcohol that results in harmful consequences to physical or 
psychological health. However, ICD-10 excludes the use of negative social 
consequences in defining ‘harmful alcohol use’ (Finch & Welch, 2006; Nelson et al., 
1999). Both classifications view alcohol dependence similarly, and both apply three 
criteria that must have been met within the previous 12 months in order for an 
individual to be diagnosed with alcohol dependence. In developed countries, the 
application of these classifications indicates that almost 5% of the population suffers 
from alcohol dependence, compared between five and 15% presenting with hazardous 
or harmful drinking (Saunders & Lee, 2000). 
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1.2.3 Alcohol and alcohol metabolism 
Alcohol, or technically ethanol (EtOH), is a psychoactive substance, the consumption 
of which can lead to dependence (Rehm et al., 2007). It is a polar molecule with a 
weak charge and a low molecular weight. It is absorbed rapidly on ingestion, with 
absorption completed in one to three hours, with ~20% absorbed from the stomach 
and the rest from the small intestine (Jones, 1996). 
Alcohol is typically consumed in beverages such as beer, wine, and spirits. Alcohol 
content in such products is usually expressed in terms of percentage of alcohol by 
volume (ABV). For example, beer identified as 9% ABV contains 9 units of ethanol 
for every 1000 mL of beer (1 unit of alcohol is equivalent to 8g of pure ethanol). In 
the 1980’s, the medical Royal Colleges endorsed the Health Education Council’s 
guidelines, which recommended that men should consume no more than 21 units (168 
g) and women no more than 14 units (112 g) per week (House of Commons Science 
and Technology Committee, 2011). Table 1-5 shows the descriptive terminology 
associated with various levels of alcohol consumption, correlated with ranges 
expressed in terms of such units. These ranges can serve as a reminder that, in 
assessing alcohol consumption in relation to health and social consequences, it is 
usually important to take account of such factors as gender, body weight, and alcohol 
tolerance, as well as the time over which a given amount of alcohol is consumed, as 
these factors can play a role in the physiological and/or psychological impact of 
alcohol (Rehm et al., 2009). 
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Table 1-5 Descriptive Terms for Alcohol Consumption Levels Correlated with 




 UK Units/day 
(1 unit = 8g of pure ethanol) 
Heavy  >10 
Sessional  >6-8 
Moderate  4-10 
Light  <4 
 
Alcohol is metabolised primarily in the liver, in a two-stage oxidation process: first to 
acetaldehyde by alcohol dehydrogenase (ADH) and then further to acetic acid by 
aldehyde dehydrogenase (ADH). The majority of ingested ethanol (~95%) is 
metabolised by the liver via alcohol dehydrogenase (ADH) into an acetaldehyde. A 
smaller amount is oxidized into aldehyde by catalase or by the enzyme CYP450 in the 
microsomal oxidising system (MEOS), as shown in Figure 1-3.  It is further oxidized 
to acetic acid by ALDH. 
1.2.3.1 Oxidative pathway 
The main oxidative metabolism of ethanol takes place in the cytoplasm of the 
hepatocyte by ADH, through the action of nicotinamide adenine dinucleotide (NAD), 
and the acetaldehyde is further oxidized to acetate by NADH (Sato & Kitamura, 
1996). The isozyme pattern and activities of ADH and ALDH have been described in 
the human mouth, oesophagus, stomach and large intestine (Dong et al., 1996; Yin et 
al., 1993, 1994, 1997). 
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Figure 1-3 Ethanol elimination pathways (Dahl et al., 2006) 
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Figure 1: The major oxidative and minor non-oxidative pathways for ethanol elimination in the human 
body (Dahl, 2006). 
2. Detection time and Sensitivity 
Helander and colleagues determined the detection times for EtG and EtS in alcoholic patients undergoing 
alcohol detoxification. They found that the detection time for urinary EtG was weakly correlated with the 
initial alcohol concentration, and that for EtG, the time range until return to below the <500 ng/mL cut-off 
limit was 40–130 hrs (median 78 hrs) with a similar time course observed for EtS. For EtG, the detection 
times after an estimated zero ethanol concentration (i.e. after no ethanol was detected) were ∼ 30–110 h 
(median 66 h) and ∼30–70 hrs (median 56 hrs) after correction for urine dilution (Helander et al., 2009). 
Stewart and colleagues evaluated the performance of urine ethyl glucuronide (EtG) and ethyl sulfate (EtS) 
in detecting alcohol use in the days preceding a clinical encounter (Stewart et al., 2013). They found urine 
EtG (sensitivity 76%, specificity 93%) and urine EtS (sensitivity 82%, specificity86%) to perform well in 













The c toc rome P450 iso-enzymes, which include CYP2E1, 1A2, and 3A4, are also 
part of the oxidative metabolism process in the liver; however, CYP2E1 plays a much 
more substantive role in the MEOS than CYP1A2 or CYP3A4  (Asai et al., 1996; 
Niemela et al., 1999; Salmela et al., 1998). Chronic alcohol consumption has been 
found to induce t e ain enzyme, CYP2E1, to metaboli  ethanol to acetaldehyd  at 
high ethanol concentrations, which thus leads to an increase in the MEOS activity 
(Lieber, 1989; Lieber & DeCarli, 1968). Although CYP2E1 is the main enzyme, it has 
bee  proposed that chronic alcohol consumptio  leads to the induction of CYP1A2 
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and CYP3A4 and may contribute to the pathogenesis of liver damage due to the 
generation of reactive oxygen species (ROS), which is key for the progression of fatty 
liver to steatohepatitis. 
One of the reasons for the increase in CYP2E1 protein during chronic ethanol intake 
is decreased proteasomal degradation, which increases CYP2E1 protein stability. The 
induction of CYP2E1 occurs within one week of the consumption of ethanol, even at 
doses as low as 40g/day in chronic alcohol consumers. Jones et al. (1992) identified 
the rate of ethanol elimination as 0.21/g/L/h. However, the degree of induction varies 
highly across individuals (Jones et al., 1992). Catalase is another enzyme that, in the 
presence of a hydrogen peroxide (H2O2)-generating system, is capable of oxidising 
ethanol. This, however, is considered a minor pathway of alcohol oxidation, except in 
a fasting state (Handler & Thurman, 1990). 
Regardless of the path by which ethanol is oxidised, the end products are 
acetaldehyde and acetate. Acetaldhyde is highly toxic and is metabolized rapidly – 
mainly by aldehyde dehydrogenase (ALDH) to form acetate, which requires the 
coenzyme nicotinamide adenine dinucleotide (NAD+), which is later reduced to 
NADH. Acetate is oxidised away from the liver, yielding the end products CO2 and 
H2O in the cells of the heart, skeletal muscles, and brain (Krebs’ cycle). Acetate is 
also metabolised into acetyl coenzyme-A, which is involved in the lipid and 
cholesterol biosynthesis of the brain peripheral mitochondria. In chronic alcohol 
consumers, it has been suggested that acetate is used by the brain as a source of 
energy instead of glucose (Zakhari et al., 2006). 
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1.2.3.2 Non-oxidative metabolism 
 Between three and ten percent of ingested ethanol is excreted via the breath, sweat, 
and urine (Jones, 1990; Jones et al., 2011). A much smaller percentage (<0.1%), 
however, undergoes non-oxidative metabolism, or phase II conjugation (Helander et 
al., 2009; Helander & Beck, 2004; Hoiseth et al. 2008). The conjugation of ethanol 
with glucuronic acid is catalysed by endoplasmic reticulum uridine diphoshate – 
glucuronyltransferase (UGT), which produces ethyl glucuronide (EtG). Ethyl sulphate 
(EtS), on the other hand, is produced by the conjugation of ethanol with sulphate, 
which is catalysed by cytosolic sulphotransferase (SULT). Other end products of this 
metabolic pathway include Fatty acid ethyl esterase (FAEE) via FAEE synthase and 
Phosphatidylethanol (PEth) via phospholipase D (see Figure 1-3). 
1.2.4 Biological tools 
1.2.4.1 Alcohol Biomarkers 
Alcohol biomarkers can be used to measure the quantity of ethanol consumed and the 
time frame in which it was ingested. Such information can be vital in screening for 
excessive alcohol use among drivers or in workplace settings, as well as in 
monitoring abstinence and/or screening for relapse in alcohol dependence treatment 
(Helander et al., 2009). Potentially useful biomarkers most typically isolated from the 
blood and from the urine are summarised in Tables 1-6. The information provided in 
the columns headed ‘Drinking behaviour targeted’ and ‘Primary indication’ is 
determined based on the properties of the biomarkers, which are identified in the 
other data columns (‘Window of assessment’, ‘Sensitivity’, etc.). In other words, 
these properties determine the potential uses of the biomarkers, based on which they 
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are divided into three categories: 1) markers for chronic alcohol consumption; 2) trait 
markers for alcohol dependence; and 3) markers for acute alcohol consumption. 
Table 1-6 Alcohol Biomarkers in Blood 
 
*GGT, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; MCV, mean corpuscular volume; CDT, carbohydrate-deficient transferrin; FAEE, 























Moderate to high 
(heavy drinking 
for 7 to 10 days) 




Similar to GGT 
(26-83) 









Lower than GGT (47) 















2 to 3 
weeks 
Screening 
Lower than GGT (AST 
56)  (Anttila et al., 
2004)    (<40) 
n/a 
FAEE 
Unknown                                                      











100 (Wurst et al., 2004) 90 
PEth 
Heavy drinking 
for ∼5 days 




99 (Aradottir et al., 
2006) _ 
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Alcohol biomarkers for chronic alcohol consumption 
Carbohydrate-deficient transferrin (CDT) is an example of a marker known to have 
properties that make it useful in detecting chronic harmful intake of alcohol (Anton, 
2001; Niemela, 2007). It is an iso-form of transferrin (a glycoprotein that is important 
in transportation of iron in plasma) that has two N-glycosylation sites (Landberg et 
al., 1995). Upon consumption of high alcohol levels for a long period, a shift in the 
carbohydrate composition in transferrin is observed and minor glycoforms 
(asialotransferrin and disialotransferrin) are detected. This shift remains detectable, 
and serum CDT levels take two to three weeks to return to normal after abstinence 
due to the long half-life of transferrin (1.5-2 weeks) (Jeppsson et al., 1993; Helander 
et al., 2001; Litten & Allen, 1998; Stibler, 1991). CDT is considered a more specific 
chronic heavy alcohol consumption biomarker when compared to other known 
biomarkers. This makes CDT suitable for use in detecting relapse (Anton et al., 2002; 
Bergstrom & Helander, 2008). However, its effective use requires that the participant 
has been drinking over a seven to 14 day period (Hannuksela et al., 2007). 
Mean corpuscular volume (MCV) (i.e., red blood cell size) is another biomarker for 
chronic heavy alcohol consumption. Red blood cells typically increase in volume as 
an individual consumes more alcohol. This is due to a secondary reaction to bone 
marrow toxicity. However, MCV is considered a poor biomarker for acute alcohol 
consumption due to the fact that erythrocyte half-life is 120 days. Other factors can 
contribute to elevated MCV, moreover, so this measure is not sufficiently reliable to 
be used on its own and should routinely be used with aspartate aminotransferase 
(AST) to rule out delirium tremens (Conigrave et al., 2003; Findley et al., 2010; 
Niemela, 2007). 
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Gamma glutamyl transferase (GGT) is a membrane-bound glycoprotein enzyme that 
is an amino acid (Goldberg, 1980). It is a useful biomarker because its levels are 
known to be elevated after years of chronic alcohol consumption. A high level of 
GGT in the serum is associated with liver damage as it is highly detected in the liver, 
kidney, and bile. It is also increased in association with the use of certain prescription 
medications, such as anticonvulsants (Conigrave et al., 2002). 
Finally, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 
measured in connection with routine screening for liver diseases, are both typically 
elevated in cases of chronic alcohol consumption (Conigrave et al., 2002). AST is 
mitochondrial enzyme present mainly in the liver. However due to its presence in 
other organs, any factors affecting the muscles can lead to its elevation. ALT is more 
specific to liver damage as it is a cystosolic enzyme mainly present in the liver tissue 
(Conigrave et al., 2003). 
Trait markers for alcohol dependence  
This category consists of trait markers that can provide information relevant to 
whether a given individual might possess a genetic predisposition that could 
contribute to his or her susceptibility to alcohol dependence. These markers are 
associated with efforts to prevent rather than to screen for and/or treat excessive 
alcohol consumption or dependence (Hellevuo et al., 1997). They include Adenylyl 
Cyclase (AC) Activity, Gamma-Aminobutyric acid (GABA), Dopamine, Serotonin, 
and Beta-Endorphin (Hoffman et al., 2002; Oroszi & Goldman, 2004; Oswald & 
Wand 2004; Ratsma et al., 2002).  
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Alcohol biomarkers for acute alcohol consumption 
Some markers that remain detectable for only a few days after alcohol use can be 
effective in detecting acute consumption within this timeframe. This class of markers 
includes serotonin metabolites 5-hydroxytryptophol (5-HTOL) and 5- hydroxyindole-
3-acetic acid (5-HIAA). In urine, the ratio of 5-HTOL/5-HIAA increases following 
the intake of high levels of alcohol. This ratio has been found to be more sensitive 
than plasma ethanol levels and to be measurable for up to 20 hours after the 
disappearance of ethanol (Helander et al., 1992; Helander et al. 1993, 1996; Helander 
& Eriksson, 2002; Voltaire et al., 1992). Davis et al. (1967) documented that an 
interaction with the metabolism of serotonin (5- hydroxytryptamine, 5HT) results in a 
shift toward the production of 5HTOL during ethanol metabolism. This shift, which is 
represented in Figure 2-2, can be explained as due to processes that favour 5HTOL 
formation over the formation of 5HIAA. These processes include: 1) increased 
cytosolic NADH/NAD
+ 
ratio; 2) the inhibition of mitochondrial ALDH by 
acetaldehyde; and 3) increased cytosolic NADH/NAD
+ 
ratio (Svensson et al., 1999; 
Walsh, 1973).  The ratio remains elevated for 6-20 hours after the disappearance of 
ethanol in plasma, which gives it an advantage over ethanol as a biomarker (Eriksson 
et al., 2002). 
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Soon after drinking alcohol, the urinary 5HTOL concentration becomes markedly 
increased and it will not return to baseline levels until several hours after the ethanol is no 
longer measurable (Helander et al., 1993). Based on this time-lag, urinary 5HTOL has been 
used clinically as a sensitive biochemical marker of recent alcohol consumption (Voltaire et 
al., 1992; Helander et al., 1994). To secure the specificity of the marker, 5HTOL should be 
expressed as a ratio to 5HIAA rather than to creatinine, because dietary serotonin (high 
amounts in banana and pineapple) might otherwise cause false-positive results. This practice 
also compensates for variations in the urinary concentration of 5HTOL caused by external and 
internal dilution of the urine (Helander et al., 1992). Gender or genetic variations in the ADH 
and ALDH isoenzyme patterns seemingly do not influence the baseline ratio of 
5HTOL/5HIAA (Helander et al., 1994; Helander et al., 1996). The only known factor apart 
from alcohol intake that increases the urinary 5HTOL/5HIAA ratio is treatment with ALDH 




























Figure 2. The interaction between serotonin (5HT) and ethanol metabolism. 
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Figure 1-4 Interaction between Ethanol and serotonin (5-HT). 
 
Other markers in this category include the products of non-oxidative ethanol 
metabolism, noted earlier. Of these, EtG (Wurst et al., 1999) and EtS (Helander & 
Beck, 2005) are both detectable in urine and remain so for up to several days after 
alcohol consumption (see Table 1-7). FAEE can be detected in blood for up to 24 
hours, but in hair it can be detected for up to two months (Auwärter et al., 2001; 
Doyle et al., 1994; Pragst et al., 2001). Compared to EtG, however, concentrations of 
FAEE in hair samples have been found to correlate less reliably with volume of 
alcohol consumed (Auwärter et al., 2001; Süsse et al., 2010; Wurst et al., 2004).  
Using Biomarkers in Combination 
Many researchers believe that the most reliable approach to detecting and assessing 
alcohol consumption involves using two or more biomarkers in combination. The 
most common combination is CDT in conjunction with GGT (Litten et al., 1995).  
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Some investigators have developed mathematical equations for assessing CDT + 
GGT measurements. Sillanaukee and Olsson (2001), for example, provide the 
equation (0.8 x ln(GGT) + 1.3 x ln(CDT)). This approach was subsequently improved 
upon by replacing absolute CDT with %CDT (Anttila et al., 2003; Hietala et al., 
2006).  
Table 1-7  Alcohol Biomarkers in Urine 
 
*HTOL, hydroxytryptophol; HIAA, hydroxyindoleacetic; EtG, ethyl glucuronide; EtS, ethyl sulfate. 
 
1.2.4.2 Detecting EtG in Hair 
EtG is highly acidic, non-volatile, non-oxidative, hydrophilic, and stable alcohol 
phase II metabolite. It was first detected in hair samples from individuals believed to 
have engaged in repeated alcohol consumption about two decades ago (Aderjan et al., 
1994). Since that time, a number of researchers have proposed EtG in hair as a stable 
marker to detect and quantify alcohol consumption (Høiseth et al., 2007; Skopp et al., 
2000; Wurst et al., 2003). 
Since its initial application, numerous studies have investigated the reliability and 
merits of measuring EtG in hair samples taken from individuals with a history of 






Detection Primary Indication Sensitivity 
5-HTOL 
5-HIAA 
 4 drinks 1 day Screening/relapse High 
EtG 
1 to 2 drinks 
(Unknown) 
Several days 







EtS 1 to 2 drinks 1 to 2 days Abstinence/relapse High 
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others have investigated current alcohol dependent patients using this technique. 
Table 1-8 shows a summary of the results of selected studies of this kind. 
Alt et al. (2000) investigated EtG in both alcohol dependents and social drinkers and 
found no EtG in samples from the latter group, whose members reported consuming 
about 20 g/day. Janda et al. (2002) detected EtG in 42% of samples from patients 
identified as alcohol dependent, compared to only one (EtG: 55pg/mg) out of the five 
samples collected from drinkers who consumed 30 g/day or less. However, the study 
did not report a correlation between the measured EtG and the reported levels of 
alcohol consumed. Similarly, Yegles et al. (2004) were successful in detecting EtG in 
alcohol dependent patients, but the authors indicated that there was no clear 
relationship between the EtG (or FAEE) concentrations and the self-reported alcohol 
consumption. Politi et al. (2006), however, reported EtG hair concentrations 
correlating with the daily alcohol consumption as assessed using a drinking 
questionnaire. Based on their results, the authors suggested cut-off values of 4 and 5 
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Table 1-8 Summary of Results of Selected Studies Measuring EtG Levels in Hair 
*EDI = Ethanol Daily Intake; SoHT = Society of Hair Testing 




Recommended range for 
cut-off values 
Alt et al. 
(2000) 
Alcohol dependent (4) 
Social drinkers (6) 
119-388      
Nd 
– 
Janda et al. 
(2002) 
Risk drinkers/alcohol 
dependent (60)          
Non-risk drinkers (5) 






dependent (10)          
Non-risk drinkers (4) 
30–415       
Nd 
– 




Consuming 2 to 60 






et al. (2007) 
Risk drinkers/alcohol 
dependent (15) 
8–261 EDI 11–40 g: 4–15 pg/mg 




et al. (2012) 
Risk + non-risk 
drinkers (32) 
Nd-1146 EDI 16 g: < *SoHT, 7 
pg/mga 
Kharbouche 
et al. (2012) 
Consuming 32 g 
alcohol for 3 months    
Consuming 16 g 
alcohol for 3 months 
Nd-11           
Nd-3 




Risk drinkers (38)      
Non-risk drinkers (44) 
Nd-1190   
Nd-32 
EDI> 60g:25pg/mg 
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In 2010 the Society of Hair Testing (SoHT) recommended cut-off levels to 
differentiate between excessive and social alcohol consumption (Albermann et al., 
2011). The proposed cut-off for EtG in hair to strongly suggest chronic excessive 
alcohol consumption is 30 pg/mg scalp hair measured in the 0-3 to 0-6 cm proximal 
segment. If samples less than 3 cm are used, it is recommended that the results be 
interpreted cautiously. An EtG concentration equal to or greater than 7 pg/mg scalp 
hair indicates alcohol consumption and provides evidence to refute a claim of 
abstinence. 
The SoHT cut-offs have been the participant of considerable debate. However, in a 
recent meta-analysis Boscolo-Berto et al. (2013) provided support for the SoHT 
thresholds, concluding that the cut-off of 30 pg/mg limits the false-negative effect in 
differentiating risk from non-risk drinkers, while the 7 pg/mg cut-off value constitutes 
sufficient evidence (only) for suspecting active alcohol use rather than complete 
abstinence. 
Due in part to the presence of variables that can affect EtG levels in hair, however, 
some researchers propose cut-offs that are lower than the current standard. These 
include a proposed threshold for detecting ‘moderate drinking’ (defined in a number 
of studies as 28-40 g/day) of between 4 pg/mg and 15 pg/mg (Kharbouche et al., 
2009; Politi et al., 2006; Stewart et al., 2013). Other studies propose cut-off values 
between 4 pg/mg (Politi et al., 2006) and 25 pg/mg (Kharbouche et al., 2012) for the 
identification of ‘risk’ drinking, often defined as consumption in excess of 40 g of 
alcohol per day. 
Clearly, further research is needed in order to achieve consensus on reliable cut-off 
values for detecting alcohol use and for differentiating use from abuse. As the WHO 
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(2007) has indicated, however, this effort should take into account a wide set of 
criteria so that the interpretation of risk drinking reflects national, gender, and 
individual differences. 
As noted above, less than 0.1% of ingested Ethanol is conjugated into EtG and EtS 
(Helander & Beck, 2004). Nevertheless, EtG and EtS remain detectable in urine for 
several days, giving these metabolites strong potential for use in screening for recent 
alcohol consumption. This section discusses some of the research findings regarding 




Figure 1-5 Chemical structure of Ethyl glucoronide (EtG). 
 
EtG, the chemical structure of which is shown in Figure 1-5, is a metabolite of 
ethanol that is formed in small amounts by reaction with uridine-5-diphospho-β-
glucuronic acid (UDPGA), which catalyses endoplasmic reticulum UDP-
glucuronosyltransferase (UGT) enzymes (Tukey & Strassburg, 2001). Methods for 
measuring EtG have been developed based on gas chromatographic-mass 
spectrometric (GC-MS) (Wurst et al., 1999) and liquid chromatographic-mass 
spectrometric (LC-MS) techniques (Stephanson et al., 2002). Using these methods, 
EtG has been established as both a sensitive and a specific biomarker for the detection 
of recent alcohol intake (Wurst & Metzger, 2002). In fact, EtG has been found to be 
useful even in screening for low levels of alcohol consumption (7 g), and, at up to 
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four days, it has a relatively long window of detection in urine (Seidl et al., 2001; 
Stephanson et al., 2002). 
Table 1-9 Summary of Studies Investigating Urinary Ethyl Glucuronide (UEtG) 
Levels in Alcohol Dependent Patients  
Study Population n* Results Window of 
Detection 
Alt et al. 
(1997) 
Male patients in 
alcohol  clinical 
study 
33 UEtG 3.6–710 mg/l  
 
Detectable up to 
75 hours 























UEtG 3.6–710 mg/l,  
 
No correlation of UEtG 
with SEC, GGT, MCV. 
Four cases UEtG 4.2–
196.6 mg/l, one case 
SEtG 4.8 mg/l 
Eight urine samples 
from seven patients 
positive UEtG 2.9–
23.49 mg/l 
Detection 57.7 ± 
16.9 hours 












Four cases positive 
 
UEtG 0.29–1.03 mg/l 
  
 







35 During 1 year: 14 of 
146 urine samples 
positive for EtG  
Other biomarkers 
giving an indication for 
lapse/relapse (breath 




*n = number of participants in the study. 
 
Table 1-9 provides a summary of results of selected studies that have investigated the 
levels of urinary EtG (UEtG) in alcohol dependent patients. One of the earliest studies 
of this kind was that of Alt et al. (1997), who found UEtG levels between 3.6 and 710 
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mg/L and, further, determined that detection remained possible for up to 75 hours. 
Later, Wurst et al. (2009) detected UEtG up to 80 hours after consumption in alcohol 
dependent patients undergoing detoxification. However, the detection window has 
been noted as highly variable across individuals. Wurst et al. 2009 found variability in 
the detection window from 40 to 130 hours for UEtG and from 55 and 110 hours for 
UEtS. Similarly, Helander et al. (2009) found that after 30 to 110 hours the presence 
of EtG resulting from alcohol intake was no longer detectable, as levels dropped to 
below the cut-off of <500 ng/mL. 
 
Although concentrations of EtS in urine (UEtS levels) after alcohol consumption are 
typically lower than those for EtG, increased attention has recently been focused on 
the potential of EtS as a biochemical marker for acute alcohol intake (Dresen et al., 
2004), and Helander & Beck (2004) have been successful in measuring its 
concentrations using LC-MS. Helander et al. (2009) investigated the levels of both 
EtG and EtS in urine samples from alcohol dependent patients undergoing 
detoxification. The authors also surveyed previous findings regarding the detection 
time frame for EtG after alcohol intake. Table 1-10 summarizes some of these results. 
Table 1-10 presents studies conducted using healthy volunteers as well as alcohol 
dependent patients or clients receiving drug treatment. The results of these studies 
indicate that increased levels of UEtG are commonly detectable between 24 and 48 
hours after alcohol consumption in healthy participants, compared to patients 
undergoing alcohol detoxification, for whom the window was found to extend up to 
80 hours (Dahl et al., 2002; Wurst et al., 1999). 
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Table 1-10 Results of Selected Studies Investigating the Measurement of UEtG and 






Major Results Study 
Population  n* Alcohol Dose 
(g/kg of body 
weight) 




 4 0.1 
(0.33 L of low-
alcohol beer 
(2.2% ethanol, 
w/w) in 15–30 
minutes)) 
≤6 – 0.1  – Intake of very small 
amount of ethanol (7 g) 
produced ethyl 
glucuronide values up 
to 8.4 mg/L after 4 
hours  
Stephanson 
et al. (2002) 
  2 0.1 13-22 22-26 0.15 0.11  Wurst et al. 
(2006) 
  9 0.15 – ≤12 0.1  –  Helander 
and Beck 
(2005) 




0.2 g/kg ethanol 
(0.2, 0.1–0.33, 
0.07) over 20–30 
minutes  
3–25 5-30 0.15 0.11  Wurst et al. 
(2006)  
 6 0.5 
( 0.5 g/kg 
(range25.0-41.5 g) 
as5% (v/v) beer in 
30 min ) 
22-32 – 0.1  – About 0.02% of the 
ingested ethanol dose 
(on a molar basis) was 
recovered in the urine 
as EtG  
Dahl et al. 
(2002) 
10 0.5 25-35 – 0.2  –  Hoiseth et 
al., (2007) 
 9 0.5 – ≤24 0.1  –  Helander 
and Beck 
(2005) 





0.5 25-48 25-39 0.1   0.1  Hoiseth et 
al. (2008) 
  7 0.5 ≤48 – 0.1  –  Wojcik and 
Hawthorne 
(2007) 
  1 0.6 ≤36 ≤36 0.15 0.11  Wurst et al. 
(2006) 
 13 0.50–0.78 27-44 23-47 0.1  0.1  Halter et al. 
(2008) 
  7 0.75–0.85 ≤48 – 0.1  –  Wojcik and 
Hawthorne 
(2007) 
 17 >1 39-
102 
– 0.1  –  Borucki et 
al. (2005) 
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More recently, Stewart et al. (2013) investigated the sensitivity and specificity of the 
information provided by both EtG and EtS in urine samples. The results indicated that 
UEtG (sensitivity 76%, specificity 93%) and UEtS (sensitivity 82%, specificity 86%) 
both performed well in identifying recent drinking, and that the performance of these 
biomarkers appeared to be unaffected by the presence or absence of liver disease. 
Although consensus may still be some way off, establishing standard cut-off limits 
and windows of detection for EtG and EtS screening is an important goal, as such 
standards can provide conformity across application contexts, including those with 
legal implications (e.g., motor vehicle operator screening) and work place drug testing 
(WDT), as well as clinical diagnosis and treatment (Helander et al., 2009). In 2012 
the Substance Abuse and Mental Health Services Administration (SAMHSA) 
published an update to its 2006 Advisory Report that included the following 
recommended terminology and cut-offs for use in screening for alcohol use by means 
of UEtG and UEtS: A ‘high’ positive (e.g.,>1,000ng/mL) may indicate: heavy 
drinking on the same day or previously (e.g., previous day or two); light drinking the 
same day. A ‘low’ positive (e.g., 500-1,000ng/mL) may indicate: previous heavy 
drinking (previous 1–3 days); recent light drinking (e.g., past 24 hours); or recent 
intense ‘extraneous exposure’ (within 24 hours or less). A ‘very low’ positive (100-
500ng/mL) may indicate: previous heavy drinking (1–3 days); previous light drinking 
(12–36 hours); or recent ‘extraneous exposure’) (SAMHSA, 2012). 
Finally, in forensic settings in which a ‘preponderance of the evidence’ is sought to 
establish ‘proof of drinking’, Skipper et al. (2004) recommend the following 
guidelines: Cut-offs: Utilize a cut-off or threshold of at least 500ng/ml for EtG and 
100ng/ml for EtS (using values normalized to creatinine 100mg/dl) for ‘proof of 
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drinking.’ It is acceptable to have a lower ‘reporting cut-off’; however, levels between 
100-500ng/ml are statistically more likely to be from extraneous, non-beverage 
sources of alcohol (SAMHSA, 2012). 
Alcohol consumption is associated with problems in a variety of populations, and the 
availability of reliable, broadly applicable measurement and monitoring mechanisms 
can have a tremendous positive impact on the success of research, clinical 
interventions, and monitoring in a variety of settings. In this regard, the biomarkers 
EtG and EtS appear to be potentially highly useful, as they possess sufficient 
sensitivity and duration for use in monitoring for relapse in clinical settings – which 
can be vital to ensuring desired treatment outcomes – as well as for use in WDT with 
populations critical to public safety, such as pilots, air traffic controllers, and medical 
personnel. Indeed, Wurst (2009) found that the use of these markers could reveal 
acute alcohol consumption in individuals who score below levels indicating ‘harmful 
drinking’ on a self-reported measure (AUDIT). Their value in screening in contexts 
that require direct and reliable measures of alcohol use should therefore not be 
underestimated. Self-reported measures, however, can still provide a more broadly 
descriptive picture of alcohol use and related behaviours than biomarkers alone. 
Therefore, in clinical and research settings, an approach that combines both types of 
tool should be considered the most appropriate.   
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1.3 Alcohol Use During Methadone Treatment and Potential 
Interaction   
1.3.1 Introduction  
A nationwide co-morbidity survey conducted in the United States estimated that 7% 
of the total population had developed a dependence on an illicit drug at some point in 
their lives (Anthony et al., 1994). Not long after, the number of drug users presenting 
for treatment in England was estimated to be 24,000, with an estimated 30,000 in the 
UK as a whole (Central Drugs Coordinating Unit, 1998). Clients presenting for 
treatment are often multiple drug users (Gossop, 2001), and multiple drug use 
presents an additional challenge for drug treatment units that has a considerable 
impact on both treatment outcomes and public health issues. Multiple drug users 
usually present with critical medical and psychiatric conditions such as HIV-AIDS 
(acquired immune deficiency syndrome), liver cirrhosis, and major depression; in 
many cases, multiple medications are prescribed, and this can result in drug-drug 
interactions (Kapur et al., 2011). 
In the UK, 3,604 deaths linked to methadone were recorded between 1993 and 2002, 
but methadone was not necessarily the cause of death in all cases (Corkery et al. 
2004). According to the WHO (2009), drug interactions are a factor in both morbidity 
and mortality, and this includes cases involving patients receiving methadone 
treatment. In the United States, 552 deaths were reported as related to methadone in 
1996, and they occurred during the first weeks of starting methadone treatment 
(Karch & Stephens, 2000). Butler et al. (2011) investigated fatalities linked to 
methadone and arrhythmias in MMT and found that out of 30 deaths due to toxicity 
only two cases were linked to arrhythmias. Results were also consistent with previous 
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studies, which indicated that 75% of deaths happened during maintenance (Butler et 
al.). 
With respect to cases of alcohol interaction in methadone overdose, Ruttenber et al. 
(1990) investigated 505 fatal heroin overdoses and found that the correlation between 
blood alcohol levels and opiate concentrations was significantly negative, meaning 
that a significant inverse correlation was found between blood alcohol and morphine 
levels (Ruttenber et al.). In other words, it appears that in the presence of alcohol a 
smaller amount of opiate/opioid can lead to a fatal overdose. The co-dependency of 
alcohol and illicit drugs, moreover, appears to be high and is also present in patients 
receiving MMT (Srivastava et al., 2008). This chapter therefore reviews the 
relationship between alcohol and methadone and highlights the importance of 
managing clients who present with alcohol problems when receiving methadone 
treatment.  
 
1.3.2 Alcohol consumption during methadone maintenance 
treatment  
The prevalence of alcohol consumption in patients receiving MMT has been well 
documented in the literature. Srivastava et al. (2008) conducted a review to determine 
whether alcohol consumption is affected during the course of MMT. The review 
identified fifteen clinical studies, of which 11 were conducted in the United States. 
Most were cohort studies, except for three that were randomised control trials 
(Schottenfeld et al., 1998; Strain et al., 1996; Strang et al., 2000). The patient 
populations varied, but the majority were recruited from methadone maintenance; 
sample size varied between 40 and 625 participants. During the MMT, three studies 
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observed an increase in alcohol use, three observed a decrease in alcohol use, and 
nine observed no change in alcohol use. The review found that alcohol use, although 
often problematic in methadone-using patients, is not likely to change upon entering 
MMT. The authors concluded, however, that although there is no significant change 
in alcohol consumption upon starting MMT, the stability of alcohol consumption 
should still be considered problematic, and that it is important to prioritise addressing 
problematic alcohol consumption in MMT (Srivastava et al.). Nonetheless, the 
appropriate management of alcohol dependent patients undergoing MMT has not 
been substantially addressed (Hillebrand et al., 2001). 
Some patients develop alcohol problems after they start methadone treatment. 
Alcohol in this case may serve as a substitute for heroin and may be used to self-
medicate in response to withdrawal symptoms in cases where the patient perceives 
methadone doses as insufficient (Gordis & Sereny, 1980). One of the largest cohort 
studies of drug misusers in the United Kingdom, The National Treatment Outcome 
Research Study (Gossop et al., 2000), looked at multisite treatment outcomes of 1,075 
drug users who were recruited from MMT and methadone reduction treatment 
programs. The study found a high prevalence of the use of illicit drugs among the 
clients as well as heavy alcohol consumption. A one-year follow-up study found a 
reduction in the use of illicit drugs, but the pattern of alcohol consumption remained 
the same (Gossop et al.). A later paper investigated alcohol outcomes and heavy 
drinking in 418 of the drug misusers from the NTORS study after four to five years 
and found that heavy drinking prior to treatment was a strong predictor of heavy 
drinking after treatment. The study also found that only a minority of the clients 
exhibiting the sample pattern of drinking was using alcohol as a substitute for opioids 
(Gossop et al., 2003). 
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Complications due to problematic alcohol consumption during MMT can include 
negative treatment outcomes, interaction between alcohol and methadone leading to 
increased medical complications – including the risk of death by overdose – and 
unstable therapeutic drug levels, which can cause patient non-compliance (Staiger et 
al., 2013). Stenbacka et al. (2007) conducted a cohort study and recruited 204 opioid 
dependent patients who were admitted to receive MMT. The patients were followed 
up between 1995 and 2000 to analyse the frequency of problematic alcohol 
consumption and the effect of their problematic drinking (both prior to and during 
MMT) on retention in treatment. Alcohol use was measured using biomarkers, 
including 5-hydroxytryptophol to 5-hydroxyindoleacetic acid ratio (5HTOL/5HIAA) 
(to indicate recent alcohol consumption), as well as any records of alcohol 
dependency treatment and any history of inpatient care. Only 96 participants were 
tested for urinary biomarkers, and about half (n=44) tested positive (> 15nmol/umol) 
at least once during the follow up. During the study about 12% of the participants 
were treated for alcohol related problems. The risk of relapse seemed to peak within 
four months after starting the treatment. The study also found an increase in relapse 
and early discharge in patients with related problematic drinking (Stenbacka et al.). 
1.3.3 Clinical and pharmacological considerations in alcohol and 
methadone co-dependence 
Alcohol and methadone have similar mechanisms of action leading to the depressant 
effects on the Central Nervous System (CNS). This could be a contributing factor in 
the adverse consequences of concurrent alcohol and methadone use, such as an 
overdose due to drug-drug interaction, which has been mainly acknowledged as a 
pharmacodynamic interaction (Best & Ridge, 2003). However, an overview of the 
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metabolic relationship between alcohol and methadone demonstrates a 
pharmacokinetic interaction that may negatively affect treatment outcomes. 
 
Depending on the amount and duration, alcohol consumption can influence hepatic 
metabolism, which in the case of patients receiving methadone maintenance treatment 
can affect the pharmacokinetics of methadone (Clark et al., 2006). Short-term 
consumption leads to a competitive inhibition of the CYP2E1 enzyme, whereas 
chronic use leads to its induction. CYP2E1 induction affects the metabolism of some 
drugs that an alcohol dependent patient may be consuming. For example, an increase 
in the clearance of warfarin, diazepam, rifampycin, pentobarbital, and alcohol itself 
occurs. This induction may lead to problematic interactions with other drugs when 
taken concomitantly. Chronic alcohol consumption, however, has been reported to 
induce production of the liver enzyme Cytochrome P450 2E1 – a key enzyme in the 
microsomal enzyme ethanol-oxidizing system (MEOS). When activated, it can lead to 
a 50% increase in alcohol metabolism. CYP450 2E1 induction causes an increase of 
alcohol elimination.  
In patients who are chronic alcohol consumers receiving methadone, hepatic 
pathophysiological changes can indirectly affect the metabolism of methadone and 
reduce the peak methadone concentration (Clark et al., 2006). Alcohol induces the 
activity of CYP3A4, causing drugs metabolised by this enzyme to decrease, including 
methadone (Klotz & Ammon, 1998; Kreek et al., 1980).  Methadone is metabolised 
by CYP3A4; therefore, the induction of the enzyme leads to a reduction in methadone 
and ethanol levels. This may explain why some patients find that their daily 
methadone dose does not remain effective for 24 hours and may need their dose to be 
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administered twice instead of once daily (Dyer & White, 1997). 
Unlike chronic alcohol consumption, acute alcohol consumption increases the peak 
methadone concentration. This is due to the different pathway by which alcohol is 
metabolised when consumed in high quantities over a short period of time. Acute 
consumption of alcohol can compete with methadone for the CYP3A4 enzyme. This 
can explain the higher methadone and alcohol levels in this patient population (Clark 
et al., 2006).  
The change in the rate of metabolism can directly affect other pharmacokinetic 
parameters, including the half-life and elimination time for both alcohol and 
methadone. Wolff et al. (2000) looked at the benefits of plasma methadone 
measurements in dosage adjustment during MMT and discussed the use of the 
methadone plasma levels to help with the clinical assessment of withdrawal 
symptoms since there has been evidence to indicate a correlation between methadone 
levels and participantive symptoms of withdrawal. However, the concomitant use of 
alcohol can be dangerous, as it can lead to drug-drug interaction affecting plasma 
methadone levels (Wolff et al., 1997). 
Although most of the literature addresses the effects of alcohol on methadone levels, 
Clark et al. (2006) assessed the impact of opioid substitution therapy on alcohol 
metabolism. Forty patients receiving opioid substitution therapy were given alcohol in 
two sessions. One session was pre-opioid pharmacotherapy and the second session 
was post-opioid therapy. The results indicated an interaction between ethanol and 
opioids after the administration of the opioid dose. Evidence of a dose-response 
relationship suggested that the blood alcohol concentration in opioid users was more 
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evident after the pre-opioid dose. The authors suggested that the interaction could be 
through microsomal enzymes and/or hormonal interactions (Clark et al.). 
El-Bassel et al. (1993) investigated predictors of alcohol dependence among 201 
patients in three MMT centres. The study found that metabolic processes in patients 
undergoing alcohol detoxification while being maintained on methadone could also 
be affected by previous hepatic pathophysiological changes caused by alcohol 
consumption, and that further adjustment of the methadone dose could be necessary to 
avoid distressing withdrawal symptoms in patients receiving MMT. Therefore, 
alcohol dependent patients receiving MMT might need different doses of methadone 
than patients who are not alcohol dependent (El-Bassel et al.). 
The complicated overlap between methadone and alcohol makes it challenging to 
fully differentiate the causes of withdrawal symptoms in dual dependent patients. 
Although a few studies have suggested that methadone plasma concentrations can be 
monitored to adjust treatment dosage (e.g., Wolff et al., 1997), measuring the 
withdrawal symptoms could be an indirect way to monitor the loss of the drug from 
the body, and this method has been used to assess the effectiveness of 
pharmacotherapy. Nonetheless, patients presenting with dual dependencies are more 
challenging to treat due to the potential that withdrawal symptoms from the two 
dependencies, as well as the effects of administered drugs such as benzodiazepine, 
could overlap and exacerbate withdrawal symptoms (de Wet et al., 2004). 
All in all, definitive knowledge exists regarding the link between alcohol and 
methadone pharmacodynamic interaction. Pharmacokinetic interaction has also been 
investigated in literature. However, a clear understanding of the mechanism by which 
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CYP3A4 contributes to this interaction remains unclear. Furthermore, the effects of 
alcohol on the ratio of EDDP/methadone have not been investigated. 
1.3.4 Illicit drug use during methadone treatment   
Methadone, when used in combination with certain drugs with depressant effects, 
such as alcohol and benzodiazepines, can result in an augmented action leading to an 
increase in its respiratory depressant effect and, in some cases, contributing to death 
(Caplehorn & Drummer 2002). In a study in New South Wales that examined 329 
heroin users, of those who overdosed, around 79% had consumed another drug 
around the time of overdose, and alcohol, benzodiazepines, and opiates were the most 
commonly used (Darke, Ross et al. 1996).  
Further studies investigating therapeutic plasma concentrations of methadone have 
indicated an overlap between therapeutic and fatal concentrations. For example, to 
achieve sufficient control of withdrawal symptoms required between 150–200 μg/L, 
and later during maintenance concentrations needed to be above 400 μg/L (Loimer et 
al., 1992). However, Worm et al. (1993) investigated cases of methadone-related 
deaths, which they divided depending on the level of alcohol present in the blood 
(>50 mg/100 ml). Methadone blood concentration was found to be 60–3090 μg/L 
(median, 280; mean, 430) in 59 cases with no alcohol. However, methadone 
concentrations in eight of the cases in which alcohol was detected ranged between 
90–650 μg/litre (median, 150; mean, 250). The study also investigated methadone 
concentrations in patients receiving methadone maintenance; in 62 patients 
methadone concentration was 30–560 μg/litre (median, 110; mean, 140), compared to 
methadone concentrations of 30–900 μg/litre (median, 90; mean, 150) in patients with 
alcohol present (Worm et al.) (see Table 1-11). 
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Table 1-11 Methadone Concentrations in Patient with or without Alcohol (Worm et 
al., 1993) 
Number of patients (n)  Alcohol Detection Methadone concentration  
59 No alcohol 60–3090 μg/L 
8 Alcohol detected 90–650 μg/L 
62  No alcohol 30–560 μg/L 
35  Alcohol detected 30–900 μg/L 
 
The toxicological report therefore confirms the overlap between clinical therapeutic 
concentrations and lethal concentrations, a finding that needs to be further 
investigated in order to avoid the overestimation of direct methadone-related deaths. 
Also, studies are yet to establish the levels of alcohol in blood in combination with 
methadone that can be fatal. In practice, guidelines recommend screening for alcohol 
using the breathalysers and drunk driving cut-offs, so that patients presenting with 
intoxication are not dispensed their daily dose of methadone to avoid concomitant 
effects of alcohol and methadone.   
1.3.5 Clinical guidelines for monitoring alcohol use during 
methadone treatment  
Clinical guidelines specifically address the lack of research in managing clients 
receiving methadone treatment who have concurrent alcohol problems. They 
recommend that risk assessments be undertaken in order to weigh the benefits of 
continuing methadone treatment. The National Treatment Agency for Drug Misuse 
(Towards Successful Treatment Completion: Good Practice Guide) addresses in detail 
the management of clients presenting with alcohol problems. The guidelines 
recommend that clinicians working with drug misusers be required to have ‘An 
awareness that alcohol misuse needs to be addressed alongside the management of 
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misuse of other drugs, competence at detecting problem drinking, an ability to give 
harm reduction and educational messages regarding misuse of alcohol, [and] 
competence to be able to manage alcohol misuse in drug misusers, including 
pharmacotherapies such as substitute prescribing.’ The guide also notes that ‘drug 
misusers who are dependent on alcohol should be offered alcohol interventions’ 
(NTA, 2010). Regarding the use of breathalysers, the recommendation is as follows: 
If a client is breathalysed and the breath alcohol level is found to be 
above the legal drink-drive limit, they should be advised not to drive. 
Further guidance on the regulations relating to driving under the 
influence of drugs or alcohol is available in the Driver and Vehicle 
Licensing Agency’s (DVLA) At a Glance Guide (DVLA, 2007) and 
also in appendix A7 of the Drug Misuse and Dependence: UK 
guidelines on clinical management (Department of Health and 
devolved administrations, 2007) (p.28).  
The guidelines also report on an audit that investigated the use of breathalysers among 
15 local practices in London. The audit indicated the following: 
Some services use breathalysers in an attempt to quantify the level of 
alcohol intoxication at the time of presentation and use this as a guide 
in the decision making process as to whether to dispense medication or 
not, sometimes refusing medication when the breathalyser reading is 
above a pre-determined point. In the audit all services stated a level of 
breath alcohol concentration above which they would not usually 
dispense or prescribe methadone – this limit ranged from 0 to 0.4mg/L, 
with most quoting the drink driving limit of 0.35mg/L. Six out of 15 
services said they would dispense above this level in certain clinical 
scenarios, such as high levels of alcohol dependence and a client 
presenting in a state of alcohol withdrawal despite being above the 
drink driving limit.  
Finally, the guidelines summarise best practices in managing alcohol intoxication or 
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dependence among clients receiving methadone treatment during supervised 
consumption (see Table 1-12). The guidelines highlight that the practice of using 
breathalysers to monitor alcohol intoxication supervised consumption is not routine in 
all clinical settings and that the alcohol drink driving limit is not always applied, with 
no scientific justification for the choice of these levels. 
Table 1-12 Guidelines for good practice in managing alcohol or benzodiazepine 
misuse in addition to an opioid prescripton (adapted fom the NTA 'Towards 






Risk assessment; increase key working; add 
psychosocial interventions; change to supervised 
consumption of opioid prescription; regular 
breathalyser testing 
Client dependent on 
alcohol/benzodiazepines 
Risk assessment; alcohol/benzodiazepine community or 
inpatient medically assisted withdrawal regimen; 
increased key working; add psychosocial interventions; 
change to supervised consumption of opioid 
prescription; regular breathalyser testing; conduct 
health assessment and reflect finding back to client; 
consider inpatient detoxification leading to residential 
rehabilitation 
 
1.3.6 Biological tools  
1.3.6.1 Alcohol screening using breathalysers during methadone 
maintenance 
Studies of alcohol consumption indicate that 0.7% of the ethanol consumed is 
excreted through breath (Ramchandani et al., 2001). It has also been shown that the 
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concentration of alcohol in blood is 2,448 times the concentration of alcohol in 
expelled air (Jones & Andersson, 2003). This relationship allows an individual’s 
blood alcohol concentration (BAC) to be measured indirectly, via the concentration of 
alcohol in his or her breath (BrAC). Although most countries report BAC as a 
mass/volume ratio, Germany and the Nordic countries report it as a mass/mass unit 
(Jones et al., 2010). In either case, the level of intoxication can be determined by the 
concentration. Table 1-13 presents the stages of alcohol intoxication according to 
NIAAA (1994). 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) 
(American Psychiatric Association, 1994) lists behaviours that define intoxication, 
including recent ingestion of alcohol, clinically significant problematic behavioral or 
psychological changes (e.g., inappropriate sexual or aggressive behavior, mood 
liability, and impaired judgment) that developed during, or shortly after, alcohol 
ingestion, One (or more) of the following signs or symptoms developing during, or 
shortly after, alcohol use: (slurred speech, incoordination, unsteady gait, nystagmus, 
impairment in attention or memory, stupor or coma), and the signs or symptoms are 
not attributable to another medical condition and are not better explained by another 
mental disorder, including intoxication with another substance. From the definition of 
intoxication and the stages mentioned above, it is clear what challenges specialists 
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Table 1-13 Stage of Alcohol Intoxication (adapted from NIAAA, 1994) 
BAC   
(g/100 ml of 
blood or g/210 l 
of breath) 
Stage Clinical symptoms 
0.01 - 0.05 Subclinical Behaviour nearly normal by ordinary observation 
0.03 - 0.12 Euphoria Mild euphoria, sociability, talkativeness; increased self-
confidence; decreased inhibitions; diminution of attention, 
judgment and control; beginning of sensory-motor 
impairment;  loss of efficiency in finer performance tests 
0.09 - 0.25 Excitement Emotional instability; loss of critical judgment;  impairment of 
perception, memory and comprehension; decreased sensory 
response; increased reaction time; reduced visual acuity; 
peripheral vision and glare recovery; sensory-motor 
incoordination; impaired balance; drowsiness 
0.18 - 0.30 Confusion Disorientation, mental confusion; dizziness; exaggerated 
emotional states;  disturbances of vision and of perception of 
color, form, motion and dimensions 
Increased pain threshold;  increased muscular incoordination; 
staggering gait; slurred speech;  apathy; lethargy 
0.25 - 0.40 Stupor General inertia; approaching loss of motor functions; markedly 
decreased response to stimuli;  marked muscular incoordination; 
inability to stand or walk vomiting; incontinence 
Impaired consciousness; sleep or stupor 
0.35 - 0.50 Coma Complete unconsciousness; depressed or abolished reflexes; 
subnormal body temperature; incontinence 
Impairment of circulation and respiration; possible death 
0.45 + Death Death from respiratory arrest 
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During methadone dispensing, identifying intoxication is important alongside 
identifying and managing patients presenting with alcohol problems. The breathalyser 
has been used in some settings, adopting roadside cut-off limits to identify 
intoxication. In roadside testing, it was not until 1967 that a defined measure of 
alcohol limit (80 mg/100 ml) was implemented as part of the Road Safety Act in the 
UK (British Medical Journal, 1967). It has remained unchanged since then. Alcohol 
screening using a breathalyser is also used in emergency care settings. 
Breathalysers are used in MMT, both for research purposes (Bickel et al., 1989; 
Helander et al., 1999; Marcovici et al., 1980) and during supervised consumption to 
screen for recent alcohol intake. One of the first studies to use breathalysers in a 
research setting among methadone maintenance patients was that of Marcovici et al., 
which investigated the relationship between methadone and problematic alcohol 
consumption in 60 male drug dependents starting methadone maintenance. The 
breathalyser was used as a tool to monitor participants’ drinking, and results indicated 
that stabilization was not etiologically associated with alcohol abuse (Marcovici et 
al.).  
A more recent study by Clark et al. (2006) used breathalysers to reflect methadone 
metabolism, investigating whether there was a dose-dependent effect of opioid 
substitution therapy on BAC by comparing BAC resulting from a standard dose of 
alcohol before pharmacotherapy with that after pharmacotherapy dose administration. 
The study also examined whether regular consumption of methadone, LAAM, or 
buprenorphine resulted in differential effects on BAC before/after dosing in opioid 
substitution therapy. The authors recruited forty opioid substitution patients, with 14 
receiving methadone, 14 receiving LAAM, and 12 receiving buprenorphine. All 
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participants received 14.7 g/70 kg of alcohol and the BAC was later measured using a 
LION SD-2 breathalyser at 30, 55, and 80 minutes. Results indicated that there was an 
evident effect of the opioid on the alcohol levels in the first 1–2 hours after the opioid 
dose, leading to a reduction in BAC in the opioid users compared to the pre-opioid 
dose. The results also indicated that although the BAC in the control group was higher 
than in the patients receiving opioids, the difference was not significant (Clark et al. 
2006). 
Helander et al. (1999) compared the efficacy of using breathalysers to testing the 
urinary 5HTOL/5HIAA ratio as a biomarker of drinking. The study aimed to estimate 
the incidence of current alcohol consumption among methadone maintained 
outpatients. Results indicated that breathalyser tests were positive in only four of the 
177 participants who reported alcohol use the previous day, which ranged between 
10–230 g. However, 17 participants had positive urinary 5HTOL/5HIAA ratios 
(Helander et al.). 
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Table 1-14 Studies that have used breathalysers in methadone maintenance 
Title Objective Breath-
alyser  
Cut-off limit Results Author, 
Year 
Risk for Alcoholism 
United and Methadone 
States Treatment. A 
Longitudinal study 
 
MAST, breathalyser, laboratory values and 
interviews, and NCA criteria were all used 




Not specified No significant changes were 
observed in alcohol 
consumption in problem or 
normal drinkers after 6 





Comparison of urinary 
5-hydroxytryptophol, 
breath ethanol, and 
self-report for 
detection of recent 
alcohol use during 
outpatient treatment: a 
study on methadone 
patients 
 
To compare the results of breath-ethanol 
testing and a sensitive biochemical marker 
of recent drinking, the urinary 
5HTOL/5HIAA ratio, with the results of a 
confidential self-report questionnaire, and, 
furthermore, to estimate the incidence of 




ter S-D2  
The detection limit of 
the method is ~0.01 
g/l (~ 0.22 mmol/l). 
The breath-ethanol 
device was tested and 
calibrated by the 
manufacturer’s local 
representative once 
every third month. 
 
59 of 190 methadone-
maintained outpatients 
(31.1%) had been drinking 
alcohol on the previous day 
according to self-report data 
and the results of urinary 
5HTOL/ 5HIAA testing, but 
only four identified by 
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To the present author’s knowledge, no study has directly investigated the use of the 
breathalyser as a tool in methadone maintenance supervised consumption to screen for 
alcohol use using the drunk driving limit. However, research investigating the impact of dual 
use of alcohol and methadone has been well established in linking the concomitant effects 
that can lead to fatal overdose.  
Furthermore, alcohol screening using breathalyser has been linked with road safety and it was 
in 1967 that a defined measure of alcohol limit of 80 mg/ 100 ml using breathalysers was 
implemented as part of the Road Safety Act in the UK and remains the unchanged since then. 
A further understanding on how methadone can influence driving can help in understanding 
the rationale behind using brethlysers in monitoring patients presenting to methadone 
maintenance clinics. The following section reviews the relationship between methadone and 
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Chapter 2 STUDY DESCRIPTION   
This chapter describes the rationale and purpose underlying this thesis. It explains the overall 
study design, including the criteria used for the selection of participants, data collection 
procedures, and measures employed. The chapter also outlines both the laboratory analysis 
procedures and the statistical analyses that were conducted on the samples, as well as 
describing the research methods employed in the three studies. 
2.1 Rationale 
Methadone is acknowledged as an effective pharmacological substitution treatment for heroin 
dependence. However, patients presenting to addiction treatment services usually have 
multiple substance misuse issues, as well as both mental and physical health and social 
problems. Excessive alcohol use in individuals receiving MMT is well established as a 
challenge to clinical treatment.  
While methods for managing single drug dependence are well established, the treatment of 
co-dependents, i.e., patients who are receiving MMT who also present with problematic 
alcohol use, has not been fully investigated. Therefore, further research is needed in order to 
explore the efficacy of current management techniques for patients with dual dependence. 
Research of this kind can help to develop new guidelines that are tailored to the complex 
dual-dependent population and thus lead to better treatment outcomes. This thesis seeks to 
explore ways in which to help clinicians improve the treatment outcomes for this group of 
patients by investigating biological tools that can be used to monitor the treatment process. 
In current clinical practice, treatment outcomes tend to be assessed in terms of patient 
retention and cessation of the use of illicit drugs while in treatment.  While these aspects of 
any pharmacotherapeutic programme are valuable, they do not provide an objective 
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indication of the efficacy or efficiency of methadone as a pharmacological agent. The aim of 
this research was to investigate biological markers that can be used to monitor methadone 
treatment and to determine whether their use can be beneficial to clinical treatment outcomes. 
2.2 Purpose of the study 
The aim of this threefold study was to investigate the potential for utilising biological tools 
with clients receiving MMT as an objective measure of the efficacy and efficiency of 
methadone treatment.  
2.3 Research Questions (Premise of the Studies) 
The research questions or premises that led to the experiments conducted for the study, and 
hence to the results and discussion presented in the chapters below, were as follows: 
1. A study to explore the relationship of methadone with its primary metabolite EDDP 
and to determine whether the EDDP:methadone ratio is useful as a biomarker in 
assessing compliance among patients receiving methadone treatment (Study 1) 
a. A secondary study to explore the impact of hazardous alcohol use on the 
EDDP:methadone ratio compared to a methadone control group 
b. A study to explore the relationship of methadone and its primary metabolite 
and determine if the EDDP:methadone ratio changes during the induction 
period (Study 1.b) 
2. A study to explore whether the urinary alcohol metabolites Ethyl glucuronide (EtG) 
and ethyl sulphate (EtS) are useful in identifying recent alcohol consumption during 
methadone treatment (Study 2) 
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3. A study to explore the assessment of recent alcohol consumption using the 
breathalyser test and to determine whether the established cut-off level is appropriate 
as a tool for clinical decisions regarding the dispensing of methadone (Study 3) 
2.4 Null Hypotheses  
1. There will be no variation in the EDDP:methadone ratio among patients receiving 
methadone treatment, irrespective of the daily methadone dose prescribed. (Study 1) 
2. The urinary alcohol metabolites EtG and EtS are not useful in identifying recent 
alcohol consumption during MMT. (Study 2) 
3. The breathalyser test is not useful as a clinical guide for decisions regarding the 
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Chapter 3 METHODOLOGY 
3.1 The research environment   
The research for this thesis was carried out in an area of approximately 11 square miles in 
South East London. Much of this region is taken up by the London Borough of Southwark, 
which is the second largest inner borough in London. It is divided into four localities:  
x Bermondsey & Rotherhithe  
x Borough & Walworth  
x Peckham & Camberwell  
x Dulwich  
Southwark has a diverse population of approximately 288,200, of which the predominant 
ethnic group is White British (52.6%). According to the latest available figures, 
approximately 43% of Southwark’s registered population falls within the ages of 25 to 44 
years, compared to 28% for England as a whole. 
According to the 2007 Index of Multiple Deprivation (IMD), Southwark is the ninth most 
deprived borough in London, although 45% of the population in Southwark is considered 
highly qualified for employment, which is well above the national average (29%). 
Approximately 14,000 people are of working age and are estimated to be unemployed in 
Southwark. Southwark also has 13% of residents who are considered to have no job 
qualifications, a little over the national average of 12%. 
In 2009 it was estimated that 12,168 individuals aged 18 and over in Southwark were 
drinking at higher risk, while 6,199 individuals were dependent drinkers. From 2011 to 2012, 
4,818 alcohol-related hospital admissions were reported in Southwark, which was an increase 
of 54% over the period from 2008 to 2009. Regarding substance misuse, NHS Southwark 
estimated in 2009 that more than 3,000 individuals in the borough used opiates and over two-
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thirds of these individuals also used crack cocaine. Of these, more than 1,000 people were 
estimated to be using drugs by the intravenous route and therefore to be in need of access to 
needle exchange services. As a result, the borough of Southwark has set a priority on 
commissioning substance misuse services from a range of providers. 
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Figure 3-1 Map with locations of supervised consumption of methadone services in 
Southwark (Southwark Council, 2011). 
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At present, NHS Southwark commissions a supervised consumption service from community 
pharmacies and other providers in order to ensure compliance with an agreed action plan. The 
service includes dispensing opioid substitution medication in specified instalments and 
ensuring that each supervised dose is correctly consumed by the patient. Thirteen community 
pharmacies (21% of those in Southwark) provide a supervised opioid substitution service, 
providing either methadone or buprenorphine to clients as prescribed by GPs or substance 
misuse clinics. Figure 5-1 shows a map of Southwark with locations offering supervised 
consumption, including the Blackfriars Road Community Clinic, where the study was 
conducted. 
3.2 Setting 
The South London and Maudsley (SLAM) NHS Foundation Trust is the main provider of 
substance misuse and mental health treatment for South-East London. Recruitment was 
carried out by one of the Trust’s Community Drug and Alcohol Teams (CDAT) at 
Blackfriars Road Clinic. CDAT was established in 1990 as part of the Lewisham and Guys 
Health Service. In 1999 the two health services were merged as part of the creation of 
SLAM; however, two community treatment facilities, Marina House and Blackfriars Road 
Clinic, which continued to operate from two separate sites until community drug services at 
Marina House were discontinued in 2010.  
Blackfriars Road Clinic is currently part of the Southwark Treatment and Recovery 
Partnership (STARP). The Clinic provides a range of services, including assessment, advice, 
referrals, treatment interventions (including needle exchange) and aftercare for individuals 
suffering from substance misuse-related problems. The site also provides opioid substitution 
therapy. The service includes a daily duty service (1pm to 4:30pm), except on Tuesdays. 
Daily brief assessment is available between 9:30am and 12:15pm. Also, methadone 
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dispensing is available to some clients daily between 10am and 12pm, Monday through 
Friday. 
3.3 Ethical approval 
Ethical approval for the research was sought from the NHS Research Ethics Committee 
(Research Ethics Committee of London-Fulham (12/LO/0762)) (see Appendix A) to ensure 
that the participants and the researcher were protected and that the research was viable and 
ethical. All participants were provided with an information sheet that outlined the purpose of 
the study and the method of data collection (see Appendix B). The information sheet also 
explained that all data received were confidential and that participants can withdraw from the 
study at any time with no explanation required and no impact on their future treatment. The 
information sheet also outlined the incentive in the form of a £10 food voucher to be 
provided to participants after the initial interview, as well as £5 for each consecutive 
interview. The participants were then asked to sign a consent form stating that they 
understood the information sheet and that they agreed to take part in the study. An 
application for extending the end date of the study was granted to ensure further data 
collection for Study 1.b. 
3.4 Research Plan 
The research consisted of a series of three cross-sectional studies designed to examine the 
usefulness of a variety of monitoring tools in the assessment of methadone treatment 
compliance and/or outcomes, as follows:  
x Study 1.a investigated the utility of urinary methadone to EDDP ratio in assessing 
compliance with daily methadone treatment. Study 1.b is a case series study 
investigated urinary methadone to EDDP ratio in assessing the compliance in daily 
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methadone treatment and change of the ratio during induction period. 
x Study 2 investigated the utility of alcohol biomarkers Ethyl glucoronide (EtG) and 
Ethyl Sulphate (EtS) in screening for recent alcohol consumption in patients 
collecting their daily methadone doses.  
x Study 3 investigated the drink driving cut-off limit used in connection with the 
alcohol breathalyser as a screening tool for patients presenting with problematic 
alcohol consumption.  
3.5 Recruitment  
Recruitment took place at the Blackfriars out-patient clinic. Potential participants were 
identified by key workers in the clinic and were subsequently approached by the researcher. 
This most often occurred when participants were at the clinic to receive their daily dose of 
methadone mixture or to collect their methadone mixture prescriptions. Participants would be 
undergoing supervised cmethadone onsumption and when they were collecting their 
methadone prescription participants were receiving their methadone dose supervised at the 
clinic. During a short initial meeting, the researcher briefed potential participants about the 
study. If they expressed an interest in taking part, the participants were escorted to a private 
room, where they were invited to read the information sheet and asked to provide written 
consent (see Appendix C). Both the information sheet and the consent form stated that the 
research was confidential and that there would be no further contact between the researcher 
and participants after the completion of the questionnaire.   
Although there was a potential of interest if participants were presenting with withdrawal 
symptoms, the researcher accommodated further weekly sample collection by allowing the 
participant to come a day after or before the inteded day of collection.  
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A random sample of participants reported methadone dose was checked with their patient 
journey records to ensure that the dose matched and to avoid conflict in the results.   
3.6 Statistical analysis 
A power analysis was employed to establish the number of participants needed in each group 
to make the study statistically significant. Based on previous research, 31% of patients 
receiving methadone were understood to have problematic alcohol consumption (Senbanjo et 
al., 2007). Thus, study B (methadone and alcohol drug interaction) it was estimated that 
approximately one-third of the participants would present with dual dependence (Srivastava 
et al., 2008). Using the Raosoft online Sample Size Calculator, given a 5% margin of error 
and a confidence level of 95%, and with an estimated population size of 200, the minimum 
recommended sample size to achieve a meaningful result was estimated to be 132 patients. 
1.6 Data analysis  
Data analysis was conducted using the Statistical Package for the Social Sciences (SPSS), 
Windows® version 15.0. Data were collected, coded and transferred to SPSS. The descriptive 
data, i.e., the demographic and background information, as well as the characteristics of licit 
substances and prescribed medication use, were analysed by calculating the frequencies, 
standard deviation, means and percentages of participant responses. Basic demographic and 
background information, including patients’ age, sex, ethnic background and employment 
status, were compared using a chi-square test. A t-test was used to compare the continuous 
variables, including the severity of withdrawal symptoms at discharge and admission (see de 
Wet et al., 2004). When data were not normally distributed, a non-parametric test was 
utilised. A Mann-Whitney U test was used to compare distribution of continuous unpaired 
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variables, while a Wilcoxon signed rank test was used to compare the distribution of paired 
variables. Data that were missing were excluded from the analysis.  
3.6.1 Inclusion criteria 
Inclusion criteria differed slightly for each study, but all participants had to meet the 
following criteria: 
x Diagnosed with heroin/opioid dependence  
x Receiving methadone maintenance treatment for at least four weeks 
x Between 18 and of 65 years of age. 
 
3.6.2 Exclusion criteria 
The following were excluded from all studies: 
x Pregnant participants were not recruited due to different pharmacokinetics of 
methadone 
x Participants unable to understand English 
x Participants who were under the influence of substances to a debilitating degree that 
could affect their responses to the questionnaire or present a risk to the safety of the 
researcher, themselves or others 
x Participants receiving opioid substitution treatment other than methadone 
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3.7 Study 1.a: Urinary methadone to EDDP ratio in patients receiving 
methadone substitution maintenance treatment   
3.7.1  Design and Purpose 
Using a cross-sectional prospective cohort design, Study 1 investigated the relationship 
between methadone and EDDP during fixed daily dosing in patients receiving methadone 
substitution maintenance treatment in order to assess whether the ratio of EDDP to 
methadone could be used effectively as a biomarker for methadone compliance. The setting, 
inclusion, and exclusion criteria have been described above unless stated otherwise (see 
sections 5.5 and 5.10). 
3.7.2  Recruitment and Procedures 



















Study 1 (n=60) 
Methadone substitution 
maintenance group (MMT)  
AUDIT score < 8 
n=30 
 
Hazardous alcohol use group 
(HAU) 






All recruited participants completed a 
questionnaire and provided a urine 
sample at day 1 
 
 
Three more interviews were arranged 
and included a short questionnaire 
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Recruitment took place in the outpatient clinic, where the participants were identified by the 
clinical consultant or members of staff. The researcher approached potential participants 
(after consultation with the clinic team) and briefed them about the study. Participants in the 
study were first asked to complete a demographic and background information questionnaire 
(see Appendix D). This questionnaire included questions related to age, route of referral, 
ethnicity, and gender. The questionnaire also included questions about licit drug use, 
including cigarettes/tobacco and alcohol use. This was followed by a urine sample collection. 
The interview and the urine sample collection took 30 minutes in total. Depending on which 
study the participant belonged to, further appointments were arranged. 
Participants were typically re-interviewed during a subsequent visit to the clinic to collect 
their methadone prescriptions or to receive their daily methadone dose. A shorter version of 
the questionnaire was administered, which included a self-report of methadone and alcohol 
use in the past 24 hours and the use of any illicit drugs. A SOWS questionnaire was also 
included, a urine sample was collected and appointments for subsequent interviews were set. 
3.7.3  Research Tools 
Each participant was asked, with the assistance of the researcher, to complete a questionnaire 
that covered general demographic information (Appendix D), including questions related to 
age, route of referral, ethnicity and gender. The questionnaire also included questions about 
licit drug use, including cigarettes/tobacco and alcohol use, as well as questions regarding 
methadone intake and dosage. 
Participants were also asked to complete the following validated research tools:  
The Alcohol Use Disorders Identification Test (AUDIT)  
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The Alcohol Use Disorders Identification Test (AUDIT) has been widely used as a screening 
tool to determine level of alcohol consumption. Developed by The World Health 
Organization (WHO), the AUDIT is a self-report instrument that is used to identify harmful 
and hazardous alcohol use in the past year (Saunders et al., 1993). Although the AUDIT was 
developed for use with primary care patients, the instrument’s use has been expanded to 
include the prediction of alcohol withdrawal symptoms (Dolman et al., 2005). All of the 
items address questions related to the preceding year, with the exception of the first two. The 
first three questions assess alcohol intake. Questions 4 to 6 enquire about aspects of alcohol 
dependence. Questions 7 and 8 address adverse reactions to drinking, and the final questions 
address alcohol-related problems.  
The items are scored on a scale from 0 to 4, on which participants report the frequency of 
various actions or effects, resulting in a total possible score of 40 (see Allen et al., 1997). The 
AUDIT total score helps healthcare professionals determine whether an individual’s alcohol 
consumption is at hazardous level (8-15), harmful level (16-19), or alcohol dependent (20 or 
more). Studies have confirmed the validity and sensitivity of the AUDIT test (Allen et al., 
1995).  
A modified shorter version of the AUDIT, which consists of the first three questions, is 
known as the AUDIT-C. Each item is scored on a scale from 0 to 4, resulting in a total 
possible score of 12. In men, a score of 4 or more is considered positive for identifying 
hazardous drinking or alcohol use disorders, while a score of 3 or more in women is 
considered positive for identifying hazardous drinking (Bush et al., 1998).  
Short Opiate Withdrawal Symptoms Scale (SOWS) 
Participants also completed the Short Opiate Withdrawal Symptoms Scale (SOWS), a ten-
item version of the Opiate Withdrawal Scale (OWS). SOWS has been validated as an 
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effective tool for assessing opiate withdrawal symptoms in clinical settings, as well as for 
research purposes, and it has been used during detoxification (Bearn et al., 1996; de Wet et 
al., 2004; Gossop et al., 1990). The ten symptoms evaluated by SOWS include feeling sick, 
stomach cramps, muscle spasm or twitching, feeling of coldness, heart pounding, muscle 
tension, aches and pains, yawning, runny eyes, and insomnia and other sleeping problems.  
The scoring of the tool is based on a numerical Likert rating scale, with 0, 1, 2, and 3 used to 
designate, respectively, none, mild, moderate, and severe symptomology. Hence, the 
maximum score obtainable, indicating the highest level of severity of withdrawal symptoms, 
is 30.   
The Treatment Outcome Profile (TOP) 
The Treatment Outcomes Profile (TOP) was developed by the National Treatment Agency 
for Substance Misuse (NTA). It is a brief instrument that consists of twenty reliable, valid 
scale and combined-item period prevalence measures. It records the frequency of illict drug 
use 28 days before treatment. The TOP records four main areas affecting the opioid 
dependent’s life: 
1 Substance use: the participant is asked about the number of days of use of alcohol, illicit 
opiates, crack cocaine, cocaine powder, amphetamines, cannabis and any other substance use 
in the past 28 days. During the development of TOP, estimates of the total quantity used on a 
typical day were recorded as follows: alcohol in standard drinks (1 UK unit = 10 ml ethanol 
by volume); verbatim reports of quantity used or money spent, based on estimated averaged 
street prices for heroin (£10 = 0.2 g); crack cocaine (£10 = 0.1 g), powder cocaine (£50 = 1.0 
g), amphetamine sulphate (£10 = 1 g), cannabis (number of ‘joints’ and/or pipes) and 
benzodiazepines (converted to 5-mg diazepam equivalents). The participant was also asked 
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about the number of injecting days in the past 28 days and about the prevalence of 
needle/syringe sharing. 
2 Health: Includes a participantive rating score between 0-20 of physical and psychological 
health status.  
3 Crime: participants are asked about the number of days they have committed shoplifting, 
other theft or drug selling, as well as about the prevalence of vehicle, property and fraud and 
assault/violent crime.  
4 Social functioning: participants are asked to rate their quality of life on a scale between 0-
20. They are asked about the number of days of paid work and attendance at 
education/training and about housing problems or risk of eviction (Marsden et al., 2008). The 
TOP also measures change and progress in these key areas at different stages of treatment in 
order to assess treatment effectiveness and progress made; outcomes at different stages can 
be measured by completing the TOP at a specific stage of the treatment. At the start of 
treatment, the TOP can provide important information about clients’ drug use before 
treatment and can act as a baseline for comparison with subsequent TOPs.  During the 
treatment, the TOP can be used as part of good practice for regular care plan reviews that are 
usually completed in 12 week (3 month) cycles. 
NDTMS requires a TOP to be reported every 26 weeks (6 months). At the end of the 
treatment, it is recommended that a TOP be completed within two weeks either side of a 
client leaving structured treatment. The TOP form may also be completed after a client leaves 
treatment, which will assist providers to measure the longer-term impact of their treatment 
(Marsden et al., 2010). 
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In this study, the TOP was used during treatment to assess methadone treatment compliance 
by collecting information related to the patient’s illicit drug use in the past month, including 
injecting behaviour. Other parameters reported, including crime, psychological wellbeing and 
housing issues, were also documented. 
3.8 Study 1.b: Methadone:EDDP Ratio During Induction   
3.8.1  Design and Purpose 
Using a case series study, the ratio of methadone:EDDP was measured during fixed daily 
dosing in patients who began receiving methadone substitution maintenance treatment 
(induction period) in order to assess whether the ratio of EDDP:methadone could be used 
effectively as a biomarker for methadone compliance and whether the ratio changes during 
the induction period. The setting has been described above unless stated otherwise (see 
sections 5.5). 
3.8.1.1 Inclusion criteria 
Participants had to meet the following criteria: 
x Diagnosed with heroin/opioid dependence  
x Started receiving methadone maintenance treatment in the past 24 hours 
x Between 18 and of 65 years of age. 
 
3.8.1.2 Exclusion criteria 
The following were excluded from this study: 
x Pregnant participants were not recruited due to different pharmacokinetics of 
methadone 
x Participants unable to understand English 
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x Participants who were under the influence of substances to a debilitating degree that 
could affect their responses to the questionnaire or present a risk to the safety of the 
researcher, themselves or others 
x Participants receiving opioid substitution treatment other than methadone 
x Participants suffering from severe psychiatric problems 
x Participants who have been receiving methadone for more than 24 hours. 
3.8.2 Recruitment and Procedures 
Recruitment took place in the outpatient clinic, where the clinical consultant or members of 
staff identified the participants who just started receiving their daily methadone on the 
previous day. The researcher approached potential participants (after consultation with the 
clinic team) and briefed them about the study. Participants in the study were first asked to 
complete a demographic and background information questionnaire (see Appendix D). This 
questionnaire included questions related to age, route of referral, ethnicity, and gender. The 
questionnaire also included questions about licit drug use, including cigarettes/tobacco, and 
alcohol use. This was followed by a urine sample collection. The interview and the urine 
sample collection took 30 minutes in total. The participants were asked to meet the researcher 
when they visit the clinic for their daily methadone dose for the next 13 days. Participants 
were re-interviewed during the subsequent visits to the clinic and a shorter version of the 
questionnaire was administered (see study 1.a). 
The research tools are the same as the ones used in study 1.a (see Appendix D). 
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3.8.3 Biological samples   
A urine sample was collected after the interview. All samples were collected at trough, i.e., 
before administration of the daily dose of methadone, in 20 mL universal tubes. One sample 
was collected weekly from each participant for four weeks. Participants were provided with a 
urine bottle and were asked to void unobserved. The urine samples were frozen in the 
laboratory at -20° C until analysis. At the end of the interview, each participant was assigned 
an appointment for his or her next interview. The whole procedure, including the structured 
interview, took 30-40 minutes. 
Quantifying methadone concentrations in biological fluids depends upon the application of 
specific, sensitive and rapid analytical methods (Fernandez et al., 2010). Various separation 
methods have been developed, such as gas chromatography (GC), liquid chromatography 
(LC) and high performance liquid chromatography (HPLC), which can be combined with 
such detection methods as ultraviolet light (UV) and mass spectrometry (MS) (Shakleya, 
2007). Capillary electrophoresis is a recently developed method that has not yet been used 
extensively.  
1) Gas Chromatography (GC) 
Coupled with other methods of detection, including nitrogenous phosphorous, electron 
capture and mass spectrometry (GC/MS) using positive chemical ionization (PCI), has 
proven successful in the analysis of methadone and its metabolite (EDDP) in serum, plasma 
or whole blood (Gunnar et al., 2006). However, the application of GC requires an extensive 
derivatisation of the methadone sample, which can be considered a drawback. Gunnar et al. 
have developed methodologies to make GC-based techniques with MS faster and more cost-
efficient in determining levels of methadone and its metabolite in the blood, and their results 
indicate a good linearity and accuracy with an LOQ of 25 ng/ml. Earlier, Bermejo et al. 
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(1998) used GC/MS to determine methadone levels in urine and plasma from patients under 
detoxification treatment and achieved mean recoveries of 64.30% from urine and 79.03% 
from plasma. However, recent studies have used LC as the method of choice in determining 
methadone in plasma for various purposes, including in TDM.  
2) High performance liquid chromatography (HPLC) 
Compared to GC, the HPLC analytical method requires less sample preparation, which 
makes this method more practical and appealing.  Like GC, HPLC methods, coupled with 
MS and UV detectors, have been successfully applied in measuring methadone in the blood, 
serum and plasma (Rook et al., 2005). However, HPLC/MS is considered the method of 
choice for TDM, especially when monitoring MMT patients, because of the possibility of co-
medication and the consumption of illegal drugs in this population (Baumann et al., 2004; 
Fernandez et al., 2010).  
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Table 3-1 Summary of Studies that Conducted Methadone Analysis using LC Analytical Methods and Applying Various Chromatography 
Conditions 
Author Matrix Method Sample preparation Column Other chromatography conditions 
Rook et al., 2005 Plasma LC–
MS/MS 
Solid phase extraction 
using mixed mode 
sorbent columns 
(MCX Oasis) 
Reversed phase Zorbax column with a 
gradient 
Mobile phase: consisting of ammonium formate (pH 4.0) and acetonitrile.  
The run time was 15 min.  
The method was validated over a concentration range of 5–500 ng/mL for all 
analytes. 
Fernández et al., 2005. Plasma HPLC–
DAD 
 250 mm × 4.6 mm i.d. XTerraRP8 column of 
5 μm particle size 
Mobile phase: was acetonitrile −0.02 M phosphate buffer pH 6.53 and eluted 
in the gradient mode. 
 
 





using a modification 
of the ElSohly method. 
Synergi Hydro-RP 80A (50 mm × 2.0 mm, 
4 μm), fitted with a C18 ODS Octadecyle 
(4.0 mm × 2.0 mm) guard column. 
Mobile phase:(gradient elution), consisting of (A) 10 mM ammonium 
formate in water with 0.001% formic acid (pH 4.5) and (B) acetonitrile, at a 
flow rate of 300 μL/min. 
Quintela et al., 2006. Plasma LC/MS Automated solid-phase 
extraction using 
Gilson Aspect XL 
3.5 μm (30 mm × 2.1 mm I.D.) reversed-
phase column  
Mobile phase: was a gradient of acetonitrile in 0.1% formic acid 
programmed as follows: 18% acetonitrile during 0.5 min, increased to 60% 
in 2 min and decreased to 18%. 
Shakleya et al., 2007. Plasma LC–APCI-
MS/MS 
 Synergi Hydro-RP 80A (50 mm × 2.0 mm, 
4 μm) column with an identically packed 
guard column (4 mm × 2.0 mm)  
mobile PHASE: Gradient elution with (A) 10 mM ammonium acetate in 
water, 0.001% formic acid (pH 4.5) and (B) acetonitrile at a flow rate of 
200 μL/min was used with a gradient program of 40% B for 2 min, 
increasing to 90% over 7 min and hold for 2 min. The HPLC column was re-
equilibrated for 6 min, giving a total run of 17 min.  




Solid Phase extraction 
using Waters Oasis 
MCX 60 mg cartridge. 
Tosoh TSK-Gel Amide-80 3 μm 
(250×4.1 mm) HILIC carbamoyl phase 
column 
The mobile phase: isocratic mobile phase consisted of 28:72 v/v 
acetonitrile + 0.01% formic acid/3 mM ammonium formate in water + 0.01% 
formic acid. 
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3.8.4 Analysis of urinary methadone and EDDP 
Urine samples were transported by the researcher from the clinic in a courier bag to 
the laboratory at the Institute of Pharmaceutical Science at King’s College London 
and were stored at -20o C.  Urine samples were analysed using High Performance 
Liquid Chromatography and Ultraviolet Detector (HPLC/UV) to measure methadone 
and EDDP concentrations. 
3.8.4.1 HPLC/UV determination of urinary methadone and EDDP  
The method originally developed by Wolff et al. (1997) for analysing methadone and 
EDDP in urine was optimized using HPLC/VU based on the methodology for liquid-
liquid extraction (LLE) and HPLC-UV.  The method has been slightly modified. 
3.8.4.2 Materials and Methods 
Reagents 
Methanol, acetonitrile, formic acid and propan-2-ol were purchased from Fisher 
Scientific (Loughborough, UK). Ammonium formate, 1-chlorobutane, ammonium 
hydroxide, 1,2-dichloroethane and ammonium perchlorate were obtained from Sigma-
Aldrich (Steinheim, Germany). Sodium hydrogen carbonate, sodium carbonate and 
ammonium acetate were obtained from BDH Laboratory Supplies (Poole, UK). Ultra-
pure water (UPW) (18.2 MΩ∙cm) was obtained from a Millipore Milli-Q water 
purification system (Bedford, MA, USA). (±)-Methadone hydrochloride (MTD), 2- 
ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine perchlorate (EDDP) and Benzhexol 
(BZX) internal standard were purchased from Sigma-Aldrich. 
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 Specimen collection 
Pre-dose urine samples (20 ml) were collected from clients receiving methadone 
substitution maintenance treatment. The samples were transported by the researcher 
from the clinic in a courier bag to the laboratory at the Institute of Pharmaceutical 
Science at King’s College London and were stored at -20o C. 
Analytical methods  
Stock solutions of MTD, EDDP and internal standard BZX were prepared at 1 mg/mL 
in methanol and stored at 4° C. Working solutions were prepared each day containing 
each component by appropriate dilution, with UPW, methanol or urine, and pH 
adjustments made depending on the analysis. Mixed standards were prepared at 10 to 
500 ng/mL (n=11) in urine and UPW for calibration studies. Replicate samples at 50 
ng/mL (n=6) were prepared at pH 7, 11 and 3 by adjustment with ammonium formate 
or formic acid, to determine recovery. Standard solutions of analytes at varying 
concentrations were prepared in UPW or methanol for chromatographic peak 
identification. 
Liquid-liquid Extraction 
A buffer solution was prepared for Liquid-Liquid Extraction (LLE). The buffer at pH 
10 was prepared by mixing 1 mol/L sodium carbonate in UPW with 1 mol/L sodium 
hydrogen carbonate (7:3), and the ratio adjusted, if necessary, to yield a solution of 
pH 10. Water saturated 1-chlorobutane was prepared by addition of 100 mL 1-
chlorobutane to a small amount of water in a separating funnel and shaken well until 
saturation was achieved. 
The extraction procedure was performed by adding 0.5 mL sodium carbonate buffer 
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to 15 mL glass conical tubes with glass stoppers. Then, 2 mL samples were aliquoted 
to the buffer before vortex mixing for 20 seconds. In a fume hood, 5 mL of water-
saturated 1-chlorobutane was added. The tubes were stoppered, transferred to a tube 
shaker and mixed mechanically for 15 minutes. Samples were then centrifuged at 4° 
C for 10 min. at 2,100 rpm. The chlorobutane upper layer was transferred to glass 
tubes and evaporated to dryness under clean air. A further 5 mL of water saturated 1-
chlorobutane was added to the lower layer and participanted again to the above 
mechanical mixing and centrifugation steps. The second upper layer was then 
transferred to the residue from the first extraction and evaporated again. Extracts were 
then reconstituted in 100 μL methanol, transferred to 300 μL conical vials, capped and 
stored at 4° C until analysis. 
Normal phase LC (NPLC) was performed on a Gilson 234/307 auto-sampler with 151 
UV/VIS detector (Bedfordshire, UK) fitted with an Apex-I silica column (5 μm 
particulate silica 250 x 46 mm) (Mid Glamorgan, UK). Extracts (50 μL) were injected 
in an isocratic mobile phase recycling at 2 mL/min. consisting of methanol, 1,2-
dichloroethane, propan-2-ol and 40 % v/v ammonium perchlorate in UPW 
(90.5:5:4:0.5). The mobile phase was filtered and degassed and re-made every week. 
Diode array detection was set to 215 nm. 
Method performance 
For validation, the method was evaluated in terms of linearity, accuracy and 
repeatability, limit of detection (LOD) and limit of quantification (LOQ), as specified 
by the U.S. Department of Health and Human Services. Linearity was determined by 
preparation of calibration standards in UPW and in urine for matrix matched analysis. 
Standard addition was employed and concentrations of 10-500 ng/mL (n=6) of MTD 
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and EDDP were spiked into UPW and urine before extraction by LLE and LC-UV 
analysis. A calibration curve was produced from the chromatogram peak areas 
produced by the analytes at different concentrations. The regression line was 
calculated using the least squares method and expressed by the coefficient of 
correlation (R2), with values of over 0.98 taken to be acceptable. In order to determine 
extraction recovery, UPW and urine samples (n=6) were spiked to 200 ng/mL 
concentrations participanted to extraction procedure and compared to matrix-matched 
standards. Recovery was calculated by comparison of the peak areas before and after 
extraction and expressed as a percentage. 
 
Precision was evaluated as the coefficient of variation (% CV) measured between 
recoveries of spiked urine extracts (n=6) and accuracy by percentage comparison of 
the ratio of achieved concentration to nominal concentration in a standard. Sensitivity 
was determined as LOD and LOQ. The LOD is the lowest concentration of analyte 
that can be detected qualitatively by the procedure. The LOQ is the lowest amount 
that can be quantitatively determined, and hence quantitation below this value is not 
deemed reliable. Both limits are determined by calculating the signal to noise (S/N) 
ratio from the height of the chromatographic peak compared to the highest and lowest 
peaks of baseline noise and applying the 3:1 S/N for LOD and 10:1 for LOQ. 
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Figure 3-2 Calibration plot for MTD following LLE from ultra-pure water or urine  
 
 
Figure 3-3 Calibration plot to show EDDP response following LLE extraction from 
ultra-pure water or urine 
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3.9 Study 2: Recent Alcohol Consumption Biomarkers (EtG and 
EtS) in Patients Receiving Methadone Substitution Maintenance 
Treatment 
3.9.1  Study Design and Purpose 
Using a cross-sectional prospective cohort design, the study investigated the 
effectiveness of using the alcohol biomarkers Ethyl glucoronide (EtG) and Ethyl 
Sulphate (EtS) to screen for recent alcohol consumption in patients collecting their 
daily methadone dose. The purpose was to help establish whether these biomarkers 
can be used to indicate recent alcohol use among clients receiving methadone 
substitution maintenance treatment. The study setting, inclusion, and exclusion 
criteria have been described in sections 5.5 and 5.10, and recruitment has been 
described on page 106. 
3.9.2  Research Tools 
Each participant was asked, with the assistance of the researcher, to complete a 
questionnaire that covered general demographic information (Appendix D), including 
questions related to age, route of referral, ethnicity and gender. The questionnaire also 
included questions about licit drug use, including cigarettes/tobacco and alcohol, as 
well as questions regarding methadone intake and dosage. Alcohol-related questions 
in the self-report included the consumption of alcohol and illicit drugs in the past 
month using TOP and the consumption of alcohol, kind and amount in the past 24 
hours.  
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3.9.3 Biological samples  
A urine sample was collected using the same procedure as previously described and 
used to determine EtG and EtS levels. The analysis was carried out by the King’s 
College Hospital Department of Clinical Chemistry using liquid chromatography 
coupled with tandem mass spectrometry (LC/MS-MS). A method adapted from that 
used by Helander & Beck (2005) was used to quantify EtG and EtS in standards and 
urine samples as described briefly below. 
3.9.4 Analysis of urinary EtG and EtS 
3.9.4.1  Materials and Methods 
Reagents 
All chemicals and solvents were of analytical grade. Ethyl-β-D-glucuronide was 
purchased from LGC Standards GmbH (Wesel, Germany). Ethyl sulphate sodium salt 
was purchased from Aurora Analytics (Baltimore, U.S.A.). Internal standards (d5-EtG 
and d5-EtS) were also purchased from Aurora Analytics. Acetonitrile was obtained 
from Rathburn Chemicals Ltd. (Walkerburn, Scotland). Formic acid and ethyl 
phosphate were purchased from Sigma-Aldrich Co (Poole, UK).   
 Equipment 
A JascoTM LC 2000 HPLC system with three PU-2085 pumps, a MX-2080-32 solvent 
mixing module, an AS-1550 autosampler and a CO-2067 column oven (Tokyo, 
Japan) was used.  This was coupled with a triple quadrupole mass spectrometer API 
3200TM (Applied Biosystems, Cheshire, UK), which could be operated with either an 
electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI) 
source.  
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Preparation of standards 
Stock solutions of the standards were prepared as follows: d5-EtG 100 mg/L was 
prepared by weighing 1 mg of d5-EtG using a 5-point balance and adding it to a 10 
mL volumetric flask, making it up with water. It was then stored at -10º C. d5-EtS 
100 mg/L was prepared by weighing 1 mg of d5-EtG using a 5-point balance and 
adding it to a 10 mL volumetric flask and making up with water. 
Calibration standards containing 0.05, 0.1, 1, 5, 10, and 50 mg/L of EtG + EtS were 
prepared by serial dilution in blank urine. A stock solution containing approximately 
5 mg/L of internal standard (d5-EtG + d5-EtS) was prepared in water and stored at 4° 
C. 
 Sample preparation  
Urine was mixed with 1:10 (v/v) with (EtG-d5 and EtS-d5). 100 µL of urine was 
mixed with 900 µL of internal standard solution and vortexed for 30 seconds, as 
described by Helander & Beck (2005). Samples were centrifuged at 10,000 RPM for 
3 min. 900 µL of the supernatant was transferred to an HPLC vial.  
3.9.5  LC-MSMS  
EtG and EtS were chromatographically resolved using a Hypercarb column (100 x 
2.1mm, 5μm; Thermo Scientific, Hertfordshire, UK). The mobile phase consisted of 
25mmol/L formic acid with 5% acetonitrile and was pumped isocratically at 
600μl/minute. This method was adapted from Stephanson et al. (2002) and was 
optimised and extended to allow detection of EtS as well as EtG. Analysis time per 
sample was 10 minutes. Injection volume was 10μl. Negative-ion mass spectra of the 
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eluates were recorded in MRM mode. Data were acquired and quantified using 
Analyst™ software version 1.4.2 (Applied Biosystems) and using peak area analysis 
corrected by comparison to the internal standard.  
 Liquid chromatography linearity 
Linearity checks were carried out with aliquots of pooled blank urine spiked with a 
combined EtG/EtS stock at different concentrations and then serially diluted with 
pooled urine. A linear relationship was observed between 0.2 mg/L and 100 mg/L for 
EtG (see Figure 5-4) and between 0.1 mg/L and 80 mg/L for EtS (Figure 5-5), with 
good correlation. For EtS, linearity and precision were acceptable down to 0.05 mg/L. 
However, the signal to noise ratio at this concentration was unacceptable and 





Figure 3-4 EtG calibration curve – 6 standards – concentrations 0.05, 0.1, 1, 5, 10 
and 50 mg/L. Standards run at the beginning and end of the batch 
 
Analyte Concentration/ IS concentration  
A
nalyte A
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Figure 3-5 EtS calibration curve – 6 standards – concentrations 0.05, 0.1, 1, 5, 10 
and 50 mg/L. Standards run at the beginning and end of the batch 
 
The lower limit of quantification (LLOQ) can be defined as ‘the point where there is a 
signal to noise ratio of at least 5:1 in addition to where 20 replicates generate 
precision within 20% and with accuracy of 80-120%’ (U.S. FDA, 2001).   
 Recovery 
To determine the recovery of the method, six urine samples were spiked with a mix of 
defined amounts of EtG/EtS standards prior to a ten-fold dilution in internal standard 
solution for analysis.  
 
Analyte Concentration/ IS concentration  
A
nalyte A
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Figure 3-6 Standard 3 (1 mg/L of each analyte) 
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Figure 3-7 Figure showing all SRMs monitored (top panel, each mass transition a 
different colour), then in bottom 4 panels, individual mass transitions for analyte 
(EtG or EtS) and their corresponding deuterated internal standard (EtG-d5 or EtS-
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3.10 Study 3: An investigation of the Use of the Breathalyser in 
Methadone Substitution Maintenance Treatment  
3.10.1 Design and Purpose 
Using a cross-sectional design, the study investigated breathalyser readings during 
fixed daily dosing in patients receiving methadone substitution maintenance treatment 
and presenting with problematic alcohol use. The goal was to help establish whether 
the current breathalyser cut-off limit for alcohol use is a suitable indicator for alcohol 
consumption among clients receiving methadone maintenance.  
3.10.2 Setting  
The setting was described above (see section 5.5). However, participants were alcohol 
users who were also prescribed methadone and participants were required to meet the 
following criteria in addition to those described in section 5.10: 
x Participants present with problematic alcohol consumption. 
x Participants who were breathalysed. 
3.10.3 Recruitment  
Recruitment took place in the outpatient clinic. The participants were identified by 
staff and were subsequently approached by the researcher during their visits to the 
clinic and briefed about the study. Upon expressing interest, potential participants 
were escorted to a private room and asked to provide written consent (see Appendix 
C).  
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3.10.4 Research Tools 
Participants were asked to complete a research interview involving a questionnaire 
that included sociodemographic questions and questions pertaining to licit and illicit 
drug use, methadone treatment and other current treatment. The questionnaire also 
included questions related to alcohol use, including most recent alcohol consumption 
and type of drink. The interview also made use of AUDIT, SAWS and SOWS 
measures (Appendix F), including questions related to age, route of referral, ethnicity 
and gender. The questionnaire also included questions about licit drug use, including 
cigarettes/tobacco and alcohol, as well as questions regarding methadone intake and 
dosage. Alcohol-related questions in the self-report included the consumption of 
alcohol in the past month and the consumption of alcohol, kind and amount in the past 
24 hours. Further sociodemographics and laboratory results were collected using 
patients’ journey files.   
Short Alcohol Withdrawal Symptoms Scale (SAWS)  
The Short Alcohol Withdrawal Symptoms Scale (SAWS) is a ten-item psychometric 
scale that is relatively easy to administer. Five items on the SAWS assess a 
psychological component of withdrawal symptoms: anxiety, confusion, restlessness, 
misery and memory problems. The other five items concern physical components of 
withdrawal symptoms: tremors, nausea, heart pounding, sleep disturbance and 
sweating. The SAWS can be used to determine the severity of alcohol withdrawal 
symptoms at the first clinical assessment and can be administered for continuous 
assessment. In administering the SAWS, a numerical Likert rating scale is presented, 
with 0, 1, 2, and 3 used to respectively designate none, mild, moderate, and severe 
symptomology. A score of 30 was the maximum obtainable, and this score was later 
used in calculating the mean total withdrawal scores. This scale has been used in an 
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in-patient setting to assess the level of management and treatment effectiveness 
(Gossop et al., 2002). 
Leeds Dependence Questionnaire (LDQ) 
The Leeds Dependence Questionnaire (LDQ) is tool used to indicate how severely 
dependent a person is and to assess how difficult it will be to achieve a positive 
outcome.  LDQ is derived from a psychological understanding of the nature of 
dependence and is, therefore, suitable for measuring dependence during periods of 
substance use or abstinence.  There are 10 items scored 0-3.  Cut offs are (<10 = low 
dependence; 10-22 = medium dependence; and >22 = high dependence). 
3.10.5 Biological samples 
A urine sample was collected following the interview; interview and urine sample 
collection together took 30-40 min.  Urine samples were frozen in the laboratory at -
20° C until analysis.  
Ethanol levels in breath (BrAC) were collected by a clinical nurse/key worker when 
participants were collecting their methadone daily dose. Ethanol levels in breath 
(BrAC) were measured using a Lion 500 (Lion Alcolmeter) as part of routine work.  
Before methadone was dispensed, the clinical nurse/key worker in charge of 
dispensing would ask the clients to take a deep breath and expire into a disposable 
mouthpiece attached to the breathalyser. Readings were regularly documented in 
patient charts.  
If the reading was above 39 mg per 100mL, methadone would not be dispensed and 
patients would be allowed to wait and try again subsequently. If the patient failed 
their breathalyser test, he or she would have to wait until 10a.m. the next day for 
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dispensing to begin again. If the patient failed to receive methadone for three days, he 
or she would need to be assessed by the consultant before being issued subsequent 
methadone daily doses. The scores were recorded in the participants’ chart and later 
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Chapter 4 EXPERIMENTS  
4.1 Study (1.a) Urinalysis measurements of methadone and EDDP 
in methadone maintained individuals  
4.1.1 Background 
Using a cross-sectional prospective cohort design, Study 1 investigated the 
relationship between methadone and EDDP during fixed daily dosing in patients 
receiving methadone maintenance in order to assess whether the ratio of 
EDDP:methadone could be used effectively as a biomarker for methadone 
compliance. Four sets of results are provided: 1) the results of the descriptive statistics 
that summarise the basic demographic and background information on the 
participants; 2) the results of the t-test comparing the severity of withdrawal 
symptoms, alcohol drinking behavior, quality of life, methadone dosage, methadone 
concentration, EDDP concentration, ratio of EDDP:methadone, AUDIT score, and 
SOWS score between the patients in the methadone maintenance group and patients 
in the hazardous alcohol drinking behavior group; 3) the results of the ANOVA that 
was performed to determine which of the variables (methadone dosage, methadone 
concentration, EDDP concentration, ratio of EDDP/methadone, AUDIT score, SOWS 
score, and pH levels) differed significantly across the study, with measurements taken 
at baseline period (time 1), time 2, time 3, and time 4; and 3) the results of the 
correlation test that was performed in order to examine the relationship between 
methadone and EDDP concentration levels. 
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4.1.2 Recruitment and Procedures 
Initial interviews and urine sample collection 
Participants were asked to take part in a structured research interview involving a 
questionnaire that included socio-demographic questions and questions regarding licit 
and illicit drug use, methadone treatment, and other current treatment.  
4.1.3 Data analysis  
Data analysis was conducted using the Statistical Package for Social Sciences (SPSS), 
Windows® version 15.0. Data were collected, coded, and transferred to SPSS. The 
descriptive data, i.e., the demographic and background information, as well as the 
characteristics of licit substances and prescribed medication use, were analysed by 
calculating the frequencies, standard deviation, means, and percentages of participant 
responses. Basic demographic and background information, including patients’ age, 
sex, ethnic background, and employment status, was compared using a chi-square 
test. A t-test was used to compare the continuous variables, including the severity of 
withdrawal symptoms (see de Wet et al., 2004). When data were not normally 
distributed, a non-parametric test was utilized. A Mann-Whitney U test was used to 
compare the distribution of continuous unpaired variables, while a Wilcoxon signed 
rank test was used to compare the distribution of paired variables. Data that were 
missing were excluded from the analysis.  
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4.1.4 Results  
4.1.4.1 Sample Characteristics  
Sixty participants at more than two weeks into methadone treatment were recruited 
for the study.  Their mean age was 41.67 ± 8.3 years (range 23 – 56 years), and the 
majority were male (65%; n = 39). The ethnic background of the participants varied, 
but the majority described themselves as White British (58.3%; n = 35); other 
ethnicities were reported as follows: Other White n = 7 (11.7%), Irish n = 6 (10%), 
Black Caribbean n = 6 (10%), White Caribbean n = 2 (3.3%), Black African n = 2 
(3.3%), Other Black (1.7%, n = 1), ‘other’ (1.7%, n = 1).  Of the 60 participants, 38 
(63.3%) reported having no formal educational qualifications, while 14 (23.3%) 
reported carrying a GCSE/O-Level, one (1.7%) reported having A-levels, four (6.7%) 
reported having vocational qualifications, and three (5%) reported having an 
undergraduate degree. The route of referral varied, with 26 participants (43.3%) self-
referred, ten (16.7%) transferred from prison, five (8.3%) referred by a GP, two 
(3.3%) referred by a family member, two (3.3%) transferred from hospital, and 15 
(23.3%) reporting other routes of referral. Only 13 (21.7%) of the 60 participants 
reported holding a driving license, while none reported driving to the clinic.  
4.1.4.2 Treatment Outcome Profile (TOP) 
The Treatment Outcome Profile (TOP) questionnaire records four main areas 
affecting the clients’ life: Substance use: the number of days substances were used in 
the past 28 days; Health: including a participantive rating score between 0-21 of 
physical and psychological health status; Crime: the number of days when shoplifting, 
theft, or drug dealing occurred, as well as the prevalence of property or vehicle theft, 
fraud, and assault and/or other violent crime; and Social functioning: including a 
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rating of quality of life on a scale between 0 - 21 (21 being good), the number of days 
of paid work and attendance to education/training, period prevalence of acute housing 
problems, and risk of eviction. 
From the TOP data section on health, crime, and social functioning, the mean physical 
health score was 10.28 r 4.7 (range 1 - 19), whereas the mean score for psychological 
health was 9.8 r 4.7 (range 1 - 18) and the mean score for of the quality of life (QoL) 
was 9.4 r 5.1 (range 1 - 18).   
When asked about problems with accommodation, 14 participants (23.3%) reported a 
problem with accommodation and six participants (10%) reported facing a high risk 
of eviction. All participants reported being unemployed, none reported receiving paid 
work, and only one (1.7%) reported spending days going to college.  In terms of 
criminality, seven participants (11.7%) reported shoplifting and one reported being 
involved in an assault in the past 28 days. 
4.1.4.3 Licit Substances   
Smoking Behaviour  
All 60 participants reported being current smokers.  A total of 42 participants (70%) 
reported smoking ‘roll-up’ cigarettes, 12 (20%) reported smoking filtered cigarettes, 
and 6 (10%) reported smoking both. The mean number of cigarettes smoked per day 
was 13.56 r 7.9 cigarettes (range 2 – 40 cigarettes).   
Alcohol Use Behaviour 
Out of the total cohort, 40 participants (66.7%) reported drinking alcohol, whereas 20 
(33.3%) described themselves as non-drinkers. Among the 40 participants who 
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reported drinking alcohol, the mean number of units of alcohol consumed per day at 
baseline was 11.12  r 8.46 (range 1 – 32) units of alcohol/day.  
The participants’ mean score on the Alcohol Use Disorders Identification Test 
(AUDIT) was 13.17 ± 13.19 (range 0 – 38 points). Out of the total cohort, 11 
participants (18.3%) scored zero on the AUDIT, indicating no alcohol use in the past 
year.  Conversely, 30 participants (50%) scored at or above the AUDIT cut-off point 
of ≥ 8, which suggests hazardous alcohol drinking behaviour, and the study 
considered these participants as a separate hazardous alcohol use (HAU) group.  
Notably, however, 21 of these participants (35% of the whole sample) registered 
AUDIT scores in the highest bracket (≥20), which identifies individuals as probable 
dependent drinkers.  The full distribution of AUDIT scores and corresponding risk 
levels across the study sample is shown in Table 4-1.  
Table 4-1 Number and percent of participants at various risk levels per AUDIT 
scores 




Low risk 0-7 30 50 
Hazardous level 8-15 5 8.3 
Harmful level 16-19 4 6.7 
Dependence likely 20-40 21 35 
Total  60  
 
AUDIT question responses identify the frequency of occurrence of a given item over 
the past year.  Except for items one, two, nine and ten, scoring is as follows: 0 = 
never, 1 = less than monthly, 3 = monthly, and 4 = weekly.  Table 4-1 summarises the 
mean scores per question on the AUDIT for sample.  As these data show, ‘zero’ was 
the most prevalent response to all items except item 1.  Thus, almost half of the 
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participants (n = 28) did not consume six or more units if female, or eight or more 
units if male, of alcoholic drinks on a single occasion in the last year, indicating no 
binging pattern in their drinking.  More than half of the participants (n = 35) said that 
they had zero occurrences in which they were not able to stop drinking once they had 
started.  Similarly, more than half of the participants (n = 34) said that they did not 
fail to do what was normally expected of them because of drinking.  Nearly two-thirds 
(n = 39), moreover, said that they did not need an alcoholic drink in the morning to 
get themselves going after a heavy drinking session, and more than half (n = 33) said 
that they did not have a feeling of guilt or remorse after drinking. More than half (n = 
33) also said that they did not experience being unable to remember what happened 
the night before because they had been drinking. Just over two-thirds (n = 41) said 
that they did not cause themselves or anyone else to be injured as a result of their 
drinking, and more than half (n = 32) said that they did not have a relative or friend or 
a doctor or another health worker express concern about their drinking or suggest that 
they cut down.  Nonetheless, the extent of participants’ drinking behaviour should not 
be minimised, as the same data show that almost half of the participants (n = 28) did 
have people concerned about their drinking, and nearly one-third (19) had injured 
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Table 4-2 Distribution and mean of AUDIT item responses across samples 
 
There is also a shorter version of the Alcohol Use Disorder Identification Test 
(AUDIT-C) that takes into account only the first three questions of the AUDIT.  The 
mean AUDIT-C score for the sample was 4.9 ± 4 (range 0 – 12). 



















How often do you have a drink containing 
alcohol? 
10 10 6 7 27 2.52 
How many units of alcohol do you drink on a 
typical day when you are drinking? 
33 10 7 4 6 1.27 
How often have you had 6 or more units if 
female, or 8 or more if male, on a single 
occasion in the last year? 
28 8 4 7 13 1.48 
How often during the last year have you 
found that you were not able to stop drinking 
once you had started? 
35 4 3 4 14 1.3 
How often during the last year have you 
failed to do what was normally expected from 
you because of drinking? 
34 6 8 8 4 1.03 
How often during the last year have you 
needed an alcoholic drink in the morning to 
get yourself going after a heavy drinking 
session? 
39 3 3 5 10 1.06 
How often during the last year have you had a 
feeling of guilt or remorse after drinking? 
33 3 2 11 11 1.4 
How often during the last year have you been 
unable to remember what happened the night 
before because you had been drinking? 
33 10 8 6 3 0.93 
Have you or someone else been injured as a 
result of your drinking? 
41 1 5 0 13 1.05 
Has a relative or friend or a doctor or another 
health worker been concerned about your 
drinking or suggested you cut down? 
32 0 3 1 24 1.75 
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Methadone Treatment  
All participants were prescribed a fixed daily dose of methadone from the community 
drug service. The mean dose for the whole sample at baseline was 62 ± 26.8 mg 
methadone/day (range 25 - 130 mg methadone/day) and the median was 55 mg of 
methadone/day. The most frequent dose prescribed by the clinic to participants was 
50 mg methadone/day (n = 9; 15%), as can be seen in Figure 6-1.  In addition to the 
prescription data summarised in this figure, seventeen participants (28.3%) reported 
using methadone on top of their prescribed daily dose. 
 
Figure 4-1 Daily methadone dose prescribed to participants in terms of frequency 
(number of participants) across the sample 
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In terms of adherence to methadone dosing, twenty-seven participants (45%) reported 
missing their daily methadone dose in the previous seven days, while 21 (35%) 
reported never missing their daily methadone dose. Of those who missed their daily 
dose, the most common reason stated was arriving late to the clinic (n = 15; 25%). 
Eleven participants (18.3%) reported that this was related to alcohol use, which could 
include being drunk, knowing that they would exceed the breathalyser cut off limit, or 
being unconscious. Four participants (6.7%) reported missing their dose to be related 
to a police arrest and another four reported being too unwell to attend.  
 
4.1.4.4 Subjective Opiate Withdrawal Scale (SOWS) 
In interviews that took place during trough, i.e., at the end of the dosing interval, 
before the next subsequent dose, participants were also asked to complete the 
Subjective Opiate Withdrawal Scale (SOWS). This tool measures the presence and 
intensity of symptoms of opiate/opioid withdrawal, including musculoskeletal, 
psychiatric, autonomic, gastrointestinal, and motor signs, from the patient’s 
perspective. The SOWS is a self-administered ten-item self-report questionnaire on 
which each item is rated on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = 
severe) (see Table 6-3). The mean SOWS score for the whole sample was 5.1 ± 5.9 
(range 0 – 27).  
Table 6-3 shows the distribution of participants’ responses to the ten SOWS items, 
which provides a picture of their withdrawal experience.  Overall, ‘none’ was the 
most common response to all items, with ‘mild’ next frequent for items 1-5 (except 
item 3), and ‘moderate’ receiving a similar or greater number of responses as ‘mild’ 
for items 3 and 6-10.  By far the most commonly cited as ‘severe’ (n = 11) was the 
symptom insomnia, which was also the symptom that received the fewest responses 
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of ‘none’ (n = 30).  
Table 4-3 Distribution and mean scores of SOWS item responses across the sample 














1.Feeling Sick  41 10 6 3 0.51 
2.Stomach cramps 45 6 6 5 0.45 
3.Muscle spasms 50 3 5 2 0.31 
4.Feelings of coldness 36 13 7 4 0.65 
5.Heart pounding 47 6 4 3 0.38 
6.Muscular tension 44 5 9 2 0.48 
7.Aches and pains 39 8 9 4 0.63 
8. Yawning 38 11 8 3 0.6 
9.Runny eyes 43 6 9 2 0.5 
10.Insomnia 30 9 10 11 1.1 
 
Additionally, a Pearson Correlation coefficient was conducted to determine the 
strength of the relationship, if any, among overall SOWS and two other variables: 
cigarette usage and methadone dose.  As can be seen in Table 4-4 below, the results 
showed the frequency of cigarette usage, size of methadone dose, and the SOWS 
score for each participant. A Pearson Correlation coefficient revealed that the 
frequency of cigarette smoking  with the mean of 13.56 ± 7.98 and SOWS score with 
the mean of 5.57 ± 6.79 were not correlated (r = 0.07, n = 60, df = 58, p = 0.59). 
There was no correlation between the size of methadone dose with the mean of 62.07 
± 26.82 and frequency of cigarette smoking either (r = 0.02, n = 60, df = 58, p = 
0.86). 
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Table 4-4 Table use, methadone dose, and SOWS scores by participant 

















1 0 45 15 31 16 40 25 
2 0 40 6 32 5 95 40 
3 0 80 2 33 0 65 15 
4 0 70 12 34 0 120 3 
5 1 30 6 35 25 50 11 
6 0 30 12 36 2 85 13 
7 0 40 14 37 7 100 14 
8 14 50 10 38 11 130 10 
9 1 40 15 39 17 80 20 
10 6 95 20 40 15 35 8 
11 4 90 15 41 8 50 10 
12 9 30 20 42 16 60 35 
13 1 50 15 43 11 70 3 
14 15 25 15 44 6 60 20 
15 8 50 10 45 23 30 13 
16 7 74 5 46 2 45 5 
17 4 25 10 47 6 70 10 
18 0 50 10 48 8 80 13 
19 3 50 3 49 0 35 17 
20 1 120 3 50 2 50 10 
21 0 30 2 51 4 30 10 
22 2 90 20 52 3 80 10 
23 0 35 10 53 5 90 20 
24 3 85 35 54 2 65 20 
25 0 70 20 55 2 40 30 
26 3 95 10 56 7 100 8 
27 0 40 15 57 0 45 20 
28 0 45 15 58 5 60 6 
29 27 120 10 59 0 60 10 
30 0 60 20 60 17 50 10 
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Data on drug use in the 28 days prior to the interview were collected using the TOP. 
Forty-three participants (72.7%) self-reported that they used heroin, and 41 (68.3%) 
reported using crack cocaine on top of their prescribed opioid.  Use of powdered 
cocaine was reported only by one participant. Twenty-eight participants (46.7%) 
reported using cannabis, and nine (15%) reported using illicit benzodiazepines. One 
participant (1.7%) used amphetamines, while four (6.7%) reported using other forms 
of drugs illicitly. A total of 25 participants (41.7%) self-reported drug use by the 
intravenous route in the past 28 days. 
4.1.4.5 Prescribed Medication   
Thirty-six participants (60%) reported being prescribed another medication along with 
their methadone; 12 participants (20%) received more than two medications, eight 
(13.3%) were prescribed antidepressants, four (6.7%) were prescribed anxiolytics, 
three (5%) were prescribed antipsychotics, and nine (15%) reported being prescribed 
other medications. 
4.1.4.6 Gender, Sample Characteristics, and Survey-Measured 
Variables 
Tables 4-5, 4-6, and 4-7 show, respectively, the characteristics ethnicity and route of 
referral and the demographic variable level of education as self-reported by the 39 
male and 21 female participants in the study. The mean age for the male participants 
was 44 ± 7.9 years compared to 38 ± 7.9 for female participants. Independent t-test 
indicated significant difference between the genders by age (t = -2.63, df = 58, p = 
0.01) with male participants slightly older than female participants. However, a Chi-
Square test indicated p-values for these variables were all greater than the level of 
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significance, indicating that there were no significant relationships by gender for the 
demographic characteristics.  
Table 4-5 Ethnicity of Participants 




White British 23 12 
White Caribbean 1 1 
Other Black 0 1 
Irish 4 2 
Caribbean 6 0 
Other White 3 4 
African 1 1 







Table 4-6 Route of Referral for Participants 






Came by self 19 7 
Transfer from hospital 1 1 
Referred by GP 2 3 
Sent by family 2 2 
Transfer from prison 6 2 
Referred by a consultant 1 0 














No formal qualifications 27 11 
GCSE / O-Level 6 8 
A-Level 1 0 
Vocational qualifications  
(e.g. HND, NVQ) 4 0 
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Table 4-8 summarises the mean scores of the survey’s self-reported variables, i.e, the 
socio-demographic information, health variables, previous drug use, treatments 
received, AUDIT scores, SOWS scores, and so on, for male and female participants.  
Again, independent t-test showed no significant differences by gender for these 
variables. 
Table 4-8 Mean scores for health, alcohol use, methadone treatment, withdrawal 
symptons and illict drug use 
Variable Male Female    (n=39) (n=21) t df p-value 
Physical Health Score 10.51 8.83 -1.69 58 0.50 
Psychological Health Score 11.03 8.90 -1.69 58 0.45 
Quality Life Score 10.38 7.60 -2.07 58 0.56 
Alcohol use 25 15 -.056 58 0.60 
Units/day 12.98 10.92 0.29 58 0.65 
AUDIT score 12.92 13.62 0.19 58 0.84 
Cigarette use/day 12.68 25.29 1.17 58 0.50 
Methadone dose (mean) 60 65 0.67 58 0.56 
Methadone use on top (yes/no) 10 7 -0.67 58 0.78 
SOWS score 5.74 5.24 -0.27 58 0.78 
Illicit heroin use 25 16 0.03 58 0.65 
Crack cocaine 38 21 -0.95 58 0.32 
Cannabis 20 8 0.97 58 0.90 
Illicit Benzodiazepine 6 3 0.11 58 0.90 
Intravenous use 17 8 0.41 58 0.68 
 
A comparison of the opiate withdrawal scores at baseline between female with a mean 
of 5.24 ± 5.33 and male with the mean score of 5.74 ± 7.51 participants was also 
conducted using independent t-test, and the results showed no significant differences 
(t = -0.27, df = 58, p = 0.78). Table 4-9 summarises the item-by-item SOWS scores at 
baseline divided among the female and male patients as well as the p-value derived 
from the t-test that was conducted to examine gender differences. No statistically 
significant difference between male and female responses was identified.  
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Table 4-9 SOWS item responses across sample by gender 
 
Number of participants scoring 



















 M/F M/F M/F M/F M/F    
1.Feeling Sick  27/14 7/3 3/3 2/1 0.48/0.57 0.35 58 0.73 
2.Stomach cramps 30/15 4/2 3/3 2/1 0.41/0.52 0.43 58 0.63 
3.Muscle spasms 33/17 2/1 2/3 2/0 0.30/0.33 0.90 58 0.90 
4.Feelings of coldness 23/13 8/5 5/2 3/1 0.69/0.57 0.43 58 0.64 
5.Heart pounding 32/15 3/3 2/2 2/1 0.33/0.47 0.39 58 0.53 
6.Muscular tension 28/16 3/2 5/3 2/0 0.53/0.38 0.16 58 0.51 
7.Aches and pains 26/13 4/4 6/3 3/1 0.64/0.61 0.53 58 0.93 
8. Yawning 24/14 8/3 5/2 2/1 0.61/0.57 0.97 58 0.86 
9.Runny eyes 27/16 3/3 7/2 2/0 0.58/0.33 0.02 58 0.28 
10.Insomnia 19/11 7/2 3/7 10/1 1.10/0.90 0.27 58 0.55 
 
4.1.4.7 Biological Measures 
Urine samples were collected at baseline (period 1) from 60 participants (4 samples 
were discarded). Three further urine samples were collected at one-week intervals, 
with 35 participants providing samples during period 2, 30 during period 3, and 17 
during period 4, for a total of 138 samples collected. All samples were analysed for 
methadone and its primary metabolite, EDDP, using High Performance Liquid 
Chromatography.  
Table 4-10 Summary of Number of Samples Collected by Data Collection Period 
Period of collection  Number of samples collected 




Total urine samples collected 138 
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As a group, 21 participants (35%) provided one sample, five (8.3%) provided two 
samples, 13 (20%) provided three samples, and 17 (30%) provided four samples. Four 
participants provided less than 2 mL of urine at baseline, which hindered the analysis. 
Urinary methadone and EDDP concentration range values 
The mean urinary methadone concentration at trough for the sample was 3497.23 ± 
4553.76 µg/L (5.90 – 20351.8) and the mean urinary EDDP concentration at trough 
was 15106.95 ± 36208.33 µg/L (0.05 – 302940). To control variation, the samples 
were arranged according to methadone dose as reported by the participants. Figure 4-
2 shows a scatter plot of the methadone and EDDP concentrations in urine in relation 
to daily methadone dose. There are three outliers, which are excluded in further 
consideration of these data. 
 
 




Figure 4-2 Scatter plot representing methadone (green hollow circles) and EDDP 
concentration (blue hollow circles) against daily methadone dose.   
 
Table 4-11 summarises the distribution of methadone and EDDP urine concentrations 
by methadone dose.  
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25 2 5 1426.71 8585.83 6.02 0.17 
30 5 9 1571.85 2524.33 1.61 0.62 
35 3 12 2381.78 3268.83 1.37 0.73 
40 6 18* 2782.73 9432.21 3.39 0.30 
45 4 7 4794.79 3222.33 0.67 1.49 
50 9* 16 2436.58 8583.89 3.52 0.28 
60 5 12 1073.68 2886.89 2.69 0.37 
65 2 5 3976.72 1608.72 0.40 2.47 
70 4 6 8670.57 11757.28 1.36 0.74 
80 4 12 2519.08 4056.67 1.61 0.62 
85 2 6 9228.51 3858.17 0.42 2.39 
90 3 8 6042.78 6323.22 1.05 0.96 
95 3 5 6003.96 6738.67 1.12 0.89 
100 1 7 2660.31 1681.94 0.63 1.58 
120 3 6 3857.81 7854.17 2.04 0.49 
130 1 4 4893.24 32970.94 6.74 0.15 
 
A Pearson correlation test was conducted to determine the relationship between the 
following variables: methadone dosage, methadone concentration, EDDP 
concentration, and ratio of methadone/EDDP. The results showed that the methadone 
concentration was significantly positively correlated with methadone dosage (r = 
0.22, df  = 136, p = 0.01) and with EDDP concentration (r = 0.24, df = 136, p<0.001). 
The results of the correlation test also showed that the methadone concentration was 
significantly positive correlated with the EDDP concentration (r = 0.39, df = 136 
p<0.001). This means that the concentration of methadone and EDDP increase when 
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methadone dose increases. However, no significant relationship was noted between 
methadone or EDDP and the metabolic ratio (EDDP:methadone). 
 
 
Figure 4-3 Scatterplot of log methadone concentration against methadone dose. 
 
Figure 4-3 shows the relationship between methadone dose and average methadone 
concentration. The graph demonstrates an increasing trend, which indicates a 
significant positive relationship between methadone dose and methadone 
concentration.  
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Figure 4-4 Scatterplot of Methadone Dose against Average EDDP concentration   
 
There was a significant correlation between methadone concentration and the AUDIT 
Scores (r = -0.16, df = 136, p = 0.05). However, methadone concentration was not 
significantly correlated with SOWS scores (r = -0.12, df = 136, p = 0.18) or between 
EDDP concentration and either the AUDIT Scores (r = -0.13, df = 136, p = 0.12) or 
SOWS scores (r = -0.03, df = 136, p = 0.65). A significant positive correlation, 
however, was observed for methadone dosage and AUDIT scores (r = 0.23, df = 136, 
p = 0.01). Also a significant positive correlation was observed with the AUDIT score 
and SOWS score (r = 0.25, df = 136, p<0.001). 
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Figure 4-5 Scatter plot of mean EDDP : methadone ratio (blacksquares) against 
methadone dose (mg/L)   
 
Results of the Pearson Correlation coefficient showed that ratio of EDDP:methadone 
19.05 ± 54.21  and methadone dosage 63.19 ± 27.78 were not correlated (r = -0.05, df 
= 136, p = 0.96) (see Figure 4-5). However, methadone concentration was negitavely 
correlated with pH level (r = -0.37, df = 136, p<0.001,) see figure (4-6). 
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Figure 4-6 Scatterplot of Log methadone concentration against pH 
 
Between-patient relationship for dose and urinary methadone concentration 
Of the 138 samples collected, the mean dose was 63.1 ± 27.7 mg/day (25 - 130) and 
the median dose was 60 mg/day. However, the most common dose linked to the urine 
samples was 40 mg/day (n = 18; 7.5%). Table 4-12 summarises the participants’ 
methadone and EDDP urine concentrations, ratios, and pH at this dose. Mean 
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Table 4-12 Methadone and EDDP urine concentrations in samples at the most 





















1 6 7219.9 15512 2.14 0.46 
2 7.28 3413.55 15349 4.49 0.22 
3 8 394.52 4252 10.77 0.09 
4 6 1362.72 1559 1.14 0.87 
5 7.72 933.01 1657 1.77 0.56 
6 6 3864.1 2131 0.55 1.81 
7 5.97 3184.99 6318 1.98 0.50 
8 7.63 1706.27 9390 5.5 0.18 
9 6 3762.69 9116 2.42 0.41 
10 7.72 8.38 1196 142.69 0.0 
11* 7 954.9 49052 51.36 0.01 
12 6.71 3084.29 10973 3.55 0.28 
13 6 8572.63 7688 0.89 1.11 
14 6.87 1413.39 2089 1.47 0.67 
15 7 312.34 981 3.14 0.31 
16 6.71 3345.41 13592 4.06 0.24 
17 8.47 49.74 3968 79.76 0.01 
18 7 6506.3 18875 2.9 0.34 
Mean 
rSD 







0.4 r 0.45 
*Sample 11 was identified as an outlier and is excluded from the graphic presentation 
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Figure 4-7 Distribution of methadone concentrations (blue bar) and EDDP 
concentrations (green bar) in 18 samples from participants receiving a dose of 40 
mg/day of methadone. 
 
As seen in Figure 4-7, EDDP concentrations were higher than methadone 
concentrations in all of the 40mg/day samples except for numbers 6 and 13. The mean 
EDDP:methadone ratio was  17.8 r 37.48 (0.5 - 142.6), with a variance of 1405.1. 
This result showed a high variability in the ratio among patients receiving the same 
dose. 
Similarly, 16 samples were collected from participants on a 50mg/day methadone 
dose. The concentrations, ratios, and pH for these samples are summarised in Table 4-
13 below.  
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Table 4-13 Methadone and EDDP urine concentration in samples from participants 



































1 8 453.4 5539 12.22 0.082 
2 7 1421.67 9410 6.62 0.151 
3 7.46 315.66 1328 4.21 0.238 
4 6 6117.17 8271 1.35 0.74 
5* 8 348.67 10943 31.38 0.032 
6 7.44 352.11 5046 14.33 0.07 
7 6.44 4760.12 11566 2.43 0.412 
8 7 1618.53 9675 5.98 0.167 
9 6 6278.74 13582 2.16 0.462 
10 6 1713.33 9403 5.49 0.182 
11 6 7079.14 38878 5.49 0.182 
12 7 1770.88 5579 3.15 0.317 
13 5.57 1854.09 2189 1.18 0.847 
14 7 1048.47 10001 9.54 0.105 
15 6.7 1498.03 2705 1.81 0.554 
16 7 2355.23 10395 4.41 0.227 
Mean  
rSD 






6.98 r  
7.545 
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Figure 4-8 Distribution of methadone concentration (blue bar) and EDDP 
concentrations (green bar) in 18 samples from participants receiving a dose of 50 
mg/day of methadone. 
 
As seen in Figure 4-8, EDDP concentrations were higher than methadone 
concentrations in all of the 50mg/day samples. The mean EDDP:methadone ratio was 
6.9 7.5 (1.1 – 31.3). The variance was 56.9, which is less than was found in the 
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Comparison of male and female participants’ urinary methadone and EDDP 
concentrations 
As there were differences in the male and female participants in this study with regard 
to methadone dose and alcohol consumption, the methadone concentrations in their 
urine samples were also considered separately. Table 4-14 summarises the 
concentrations and ratios by gender. 
Table 4-14 Dose vs average urinary methadone and EDDP concentration frequency 




















Male (n=39) 100 3187.21 10503.45 20.04 1.72 
Female(n=2) 38 4311.95 27209.06 16.43 0.44 
t  -1.3 -2.55 0.34 0.67 
df  136 39 136 136 
p-value  0.19 0.11 0.72 0.56 
 
Using an independent t-test, results indicated that there was no significant difference 
between males and females in methadone, EDDP concentration, or Methadone EDDP 
ratio. EDDP:methadone ratio also did not indicate significant difference between male 
and female. Figure 4-9  presents the differences graphically between methadone and 
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Figure 4-9 Differences in methadone (blue bar) and EDDP concentration (green bar) 
between males and females across all samples collected (138)  
 
4.1.4.8 Methadone Maintenance Group (MMT) versus Hazardous 
Alcohol Use Behaviour Group (HAU) 
A comparison was undertaken between participants who had AUDIT scores at or 
above the cut-off (≥8) for hazardous drinking (i.e., the hazardous alcohol use 
behaviour group, HAU) and the remainder of the sample (methadone maintenance 
group, MMT) (n = 30; n = 30). 
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Sample Characteristics and Demographic Data 
The mean age of the HAU group was 41.1 ± 7.7 years (range 26 - 56 years). The 
ethnic background was varied in both groups; however, the HAU group contained a 
slightly higher proportion of White British participants (70%, n = 21) as shown in 
Table 4-17. A total of 5 HAU participants (16.7%) reported having completed 
GCSEs/O-Levels, fewer (6.7%, n = 2) had received a vocational qualification and 
(6.7%, n = 2) had an undergraduate degree. About two-thirds (60%, n = 18) did not 
have any formal qualifications. The route of referral varied, but half reported being 
self-referred (50%, n = 15). Five participants (16.7%) were referred by a general 
practitioner, three (10%) transferred from prison, one (3.3%) was sent by their family, 
one (3.3%) reported being transferred from hospital, and one (3.3%) was referred by a 
consultant. Four participants (13.3%) reported other routes of referral (see Table 4-
15).   
 
Methadone Maintenance Group 
A total of 30 participants of which (70%, n = 21) were male scored ≤8 on the AUDIT. 
The mean age in this group was 42.2 ± 8.9 years (range 23 - 56 years). The ethnic 
background of the participants varied but majority described themselves as White 
British (46%, n = 14) while other ethnicities were reported in smaller numbers: 
Caribbean (20%, n = 6), White Caribbean (6.7%, n = 2), Irish (10% n = 3), and Other 
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Table 4-15 Summary of comparative demographic data for methadone maintenance 
and hazardous alcohol use groups – referral source and education 
Demographic parameter MMT Group HAU 
Group 
Referral source   
Transfer from hospital 1 1 
Referred by GP 0 5 
Sent by family 3 1 
Transfer from prison 5 3 
Referred by a consultant 0 1 
Other 10 4 







Education   







A total of 9 participants (30%) reported having completed GCSEs/O-Levels, fewer 
(6.7%, n = 7) had received an occupational training and only one participant (3.3%) 
had an undergraduate degree. More than half (60%, n = 18) did not receive any formal 
qualifications. The route of referral varied; (36.7, n = 11%) were self-referred, five 
participants (16.7%) reported being transferred from prison. Only three (10%) were 
sent by their family and one (3.3%) reported being transferred from hospital. Ten 
participants (33.3%) were referred by other routes (Table 4-15).  A Chi-Square test 
was conducted and found no significant relationship in all the parameters between the 
two groups. An independent t-test indicated no significant difference between the two 
groups in the age (t = -0.5, df = 58, p = 0.62).  
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Table 4-17 A summary of the comparative demographic data for MMT and HAU 
groups in terms of ethnicity 







White Caribbean 2 0 
Other Black 0 1 
Irish 3 3 
Caribbean 6 0 
Other White 3 4 
African 1 1 







4.1.4.8.1.1 Treatment Outcome Profile (TOP) 
According to the TOP data, the mean physical health score of the HAU group was 
10.7 whereas the mean score for psychological health was 9.57. The mean score for 
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the quality of life (QoL) was 5.15.  Using t-test analysis there were no differences in 
the scores when compared to MMT group. Table 4-18 summarises the data. 
Table 4-18 A summary of the comparative demographics data for MMT and HAU 






t df p-value 
(TOP) 











Psychological Health Score 9.57 9.27 0.22 58 0.82 
Quality Life Score 5.154 4.232 0.68 58 0.49 
 
Hazardous Alcohol Use behaviour 
The mean AUDIT score for the HAU group was 24 ± 8.4 (range 9 - 38), while the 
mean number of units of alcohol consumed per day was 14.2 ±11.8 units (range 3-60 
units). The majority of participants in this group consumed strong beer (73.3%, n = 
22) compared with (16.7%, n = 5) in the MMT group, only two participants consumed 
wine (6.7%) and one participant reported consuming mixed kinds of alcohol (3.3%). 
The most common alcohol percentage consumed was 9% (60%, n = 18).  
The mean MMT AUDIT score mean was 1.6 ±1.8 (range 0 - 6) as two thirds. More 
than half of the participants in the MMT did not consume alcohol (66.7%, n = 20). 
However, six participants (20%) had consumed alcohol in the past 24 hours and four 
(13.3%) had consumed alcohol at least once in the past week. The mean number of 
units of alcohol consumed per day was 1.1 ± 2.1 units (range 0 - 9 units). When 
alcohol was reported by the HAU group to be consumed, strong beer was the most 
common (16.7%, n = 5); few reported consuming spirits (6.7%, n = 2), only one 
participant reported drinking wine, and one reported drinking beer.  
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Table 4-19 Summary baseline characteristics for MMT and HAU groups 
Characteristic MMT HAU t df p-value 
Cigarette use /day 12.50 14.62 -1.2 58 0.3 
Alcohol units/day 3.71 14.18 -7.7 58 0.02 
 
Table 4-19’s results indicate that a significant difference using an indepednet t-test in 
parameters related units of alcohol reported. Cigarettes use was not found to be 
different between the two groups.  
Methadone Treatment and illicit drug use  
The mean methadone dose was found to be higher in the HAU group (65.6 ± 26mg; 
range: 30mg -130mg methadone/day) when compared to the population of the MMT 
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Indepednet t-test (t = -1.04, df = 58) indicated no significant difference (p = 0.30) 
between the prescribed doses between the methadone maintenance and the hazardous 
alcohol drinking behaviour group (See Table 4-20). There was no significant 
difference reported in the amount of the illicit drug use including heroin or crack 
cocaine. There was a slight difference in the number of participants who reported 
using illicit benzodiazepine, but it was not found to be signficiant. The SOWS score 






Group t df p-value 





-1.04 58 0.30 








square df p-value 
Missed dose (No. of 
participants) 
In the last week 
10 17   
 
0.84 In the last month 3 6 6.66 3 
Never 15 6   
In the last year 1 1   
Methadone use on top 
(yes/no) 
8/22 9/21 0.08 1 0.77 
Other medication (yes/no) 21/9 17/13 1.15 1 0.284 
SOWS score (Mean ±SD) 3.63 ±6.02 7.5 ±7.05 -2.2 58 0.02 
Illicit heroin use (%) 21 22 0.08 1 0.77 
Crack cocaine (%) 18 23 1.93 1 0.16 
Illicit benzodiazepines (%) 3 6 1.18 1 0.27 
Intravenous use (%) 10 15 1.71 1 0.19 
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HAU were presenting with more severe withdrwal symptoms compared to the MMT 
group. The following section will explore scores in each item of the SOWS. 
4.1.4.9 Severity of withdrawal symptoms 
The independent t-test was conducted to compare the severity of withdrawal 
symptoms between MMT group and HAU. The severity of withdrawal symptoms was 
obtained using the SOWS instrument to assess withdrawal symptoms during 
methadone treatment. The SOWS items include feeling sick, stomach cramps, muscle 
spasm or twitching, feeling of coldness, heart pounding, muscle tension, aches and 
pains, yawning, runny eyes and insomnia. Higher score in the items indicate higher 
severity of withdrawal symptoms. 
The mean score of withdrawal symptoms as reported from the SOWS questionnaire 
for the whole sample was 5.57 ± 6.79 (range 0 - 27). For the HAU group it was 7.5 ± 
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Table 4-21 A breakdown of the different symptoms of opiate withdrawal for the HAU 
and MMT groups  




t df p-value 
Feeling sick MMT 0.20 0.61 -2.99 58 0.001 
HAU 0.83 0.99    
Stomach cramps MMT 0.33 0.76 -1.03 58 0.30 
HAU 0.57 0.97    
Muscle spasm MMT 0.17 0.65 -1.52 58 0.13 
HAU 0.47 0.86    
Feeling of 
coldness 
MMT 0.47 0.90 -1.53 58 0.13 
HAU 0.83 0.95    
Heart pounding MMT 0.27 0.78 -1.09 58 0.27 
HAU 0.50 0.86    
Muscle tension MMT 0.30 0.75 -1.65 58 0.10 
HAU 0.67 0.96    
Aches and pains MMT 0.43 0.90 -1.61 58 0.11 
HAU 0.83 1.02    
Yawning MMT 0.37 0.72 -2.04 58 0.04 
HAU 0.83 1.02    
Runny eyes MMT 0.27 0.69 -2.13 58 0.03 
HAU 0.73 0.98    
Insomnia MMT 0.57 0.86 -3.27 58 0.001 
HAU 1.50 1.31    
*Standard deviation  
Descriptive statistics of the ten opiate withdrawal symptoms between the two groups 
of patients in the MMT group and patients in the HAU group were investigated in 
Table 4-21. It can be observed that the patients in the HAU group have higher scores 
than those of the MMT group in all symptom areas: feeling sick, stomach cramps, 
muscle spasm or twitching, feeling of coldness, heart pounding, muscle tension, aches 
and pains, yawning, runny eyes, and insomnia. Furthermore, the mean scores of all 
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ten withdrawal symptoms were higher in those of the patients in the HAU group. The 
mean difference will be further validated by the t-test of difference to see if the 
difference is significance or not based on the t statistics at the level of significance of 
0.05. 
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Table 4-22 Descriptive Statistics of SOWS Scores by Grouping of Methadone 
Maintenance Group (MMT) and Hazardous Alcohol Use Behavior Group (HAU) 
 Group Mean SD t df p-value 
Feeling sick MMT 0.20 0.61 -2.99 58 0.001 
HAU 0.83 0.99    
Stomach cramps MMT 0.33 0.76 -1.03 58 0.30 
HAU 0.57 0.97    
Muscle spasm MMT 0.17 0.65 -1.52 58 0.13 
HAU 0.47 0.86    
Feeling of 
coldness 
MMT 0.47 0.90 -1.53 58 0.13 
HAU 0.83 0.95    
Heart pounding MMT 0.27 0.78 -1.09 58 0.27 
HAU 0.50 0.86    
Muscle tension MMT 0.30 0.75 -1.65 58 0.10 
HAU 0.67 0.96    
Aches and pains MMT 0.43 0.90 -1.61 58 0.11 
HAU 0.83 1.02    
Yawning MMT 0.37 0.72 -2.04 58 0.04 
HAU 0.83 1.02    
Runny eyes MMT 0.27 0.69 -2.13 58 0.03 
HAU 0.73 0.98    
Insomnia MMT 0.57 0.86 -3.27 58 0.001 
HAU 1.50 1.31    
*Standard deviation  
 
Results of the independent sample t-test showed that the severity of the withdrawal 
symptoms in SOWS of feeling sick (t = -2.99, df = 58, p < 0.001), yawning (t = -2.05, 
df = 58, p = 0.05), runny eyes (t = -2.13, df = 58, p = 0.04), and insomnia (t = 3.27, df 
= 58, p < 0.001) were significantly different between patients in the methadone 
maintenance group and patients in the hazardous alcohol drinking behaviour group.  
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Urine concentration range values 
In the HAU group, the mean methadone concentration in urine at trough was µg/L 
2634.5 r 3431.9 µg/L (8.38-15901.6). The mean EDDP concentration at trough was 
11809.7 r36647.8 µg/L (186.2 - 302940.2). In the MMT group, the mean methadone 
concentration in urine at trough was 4450.3 r 5356.9 µg/L (11 - 20351.8) and the 
mean EDDP concentration at trough was 19072.5 µg/L r 36647.8 (68 - 258161.8). 
The methadone concentration was divided by EDDP concentration to produce urine 
methadone/EDDP ratio. The mean methadone/EDDP ratio was 0.49 r 0.62  (0.00 - 
4.01) compared to the mean methadone:EDDP ratio in the HAU group which was 
0.54 r 0.56 (0.0 - 2.38). 
Results of the independent sample t-test showed that the quality of life scores (t = 
0.23, df = 53, p = 0.82), methadone concentration (t = 1.41, df = 53,  p = 0.16), EDDP 
concentration (t = 1.78, df = 53,  p = 0.08), and ratio of methadone and EDDP (t = -
1.22, df = 53,  p = 0.23) were not significantly different between the groups. 
Therefore, the mean differences observed in the descriptive statistics analysis were 
not validated.   
4.1.4.10 Comparison of Severity of Methadone Dosage, 
Methadone Concentration, EDDP Concentration, Ratio of 
Methadone/EDDP, pH Levels across each Time Period 
The ANOVA test was conducted to determine which of the study variables 
(methadone dosage, methadone concentration, EDDP concentration, ratio of 
methadone:EDDP, AUDIT score, SOWS score, and pH levels) were significantly 
different in the time period of the baseline period time 1, time 2, time 3, and time 4.  
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The results showed that the dependent variables of methadone dose (F = 0.26, df = 
3.31, p = 0.85), methadone concentration (F = 0.42, df = 3.13, p = 0.74), EDDP 
concentration (F = 1.02, df = 3.13, p = 0.38), ratio of methadone:EDDP (F = 0.42, df 
= 3.13, p = 0.74), pH levels (F = 0.72, df = 3.13, p = 0.54), AUDIT score (F = 0.00, df 
= 3.13, p = 1.00), and SOWS score (F = 1.57, df = 3.13, p = 0.20)  were not 
significantly different across the four time periods. 
The urinary methadone concentration was divided by the urinary EDDP concentration 
to produce the urinary methadone/EDDP ratio. The mean methadone/EDDP ratio for 
all participants was 0.462 r 0.36 (range 0.0 - 1.8) as shown in Figure 4-10 averaged 
for each week of the whole month long study for the whole group.  
 
Figure 4-10 Urinary methadone/EDDP ratio during each week of the month long 
study for the whole group.   
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4.2 Study (1.b) Urinary methadone and EDDP measurements in 
patients being inducted onto methadone 
4.2.1 Background 
The induction phase of methadone treatment harbours a significant risk of overdose. 
Compared to other medications, methadone has a narrow index between the ratio of 
fatal dose and the maximum recommended initial dose (Repchinsky et al., 2003). 
Some studies reported deaths associated with low methadone doses between 30 mg 
and 50 mg (Nilsson et al., 1982). 
An Australian study reported similar findings, with previous episodes of treatment 
associated with reduced risk during treatment induction (Degenhardt et al., 2009) 
Degenhardt and colleagues also found that the majority of these induction deaths 
occured in the first two treatment episodes.  
Induction of CYP3A4 at the beginning of MMT probably explains, at least in part, the 
increased EDDP/methadone ratio, the increased clearance, the decreased elimination 
half-life and the decreased methadone steady-state plasma concentrations measured in 
patients at the first month of treatment (Wolff et al., 2000) and justifies the need for 
dosage adaptation.  
4.2.2 Methods  
Using a case series study, methadone and EDDP were measured at the onset of 
treatment (induction) in order to assess whether the ratio of EDDP:methadone could 
be used effectively as a biomarker for methadone compliance. The setting, inclusion, 
and exclusion criteria have been described in Chapter 5 above unless stated otherwise.  
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Six potential participants were approached to participate in the study, and three gave 
their consent. 
4.2.3 Results 
Three participants were recruited on the day they started their methadone. Participant 
number one was a 43-year-old male, who was self-referred and had no formal 
qualifications. He reported his ethnic background as ‘Other’. His methadone-starting 
dose was 50 mg/day. Participant number two was a 45-year-old female who reported 
not having any formal qualifications and described her ethnic background as White 
British. Participant number three was a 55-year-old male, who was also self-referred 
and reported having a GCSE/O-Level qualification. He described his ethnic 
background as White British. All of the participants in this study were unemployed 
and all smoked cigarettes, with an average of 15 r 8.6 cigarettes per day (10 - 25). 
None reported regular alcohol consumption and all scored zero on the AUDIT. 
However participant one described himself as a social drinker. 
Participant one reported receiving 50 mg/day of methadone compared to participant 
two and three who revealed receiving 30 mg/day of methadone at induction. When 
asked about receiving any other medication, only participant one reported receiving 
medication – he was prescribed an antidepressant. 
Participants also reported a history of using illicit methadone, with participant number 
one reporting using up to 200 mg of illicit methadone compared to participant two 
who reported using only 30 mg, and participant three who reported using 20 mg. 
Participants were asked about their illicit drug use in the past 28 days. Table 4-23 
summarises the illicit drug use reported. All participants reported using heroin with 
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participant number three reporting the highest amount of heroin use in the past month. 
Only participant one reported use of other illicit drugs: crack cocaine, cannabis and 
benzodiazepine which he described as a 5 mg valium pill. 
Table 4-23 Illicit drug use within methadone induction group as reported using the 


















1 Yes 4.2 Yes Yes 80 Yes 140 
2 Yes 5.6 No No - No - 
3 Yes 16.8 No No - No - 
 
4.2.3.1 Biological measurements 
A daily sample of urine was collected every day for 13 days from each participant. 
Table 4-24 summarises data from participant number one. The mean methadone 
concentration was 1467.2 ± 1595.9 (58.9 – 6506.8), the mean concentration of EDDP 
was 4151.4 ± 2819.7 (1108.7 – 107080.1), and the mean concentration of the 
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Table 4-24 Daily methadone urine concentration, EDDP urine concentration, and 



















1 30 788.4 3891.8 7 1.2 
2 30 58.9 1108.7 8 1.5 
3 30 1218.9 1844.7 6 1.6 
4 40 1776.9 2231.3 6 1.6 
5 40 638.6 1793.9 6 1.7 
6a 50 589.5 1667.8 7 2.1 
7a 50 1065.3 2526.2 6 1.7 
8 50 2052.9 4153.8 6 1.9 
9 50 1100.5 7408.1 7 1.6 
10 50 897.5 6789.1 7 1.0 
11 50 1163.1 5136.8 7 1.4 
12 60 6505.8 10780.1 6 2.7 
13a 60 1217.8 4636.0 7 2.5 
aWeekend 
 
Table 4-25 summarises data from participant number two. The mean methadone 
concentration was 2626.1 ± 3694.4 (40.7 – 9843.5), the mean concentration of EDDP 
was 5855 ± 7080.8 (215.2 – 23143.5) and the mean concentration of the 
EDDP:methadone ration was 6.6 ± 11.9 (1.5 –  42.4).   
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Table 4-25 Daily methadone urine concentration, EDDP urine concentration, and 
















1 30 778.7 2216.4 7 2.8 
2 40 1246.1 5725.2 7 4.6 
3* - -           - - - 
4 0 161.6 350.7 7 2.2 
5 40 160.7 1045.0 8 6.5 
6* - - - - - 
7 0 - 53.1 7 - 
8 40 9797.2 23143.5 6 2.4 
9* - - -       -  - 
10 0 40.7 1724.3 9 42.4 
11 40 2626.6 6469.7 6 2.5 
      12 40 9843.5 14536.8 6 1.5 
 13 40 2988.6 6418.3 6 2.1 
 14a 40 1189.5 2560.1 6 2.2 
*Missed methadone dose the day before 
aWeekend 
 
Table 4-26 summarises data from participant number three. The mean methadone 
concentration was 2481.9 ± 1461.8 (245.7 - 5461.4), the mean concentration of EDDP 
was 4021.2 ± 2431.6 (614.1 - 8958.9) and the mean concentration of the 
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Table 4-26 Daily methadone urine concentration, EDDP urine concentration, and 













pH EDDP/methadone Ratio 
3 
1 50 4033.8 4823.1 6 1.2 
2 50 2626.8 3918.4 6 1.5 
3a 40 5461.4 8958.9 6 1.6 
4a 40 3307.8 5317.6 6 1.6 
5 40 3250.7 5559.1 6 1.7 
6 50 2906.3 6206.8 6 2.1 
7 40 2975.7 5111.2 6 1.7 
8 50 2551.9 4973.6 6 1.9 
9 50 1690.6 2649.8 6 1.6 
10a 50 1672.0 1615.7 6 1.0 
11a 50 1258.4 1769.2 6 1.4 
12 50 283.7 757.6 7 2.7 




    158 
 
 
Figure 4-11 Presentation of three participants methadone concentration across the 
days of collection 
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Figure 4-12 Presentation of three participants’ EDDP concentration across days of 
sample collection  
 
A One-way ANVOA test indicated that there was no significant difference between 
the means of the methadone concentrations (F = 0.82, df = 1, p = 0.43) or mean of 
EDDP concentrations (F = 0.7, df = 1, p = 0.5). However, the EDDP:methadone ratio 
presented a significant difference (F = 3.1, df = 1 , p = 0.05) between the three 
patients. 
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Figure 4-13 Presentation of three participants’ EDDP concentration across days of 
sample collection  
 
From figure 4-1 we can see that patient number two had a peak of EDDP and 
methadone ratio. The other patients, however, exhibited ratios that were more stable, 
especially patient number three. The ratio seems to slightly increase on day number 
13 compared to day 1. Patient one reported the highest dose (50 mg); however, his 
ratio peaked on the second day of induction and then stabilised, with a slight peak on 
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4.2.4 Discussion  
Methadone was first introduced as a substitution treatment for heroin dependence in 
the 1960’s. The effectiveness of methadone was reflected in the reduction of crime, of 
the risk of HIV and Hepatitis C infections, and of mortality. The stabilisation and 
retention in the treatment led to patients increasing their contribution to society 
(Farrell et al., 1994). 
As outlined in Chapter 1, previous studies have focussed on plasma concentration of 
methadone; the relationship between dose and its trough plasma concentration has 
been established (Rostami-Hodjegan et al., 2001). However, using plasma in a clinical 
setting as a means to assess patients’ compliance is not routinely performed.   
Methadone concentration has also been investigated in urine samples. Recent studies 
have investigated methadone, its inactive metabolite EDDP, and the attempts to utilise 
these concentrations as a mean of monitoring patients’ compliance. However, a high 
degree of inter-individual variability has been reported. This may be due to the nature 
of the design of the studies in which samples were not linked to the clinical 
participants’ history including use on top of prescribed doses.  
The first study investigated the trough urinary concentrations of methadone and 
EDDP in sixty patients receiving methadone treatment to address the potential of 
utilisation of EDDP:methadone ratio as a biological tool to assess patients’ 
compliance. 
The main finding indicated that the over the 4 points of collection there was no 
significant difference in the EDDP:methadone ratio. However, it was reported with 
high inter-individual variability.  Further variables that were examined, including 
methadone concentration, EDDP concentration, SOWS scores, EDDP:methadone 
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ratio and methadone:EDDP ratio, did not present significant differences. This may be 
due to the fact that the patients collected in this study were all maintained on 
methadone during a steady state.  
Further investigation of the samples in the study reported extremely high values of the 
EDDP:methadone ratio compared to previous studies. Kreek et al. (1973) reported a 
mean ratio of 1.55 and range of 0.45-5.07 in urine samples collected from participants 
receiving a methadone dose between 80 mg and 100 mg. The high variability in this 
study’s results may be partially due to the fact that samples were collected at trough 
rather than 24-hour urine collection. However, it is more clinically realistic to collect 
at trough, as patients will be visiting the clinic to collect their daily dose and that is 
the most suitable time to collect urine samples to assess compliance. 
The study also found that the concentration of EDDP was higher than methadone in 
urine samples. The mean urinary methadone concentration at trough for the whole 
study population was 3497.23 ± 4553.76 µg/L (5.90 - 20351.8) and the mean urinary 
EDDP concentration at trough was 15106.9482 ± 36208.33 µg/L (0.05 - 302940). The 
concentration presents a high variability, which is consistent with previous findings 
indicating that the high variability measured in urinary concentrations limited the 
possible utilisation of excretion data (George & Braithwaite, 1999). However, unlike 
previous studies, our study investigated the concentrations of methadone and EDDP 
and the ratio between them at specific doses, and samples were collected at trough to 
control time of consumption variability. 
To further control variability, the samples in the study were analysed according to the 
doses that each participant reported receiving. Although the variability was still 
detected, the mean ratio was 17.8 ± 37.48 (0.5 – 142.6) in participants who received a 
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dose of 40 mg/day compared to 0.9 ± 7.5 (1.1 – 31.3) in urine samples in which 
participants reported receiving 50 mg/day. This variation between the ratios may be 
due to outliers in the group, who, when investigated, included a participant that had 
only been on methadone for 10 days, which might account for the variability in ratio. 
A study by Nielsen et al. (2013) investigated the possibility of utilising the ratio as a 
means of predicting the cause of death in patients receiving methadone maintenance. 
They predicted that it would be in those patients who had abstained from treatment, 
rather those who had complied, in which a wide difference between the metabolite 
and drug would be observed. The observation of this phenomenon was apparent in a 
few cases; however, only one participant was reported to have died. The cause of 
death was not linked to the methadone dose; instead it was due to alcohol 
complications. 
Methadone concentration and EDDP concentrations were also investigated separately. 
In accordance with previous findings, methadone and EDDP concentrations were 
significantly correlated with the methadone dose administered. However, this positive 
relationship was observed to become slower as the dose increases. This could be 
explained by the non-proportional change of metabolic formation when the metabolic 
pathway is saturated. 
The most common methadone dose of the 138 samples collected in the study was 40 
mg, closely followed by 50 mg. This indicated that the patients in this study were 
prescribed a lower dose than the 80 mg that other studies have recommended as an 
effective dose (Dole et al., 1965). High doses of methadone prescription have been 
found to be associated with higher treatment retention and less illicit drug use (Farrell 
et al., 1994). This is consistent with the findings of the results of self-report related to 
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illicit drug use in this study, with a high prevalence of heroin and cocaine use, where 
more than half of the participants (72.7%, n = 43) self-reported that they used heroin 
and also crack cocaine (68.3%, n = 41). Other substances were used less frequently; 
however, some participants reported using cannabis and benzodiazepine. These 
results indicated a strong correlation between dose, methadone concentration, and 
EDDP concentration. This is consistent with results presenting the relationship at 
trough between methadone dose and plasma (Rostami-Hodjegan et al., 2001); 
however, the study found a high degree of inter-individual variability, in which dose 
explains only a small part of the variation in methadone plasma concentration (Eap et 
al, 2000). 
Comparison between methadone maintenance and hazardous alcohol users  
In general, the observed findings show that the opioid co-dependent participants 
(HAU) had significantly higher scores on the withdrawal symptoms scales when 
compared with methadone maintenance group (MMT), who were identified by 
scroing less than 8 on the AUDIT score. These results indicate that patients who 
present with problematic alcohol use during the methadone maintenance can 
exacerbate withdrawal symptoms.  
This significant difference in the SOWS score between MMT and HAU groups could 
support a link between the endogenous opioid system and excessive alcohol 
consumption. Withdrawing from either of these types of substances affects the 
noradrenalin, GBA and NMDA neural circuit as well the depletion of dopamine levels 
(Volkow et al., 1999; Gianoulakis, 2001; de Wet et al., 2004). 
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The literature indicates that alcohol consumption in moderation stimulates the release 
of opioid peptides in those brain regions that are associated with reward and 
reinforcement, and mediates the reinforcing effects of alcohol. However, it was found 
that the central opioid deficiency is induced when larger amounts alcohol are 
consumed. This may be the reason why patients percieve the symptoms as opioid 
withdrawal, which may promote alcohol consumption through the mechanisms of 
negative reinforcement (Gianoulakis, 2001).  
These findings were in parallel with the concentration levels observed in which the 
methadone concentration was significantly lower in the HAU group than   in 
concentrations measured in the MMT group. This could be a reflection of the fact that 
methadone metabolism is directly affected by alcohol consumption. This is in line 
with previous studies that show that alcohol consumption can increase methadone 
peak concentration when it is acute but cab decrease methadone concentration when it 
is chronic (Clark et al., 2006). This can also be correlated with the fact that patients 
from the hazardous alcohol use group scored significantly higher on their SOWS 
scores than those in the MMT group. The more severe the withdrawal symptoms, the 
more likely patients are to use heroin on top and not comply with their methadone 
maintenance. The EDDP:methadone ratio was also significantly different between the 
two groups, which could again be related to methadone metabolism. 
Methadone and EDDP ratio in urine 
Previous studies have addressed the urinary excretion of methadone and its inactive 
metabolite EDDP (Leimanis et al., 2012), but few studies have addressed the potential 
of using methadone/EDDP ratio as a marker for metabolism in methadone treatment 
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by investigating the ratio at different stages of treatment and investigating the effect 
of alcohol consumption on the methadone/EDDP ratio.  
Although both EDDP and methadone concentrations indicated a positive relationship 
between both methadone concentration and EDDP concentration in urine and the 
methadone dose, EDDP was always reported to be higher concentration than 
methadone. However, the results also indicate variability in the methadone and EDDP 
concentrations between the participants in the group analyzed (HAU) but remained 
constant within individual participants over the period of a month. This is consistent 
with other research that has investigated methadone and EDDP concentration. 
However, the patients in these studies were receiving methadone for pain 
management, indicating much lower levels of methadone and EDDP concentrations 
(Leimanis et al., 2012). 
Induction is a critical stage of methadone treatment where the main dose adjustment 
occurs (Krambeer et al., 2001). It was indicated that there was no significant 
relationship between the EDDP:Methadone among the three patients. Previous studies 
managed to identify a 6-fold increase in the ratio during induction period; however, 
the study results indicated an increase in the ratio in only one patient. Patient number 
two exhibited a strikingly different pattern characterised with a peak during the days 
the patients missed her doses. The patient revealed in her self-report questionnaire a 
history of using illicit methadone which could be argued as responsible for the spikes 
in the graphs.  Further collection of urine samples for up to 40 days might have been 
useful. A limitation of this study was that the patients were asked to collect and store 
their urine samples over the weekend. Future work investigated patients in an 
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inpatient setting might help with eliminating variables that can affect the 
EDDP:methadone ratio.  
Demographics and characterisation 
The majority of patients in the study were male (62%). This correlates well with 
previous findings, indicating higher numbers of male patients receiving treatment for 
opioid dependence (Marsden et al., 2000; Gerra et al., 2003; Senbanjo et al., 2007). 
However, it is important to highlight that the smaller number of female patients does 
not indicate that the problem is less severe in this group. 
More than half of the sample (57%) described themselves as White British, although 
this could be a reflection of the location of the study in the South-East London 
borough of Southwark.  In this borough, the local authority’s statistics suggest that 
White British is the common ethnicity (Gossop et al., 2003).  
The study sample were socially deprived; all of the participants reported that they 
were unemployed, and the majority had secured no formal educational or vocational 
qualifications. The influence of social deprivation has been argued to affect the level 
of alcohol consumption in general, as well as that among patients receiving 
methadone maintenance treatment (Rodham et al., 2005; Senbanjo et al., 2007).  
Drug use and injecting behaviour 
Throughout the interviews, illicit drug use was high in both groups during the 
maintenance phase. The pattern of use was also very similar, with no amphetamine 
and only one case of powdered cocaine reported. However, heroin use continued 
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throughout the treatment, indicating non-compliance. There was no significant 
difference between the reported drug use between the groups  MMT and HAU groups. 
 Limitations  
The potential limitations of the study include the following: 
Recruitment and sampling method 
The present study requited participants at 4 points ideally once a week. This was to 
investigate variability in the ratio over time within the same participant; however, due 
to the sometimes chaotic nature of the participants in the study it was difficult to 
ensure compliance with itnerviews. 
Further sample collection was more successful with participants from the alcohol 
hazardous group because they were required to collect their methadone dose from the 
outpatient centre and to use a breathalyser before receiving their daily dose. However, 
it was sometimes difficult to engage with the participants when they presented with 
alcohol withdrawal symptoms. The urine sample was required to be collected before 
the participants received their daily dose (at trough), which was problematic with 
patients who exhibiting exhibited methadone withdrawal symptoms. 
4.2.4.1 Conclusion 
Concentrations of methadone and EDDP exhibited high variability in 
EDDP:methadone ratio. Although attempts to control some variables were presented 
in some sub-experiements in the study including investigating gender difference, 
dose, and alcohol consumption, variations were still observed. Although 
EDDP:methadone ratio might not be a specific tool for compliance, measuring the 
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EDDP and methadone can be utilised as specific biomarkers to indicate that patients 
had consumed their dose. 
4.3 Recent Alcohol Consumption Biomarkers (EtG and EtS) in 
Patients Receiving Methadone Substitution Maintenance 
Treatment 
4.3.1 Background 
Alcohol use among methadone maintenance patients has been well documented in 
literature. However, a means of assessing alcohol use in this population using 
objective measures has not been well established. Urine screening for illicit drug use 
is routinely clinically applied. Alcohol use among patients receiving methadone, 
although problematic, is not necessarily dependence. However, in some cases it may 
affect treatment outcome and can even lead to death. Traditional biomarkers measure 
alcohol indirectly and are therefore limited in aspects related to the time period since 
last consumption. Recently, there has been a focus in measuring direct alcohol 
metabolites including EtG and EtS. Data on the utilisation of the direct biomarkers of 
alcohol consumption (EtG and EtS) are limited. For this reason, using a cross-
sectional prospective cohort design, Study 2 investigated the effectiveness of Ethyl 
glucoronide (EtG) and Ethyl Sulphate (EtS) to screen for recent alcohol consumption 
in patients collecting their daily methadone dose. The purpose of the study was to 
help establish whether these new biomarkers could be used as tools for indicating 
alcohol use among clients receiving methadone substitution maintenance treatment.  
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4.3.2 Methods 
Sixty participants were recruited and provided signed written informed consent. Self-
reported data were collected regarding licit and illicit drug use, methadone treatment 
and other current treatment (See Appendices E and F). A urine sample (20 mL) 
voided unobserved was collected after the interview, and before administration of the 
daily dose of methadone (at trough). The study was conducted over a period of one 
month and participants were asked to provide a urine sample each week. The urine 
samples were frozen in the laboratory at -20° C until analysis. The consecutive 
interviews included a shorter version of the self-report questionnaire and related to 
alcohol and drug use in the past 24 hours. Urine samples were analysed for recent 
alcohol consumption biomarkers EtG and EtS using Liquid Chromatography coupled 
with Mass Spectrometry, as described in Chapter 5. 
4.3.3 Results  
Sixty participants, who were more than two weeks into methadone treatment, were 
recruited to the study (see chapter 6).  Almost half of the participants (53.3%, n = 32 
were in the age range of 39 to 47 years old. The mean age of the whole sample was 
41.67 ± 8.3 years (range 23 – 56 years). The majority of the participants described 
themselves as White British (58.3%, n = 35) and more than half of the participants 
were male (65%, n = 39). The mean methadone dose at baseline for the 60 
participants was 62 ± 26.8 mg methadone/day (range 25 –130 mg methadone/day).  
4.3.3.1 Alcohol Use Behaviour at Baseline  
Participants reported their alcohol use and results indicated that the mean number of 
units of alcohol consumed per day was 5.4 ± 6.2 units per day (0.0 – 40 units per day). 
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Participants mostly reported drinking strong beer (45%, n = 27). Some reported 
drinking ordinary beer (33.3%, n = 20), and a few reported drinking wine or spirits. 
Only one participant reported mixing the kinds of alcohol he or she drinks. The mean 
score of AUDIT was 13.1 ± 13.1 (0 – 38). Table 4-27 summarises the frequency of 
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Units per day 
1 2 0 31 30 19.5 
2 3 9 32 26 28 
3 0 0 33 26 12 
4 3 3 34 27 6 
5 0 0 35 38 5 
6 3 0 36 29 10 
7 2 0 37 9 9 
8 6 0 38 15 9 
9 0 0 39 33 21 
10 0 0 40 17 9 
11 0 0 41 24 4 
12 0 0 42 31 9 
13 1 0 43 31 8 
14 0 0 44 28 12 
15 1 0 45 37 12 
16 2 0 46 18 3 
17 2 0 47 36 30 
18 0 0 48 12 2 
19 1 3 49 12 4 
20 1 0 50 30 20 
21 2 0 51 16 15 
22 1 4 52 28 15 
23 6 3 53 33 32 
24 0 0 54 22 15 
25 6 0 55 30 16 
26 0 0 56 26 12 
27 2 3 57 20 6 
28 4 1 58 9 6 
29 0 0 59 32 27 
30 1 0 60 16 9 
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 Of the cohort (33.3%, n = 20) described their selves as non-drinkers. The mean 
number of units of alcohol per day consumed by the 40 participants was 12.4 ± 11.5 
(range 1 – 60) units of alcohol. The mean score for the Alcohol Use Disorders 
Identification Test (AUDIT) for the drinkers in the cohort was 13.1 ± 13.1 out of a 
possible 40 points (range 0 – 38 points). Out of the total cohort, 11 participants 
(18.3%) scored zero on the AUDIT score. 
Table 4-28 summarises the number of participants at risk level depending on AUDIT 
score. Although half of the participants were considered at low risk according to their 
AUDIT score (50%, n = 30), twenty-one participants (35%) were at high risk and 
were considered likely to be alcohol dependent.  
Table 4-28 Number of participants at risk level depending on AUDIT score 




Low risk 0-7 30 50 
Hazardous level 8-15 5 8.3 
Harmful level 16-19 4 6.7 
Dependence likely 20-40 21 35 
Total  60  
 
4.3.3.2 Urinary measurements of EtG and EtS 
Of the 60 participants receiving methadone maintenance, 56 urine samples were 
collected at baseline. Following baseline sample collection, the study attempted to 
collect a further three weekly urine samples from each participant.  In total, 138 urine 
samples were collected from the 60 participants. 
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Table 4-29 The provision of samples by the participants is shown 
Point of collection 
Number of samples 
 collected 
Number participants 
Baseline 56 22 
2 35 4 
3 30 13 
4 18 17 
Total  138 56 
 
A synopsis of the 56 samples collected at baseline is summarised in Table 7-3). A 
total of 138 samples were analysed for EtG and EtS. In those who screened positive 
for both EtG and EtS, the mean urinary concentration was 115.11 ± 199.87 mg/L 
(range 0.07 – 1000 mg/L) and the mean urinary EtS concentration was 49.32 ± 82.46 
mg/L (range 0.70 – 445 mg/L).  
In the positive urine samples, a statistical comparison between EtS and EtG 
concentrations using a Spearman’s Rank revealed a highly significant linear 
correlation across the different amounts of alcohol consumed. There was a strong 
relationship between EtG and EtS (rs = 0.97, df = 136, p<0.001). R2 was 0.951, 
indicating strong linearity, as shown in Figure 4-14. 
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Figure 4-14 Scatter plot of EtG concentration in relation to urinary EtS 
concentration (n=138) presenting a strong linearity  (p< 0.001, R2=0.951) 
 
The mean of the EtG/EtS ratio was 2.14 ± 1.06 (range 0.39 – 2.14) for the subjects 
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EtG and EtS urine concentration and self-report  (AUDIT score) 
The mean urinary EtG and EtS concentrations were calculated in all the samples 
collected (n = 138) and the range was calculated according to each alcohol risk level 
group depending on their AUDIT score  (see Table 4-30).  
 
Table 4-30 Descriptive statistics for urinary EtG and EtS concentration identified 















Mean ± SD 
(Range) 
 













Mean ± SD 
(Range) 
 
3.50 ± 9.51 
 (0.02 - 52.5) 
48.95 ± 131.71 
(0.05 - 445) 
91.38 ± 93.03 
(4.58 - 298) 
68.6 ± 84.53 
(0.05 - 393) 
 
Further investigation was carried out to determine if there was an association between 
urinary EtG concentration and AUDIT score shown in Figure 4-15. The AUDIT score 
can be seen in Figure 4-15. Using Pearsons Correlation coeffecient a significant linear 
correlation was found between urinary EtG concentration and AUDIT score (r = 0.43, 
df = 136, p<0.001). This indicates that urinary EtS concentration also correlated 
significantly with AUDIT score (r = 0.42, df = 136, p<0.001). 
Results of a One-way ANOVA indicated significant differences in both EtG (F = 
10.1, df = 3, p< 0.001) and EtS (F = 10.9, df = 3, p< 0.001) concentrations across risk 
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level groups (low risk, hazardous level, harmful level, alcohol dependent). This was 
followed by a Post Hoc test using Bonferroni, which indicated that the EtG 
concentration in the group with AUDIT scores ≥ 20 (M = 161.28, SD = 30.18, p = 
0.01) was significantly higher compared with the other AUDIT score groups. The EtS 
concentration in the group with AUDIT scores ≥ 20 (M = 64.55, SD = 12.41, p = 
0.01) was also significantly higher compared with the other AUDIT score groups. 
 
 
 Figure 4-15  Average urinary concentration of EtG and EtS in different risk level 
groups depnding on AUDIT score. One-way ANOVA analysis revealed significant 
differences in EtG concentrations (p < 0.001) and EtS concentrations (p < 0.001) 
between participants scoring (0-7) compared to participants scoring (>20) 
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EtG and EtS urine concentration and self-report   
At baseline, 56/60 participants had trough urine samples analysed for EtG and EtS 
and this was compared to self-reported alcohol use in the past week. Of the 56 
participants, 33 reported consuming alcohol in the past 24 hours while seven 
participants reported consuming alcohol earlier in the week. Twenty participants 
reported not drinking (33.3%).  
Related samples were analysed for EtG and EtS and found most of the samples were 
positive for both EtG and EtS (70%, n = 42) and only five samples were negative 
(8.3%). However four participants (7.1%) were only positive for EtS, which may 
indicate drinking earlier in the week. Five participants were only positive for EtG, 
which could be attributed to sample fermentation or degradation due to bacterial 
growth. 
During the rest of the study participants were asked about their alcohol use in the past 
24 hours. In the further 78 interviews that took place after the initial baseline 
interviews, alcohol use was reported forty-nine times (62.8%) while twenty nine 
(37.2%) reported not using alcohol in the past 24 hours. Urine samples were collected 
and analysed for EtG and EtS (n=78). Only 14 samples (17.9%) presented with 
negative urine EtG and EtS. Fifty-seven samples (73.1%) were positive for both EtG 
and EtS while 4 (5.1%) were only positive for EtG; and 3 samples (3.8%) were 
positive for EtS only. 
EtG and EtS urine concentration and alcohol units consumed    
Pearson Correlation analysis established a significant relationship between EtG and 
self-reported alcohol use (r = 0.46, df = 136, p< 0.001). 
The amount of alcohol consumed in the past 24 hours reported by participants was 
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found to be 5.4 ± 6.2 units per day (0.0 – 40 units per day).  A Spearman Correlation 
indicated that there was a significant correlation between the level of consumption 
and the EtG (rs = 0.71, df = 136, p< 0.001) and EtS (rs = 0.72, df = 136, p< 0.001) 
concentrations identified in participants’ urine samples (see Figure 4-16). 
 
 
Figure 4-16 Scatter plot of EtG and EtS urinary concentration (mg/L) in samples 
collected from participants receiving methadone substitution (n=138) in relation to 
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Comparison of male and female participants for urinary EtG and EtS 
Comparison of the demographics, AUDIT score, SOWS scores, EtG, and EtS 
concentration between female and male participants was conducted. An independent 
t-test was used to compare these variables between female and male participants. A 
level of significance of 0.05 was used in the statistical analysis.  
Table 4-31 summarised the comparison of demographic data, which include age, and 
AUDIT score, divided among the female and male patients as well as the p-value of 
the t-test to show the significance of the difference of the two gender groups. All the 
p-values in Table 4-31 were greater than the level of significance except for age, 
indicating that there were no significant differences between the genders in the study. 
A comparison of the opiate withdrawal scores at baseline between female and male 
participants was also conducted and the results showed that there no significant 
difference was indicated (t = -0.27, df = 58, p = 0.77). This indicated that the female 
participants did not experience more severe withdrawal symptoms compared to those 
of the men in the study group. 
Table 4-31 Demographics and alcohol use behaviour at baseline for male and female 
participants 
 Male (n=39) 
Female 
(n=21) t df p-value 
Age  
Mean  ±  SD 
43.6  ± 
7.9 
38  ± 
7.9 -2.63 58 0.01 
AUDIT score  12.9 13.6 0.19 58 0.85 
Self reported alcohol use (yes) 25 15 -0.57 58 0.57 
Methadone dose (mg/day) 
Mean ±SD 
60  ± 26 65  ± 28 0.67 58 0.51 
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Table 4-32 summarises the comparison of EtG, EtS, and ratio EtG/EtS concentration 
divided among the female and male patients as well as the p-value of the t-test to 
show the significance of the difference between the two gender groups. The p-value 
of the t-test showed that the EtG, EtS, and ratio EtG/EtS concentration failed to show 
a statistical significant difference between men and women, since all the p-values 
were greater than the level of significance of 0.05.  
Table 4-32 The concentrations of biomarkers for male and female participants in the 
study 
 Male (n=39) 
Female 
(n=21) t df p-value 
 






69.8 -0.57 135 0.56 





33.5 -0.23 135 0.93 
EtG/EtS 
ratio 2.12 1.82 -0.71 135 0.52 
 
Figure 4-17 presents the mean urinary concentration of EtG and EtS in female and 
male participants using One-way ANOVA analysis which revealed no significant 
difference between them. 
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Figure 4-17 Mean urinary concentration of EtG and EtS in female and male 
participants One-way ANOVA analysis revealed no significant difference between 
them. 
 
4.3.3.3 The relationship Between Methadone Concentration and 
Alcohol Self Report and Objective measure  
Table 4-33 summarises the descriptive analysis of methadone concentration in the 
different risk group according to the AUDIT score. A one way ANOVA followed but 
a Post Hoc test found no significant difference between the groups and the methadone 
concentration (F = 1.8, df  = 3, p =  0.1).  
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Table 4-33 Description statistics for the methadone concentration in alcohol risk 







Interval for Mean 
Min Max 
   Lower Upper  
Low risk 
(0-7) 
4346.44 5452.05 2925.62 5767.25 5.9 20351.8 
Hazardous 
(8-15) 
1562.77 1865.20 309.70 2815.83 108.6 5516.8 
Harmful 
(16-19) 
2325.71 2552.51 -34.96 4686.38 192.74 6506.3 
Dependent 
>20 
2944.34 3534.93 1894.59 3994.09 49.74 15901.6 
Total 3458.13 4497.2 2655.40 4260.85 5.9 20351.82 
 








    184 
 
Figure 4-18 Scatterplot presenting the relationship between EtG and methadone 
concentration. 
 
From figure 4-18 we can observe no relationship between methadone concentration 
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4.3.4 Discussion 
4.3.4.1 Recent Alcohol Consumption Biomarkers (EtG and EtS) in 
Patients Receiving Methadone Substitution Maintenance  
The aim of study 2 was to investigate the application of the new recent alcohol 
urinary biomarkers EtG and EtS during methadone substitution treatment. In total, 60 
participants were interviewed at baseline and a total of 138 urine samples were 
collected after further interviews within four weeks of the first interview.  
The main findings indicated that EtG and EtS were both detected in this group of 
patients. In our study, 100 out of 138 samples were positive for both EtG and EtS 
(41%). The use of direct alcohol biomarkers has been of increasing interest and has 
been investigated in recent studies; however, patients were mainly alcohol dependents 
and the biomarkers were aimed at investigating abstinence (Wurst et al., 1999).  
At baseline the findings of the study indicated a high level of agreement between 
positive EtG and EtS urine levels and self report in the past 24 hours or past week 
(Cohen’s Kappa 0.169). Wurst et al. measured urinary EtG and EtS in patients 
receiving methadone substitution and were able to detect positive results in 15 
patients out of 26 who reported alcohol use in the past 7 days. Reassuring the patients 
about the confidentiality of the results may influence the high agreement between 
EtG/EtS levels and reported alcohol use in the study. However, further analysis of the 
samples collected indicated that several patients with positive EtG and EtS levels did 
not report any alcohol use in the past 24 hours (n = 29). These findings, however, 
might be due to consumption of alcohol before the 24 hour period. Studies have 
reported the detection of EtG for up to 4 days after alcohol consumption among 
participants who reported drinking heavily (Seidl et al., 2001). Another explanation 
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for this observation is that EtG might accumulate in prolonged drinking (Schmitt et 
al., 1997). Therefore, although EtG and EtS can be utilised in detecting alcohol use 
among patients receiving methadone, positive results may indicate a longer time-
frame in which alcohol was consumed. However, no studies have reported detecting 
EtG or EtS for longer than 7 days.  
The relationship between EtG and EtS was investigated using a Spearman’s Rank 
Correlation, which indicated a strong association between the two analytes (R2 = 
0.95). Further investigation using linear regression was conducted to allow more 
accurate visualisation of the relationship. Linear regression presented in a scatter plot 
indicated that concretions with lower values had a better relationship. A histogram 
was also used to indicate the range of the ratio measured in the samples, which had a 
mean of 2 and ranged between 0.39 and 24. One sample had an extremely high ratio 
(24) and further investigation indicated that the sample was only negative for EtS. In 
total there were eight samples that were only negative for EtS and another eight that 
were only negative for EtG. In the case of a negative value for EtS, this could be 
attributed to the false positive of the EtG, which has been documented in previous 
studies (Dahl et al., 2002) as arising from urine bacterial contamination.  However, 
the studies have shown that it is only EtG that degrades through bacterial hydrolysis 
and not EtS. This is related to the presence of the B-Glucuronidase in most E.coli 
strains, which is the most common pathogen in urinary tract infections, indicating that 
there is a risk of false EtG results (Ronald et al., 2002). However, EtS is not affected 
by bacterial hydrolysis and due to the similar time course in detection, measurements 
of both EtG and EtS have been recommended to avoid false positives (Helander and 
Beck, 2004; Helander and Beck, 2005).  
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In those participants who screened positive for both EtG and EtS, the value of EtG 
and EtS concentrations had a wide range. The mean urinary concentration was 115.11 
± 199.87 mg/L (range 0.07 - 1000 mg/L) and the mean urinary EtS concentration was 
49.32 ± 82.46 mg/L (range 0.70 - 445 mg/L).  
These findings correspond with previous studies indicating that EtG levels are usually 
higher than EtS levels. Both our studies, and other studies of EtG and EtS in blood 
and urine (Helander et al., 2009) indicated that levels of EtG were higher than the 
corresponding levels of EtS, even when the levels are corrected for their different 
molecular weights, with molar EtG/EtS ratios reported as 1.7. Only one study 
(Helander  et al.) in urine showed higher concentrations of EtS than EtG .  
Previous studies have mainly been in healthy participants (Wurst et al., 2006; Lostia 
et al., 2013). Studies investigating alcohol patients have reported a higher EtG 
concentration of 130 mg/L and a higher concentration of 110 mg/l for EtS. However, 
these levels may be due to the objective of the study, which was to look at alcohol 
levels during alcohol detoxification (Helander et al., 2009). Slightly higher results 
were reported by Dahl et al. (2011) in a group of patients who received methadone 
substitution: altogether, 26% of the urine samples from 12 of 24 patients tested 
positive for EtG (0.5–434 mg/l) and/or EtS (0.1–87 mg/l). 
In this study, the value of EtG and EtS were given the absolute amount of (mg/L) and 
were not normalised to creatinine content. Although correction to creatinine is a 
common practice to compensate for diluted urine samples (Bendtsen and Jones, 
1999), studies have indicated that the inter-individual variability is noted even after 
the correction in excretion (Goll et al., 2002), and even when the same dose of alcohol 
has been administered (Sarkola et al., 2003). 
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Cut-off values have been established in clinical studies to avoid false positive results 
(exposure to mouth washes and sanitizers). However, there is no reporting limit 
established for urinary EtG and EtS. In this study, a threshold of 0.05 mg/L for both 
EtG and EtS was used. Eight samples were found to be EtS positive only. All the 
samples were from patients who scored less than 8 on the AUDIT. This can be an 
indication of alcohol consumption earlier in the week and possible under-reporting of 
alcohol consumption. 
One aim of the study was to identify the use of alcohol using a self-report screening 
tool compared to objective measures. Our findings indicated that AUDIT was 
successful in screening patients with problematic alcohol consumption. The use of 
screening tools to identify alcohol use among patients receiving methadone 
substitution treatment has been reported in the literature in Chapter 2. Teplin et al. 
(2007) used the MAST questionnaire and were successful in finding that 76% of 
patients presenting to clinics in the province of Ontario presented with alcohol 
problems, of which 9% suggested alcohol dependence. However, the author reported 
that the high prevalence of reported alcohol consumption may have been influenced 
by the reassurance that the data will be confidential. Another study by Senbanjo et al 
(2007) used the AUDIT among methadone patients to evaluate the impact of 
excessive alcohol consumption on quality of life. Although the evidence of alcohol 
consumption among patients receiving methadone treatment has been well 
established, there is a lack of clear guidance and policy for alcohol screening and 
testing in methadone treatment clinics. The clinic from which the participants in our 
study were recruited did have a protocol in place: patients who had been identified as 
having problematic alcohol consumption were required to be screened daily using a 
breathalyser. However, it is likely that some patients who do not present with alcohol-
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related problems would remain undetected in the absence of a screening procedure. 
Thus patients who drink in a binge pattern risk being undetected. The results also 
indicated that some of the patients who scored less than 8 on the AUDIT, i.e., those 
who were low risk, had urine samples that were positive for EtG/EtS, indicating that 
they had consumed alcohol in the past 72 hours. This is consistent with findings by 
Gossop et al. (2003). The findings of our study indicate that a high number of patients 
who are presenting with alcohol problems scored 20 or more on the AUDIT, 
indicating the likelihood that these patients are alcohol dependent. 
This evidence of problematic alcohol consumption in individuals on a methadone 
substitution programme is consistent with previous studies, where up to 50% of 
heroin dependents in receipt of methadone treatment also had alcohol-related 
problems (Rittmannsberger et al., 2000; Hubbard et al., 1986; Ottomanelli et al., 
1999). In the United States, the Drug Abuse Treatment Outcome Studies (DATOS) 
indicated that of all methadone treatment patients, between 20% and 50% present 
with alcohol related problems (Hubbard et al., 2003). The concurrent dependence on 
alcohol among patients receiving methadone substitution treatment has also been 
highlighted in the literature. However, studies have indicated that the numbers are 
usually lower than anticipated and alcohol dependence is more likely to be present in 
patients who also found to be cocaine dependent and are therefore polysubstance 
users (El-Bassel et al., 1993; Senbanjo et al., 2007).   Using AUDIT as a screening 
tool, of the patients scoring 8 or more, 35% (n = 21) scored 20 or more, indicating 
alcohol dependence.  
Although more male patients presented with hazardous or harmful alcohol 
consumption, the excess was not significant. This is also consistent with previous 
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findings of Grella et al. (1999), suggesting that in a methadone maintenance clinic, 
male patients are more likely than female patients to misuse alcohol. 
Of the 138 samples, 100 were positive and 22 were negative. Eight samples were  
positive for EtG only and another eight were  positive for EtS only. Previous work 
(Dahl et al., 2011) has expressed concern regarding false-positive results due to 
accidental exposure, such as the use of hand sanitizers or alcohol mouthwash. The 
introduction of a cut-off between 100-250 ug/L to exclude any accidental exposure of 
alcohol and to measure EtS simultaneously would limit this false positive. The 
potential of false positives has also been investigated in in vitro formation and 
degradation of EtG and EtS, highlighting the potential of causes due to urinary tract 
infections. One study indicated a complete degradation of EtG within 3-4 days by 
E.Coli; however EtG remained stable for up to 11 days (Helander et al., 2007). 
The findings of the self-reports of alcohol were more consistent in patients who 
scored more than 8 in the study compared to patients who scored less than 8. This 
might be explained as due to the fact that these patients were more likely to be 
breathalysed and were informed that the data were confidential. This is consistent 
with previous research, demonstrating that EtG has high specificity by Wurst et al. 
(2003). 
Findings also indicated that both EtG and EtS were significantly correlated with 
AUDIT scores. This indicates that AUDIT could be used as a reliable participantive 
measure of alcohol use.  However, some participants who scored below 8 presented 
with positive urinary EtG and EtS, indicating recent consumption, possibly low 
amounts of alcohol. Even low or infrequent alcohol consumption on a methadone 
treatment programme has the potential to be problematic, and in some instances, it 
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can be fatal. The importance of monitoring participants who consume alcohol, even 
those who consume alcohol in a less overtly problematic fashion, is still important, 
because episodic alcohol consumption in this group can be risky. No previous studies 
have investigated the correlation of AUDIT and EtG or EtS levels.  These findings are 
consistent with Wurst et al.’s results (2008a): using the total score of the AUDIT, Hair 
EtG confirmed 10 more cases positive for alcohol, and of the 14 participants who 
reported no alcohol intake during the previous 7 days, 4 were Urine EtG positive.  
4.3.4.2 Clinical Implication 
The data from the present study provide supportive evidence of the usefulness of 
measuring recent alcohol biomarkers urinary EtG and EtS in patients receiving 
methadone maintenance. The results indicated that these new biomarkers were able to 
detect alcohol use in both patients presenting with problematic alcohol consumption 
as well as patients who are not routinely monitored by the clinic but who however 
might drink in a binging pattern or use alcohol less frequently. 
The results also indicate a high correlation between biological markers EtG and EtS in 
urine and the AUDIT positive scores. Therefore dual use of objective and 
participantive measure can be utilised to provide a more sensitive and specific means 
of identifying alcohol recent consumption. This can be useful at the beginning of the 
treatment where patients who consumed alcohol excessively can be detected early in 
the treatment and receive the intervention, which addresses a range of alcohol 
problems. The application of these tools are also useful during maintenance treatment, 
especially in cases where patients are not attending daily or have missed their doses 
for one or more days or over the weekend. It is also important to note that pattern of 
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alcohol consumption affects the methadone metabolism as discussed in Chapter 6. 
Acute alcohol consumption leads to methadone interaction and increases the potential 
of overdose. This also highlights the potential application of EtG and EtS, which, in 
comparison to liver biomarkers for chronic alcohol consumption, can detect cases of 
binge drinking.  
In conclusion, alcohol consumption can be problematic among patients receiving 
methadone. Alcohol use may hinder methadone treatment outcomes and in some 
cases can cause overdose and death. The use of traditional biomarkers do not directly 
measure alcohol. Liver enzymes are difficult to interpret in patients receiving 
methadone treatment due to the high prevalence in this population of hepatitis C 
infections. Substitution treatment represents a common challenge. In some cases, 
patients present with concomitant alcohol dependence that leads to negative treatment 
outcomes including disengagement with treatment (Stenbacka et al., 2007). The 
results of this study indicates that urinary EtG and EtS testing among patients 
receiving methadone substitution was successful in objective screening for recent 
alcohol use. Therefore EtG and EtS can be considered valuable objective tools to 
assist with obtaining a fuller clinical picture during methadone substitution treatment.    
4.4 Study 3: An Investigation Exploring the Use of the Breathalyser 
during Methadone Treatment 
4.4.1 Background 
This study investigated breathalyser readings in patients receiving methadone 
maintenance who were on fixed daily dosing regimes and who met criteria for 
hazardous/harmful alcohol use. The aim of the study was to help establish whether the 
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clinic’s breathalyser cut-off limit for alcohol use among clients receiving methadone 
replacement was a suitable measure of their alcohol consumption.  
4.4.2 Methods 
Validated questionnaires were administered, including the AUDIT (screening), LDQ 
(a measure of dependence), and the SOWS and SAWS, both measures of withdrawal 
(see Appendix F). Questions related to alcohol included family history, amount 
consumed on a typical day and time of last consumption when collecting methadone. 
A urine sample was collected after the interview to measure EtG and EtS levels. All 
samples were collected in 20mL universal tubes at trough, i.e., before administration 
of the daily dose of methadone. Participants were provided with a urine bottle and 
asked to void unobserved. The urine samples were frozen in the laboratory at -20° C 
until analysis. At the end of the interview, each participant was assigned an 
appointment for his or her next interview. The whole procedure, including the 
structured interview, took approximately 30-40 minutes.  
4.4.3 Results  
4.4.3.1 Demographic Information  
Table 8-1 summarises the demographic information regarding the 23 study 
participants. Since the data were measured categorically, frequency and percentage 
summaries were used. Almost half of the participants were either self-referred 
(21.7%, n = 5) or were referred by a consultant (21.7%, n = 5).  More than half were 
White British (73.9 %, n = 17) and only two were currently employed (8.7%). The 
majority  (73.9%, n = 17) of the patients had no formal educational qualifications, 
    194 
while four (17.4%) had GCSE or O-level qualifications. The mean age was 41.5 years 
old (range 29-57). Almost half (53.3%, n = 16) were in the age range 38 to 45 years.  
Further demographics related questions were collected from the subjects’ medical 
records. Of the 23 subjects, only four were receiving benefits (17.4%). In terms of 
housing, most of the subjects’ accommodation type was known (39.1%, n = 9): eight 
subjects lived in council accommodation (34.8%) and four reported being homeless 
(17.4%). Only one subject reported owning property and one reported privately 
renting. More than half of the subjects reported living alone (56.5%, n = 13). 
Participants were asked about their driving history and results indicated only one 
participant out of the 23 reported having a valid driving licence. Five participants 
(21.7%) reported having previously held a licence and (21.7%) also reported being 
held for drink or drug driving. None of the participants reported driving to the clinic. 
Table 4-34 Frequency and Percentage Summary of Demographic Information in 
terms of sex, ethnicity, and referral route 
Demographic Frequency (n) Percent (%) 
Sex   
Female 7 30.4 







Irish 3 13 
Caribbean 1 4.3 
Other 2 8.7 
Referral route 





Referred by GP 1 4.3 
Sent by family 3 13 
Transfer from prison 3 13 
Referred by a consultant 5 21.7 
Other 6 26.1 
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Table 4-35 Frequency and Percentage Summary of Demographic Information in 
terms of employment, benefits, accommodation, living status, and education 
Demographic Frequency (n) Percent (%) 
Employment    
Employed 2 8.7 
Unemployed 16 69.6 
Other 5 21.7 
Benefits   
Receives benefits 4 17.4 
Do not receive benefits  19 82.6 
Accommodation    
Council 8 34.8 
Owned 1 4.3 
Homeless 4 17.4 
Rent  1 4.3 
Not known  9 39.1 
Living Status   
Lives alone 13 56.5 
With a partner 2 8.7 
With family 3 13.0 
With a friend  1 4.3 
Not known 4 17.4 
Education   
No formal qualifications 17 73.9 
GCSE / O-Level 4 17.4 
Vocational qualifications  2 8.7 
 
4.4.3.2 Medical Health  
Participants completed two scales adapted from the Treatment Outcome Profile (TOP) 
relating to health, which included a subjective rating score between 0-20 for physical 
and psychological health status. The mean subjective physical health score was 8.7 r 
4.2 (range 3-18), whereas the mean subjective score for psychological health was 10.1 
r 5.2 (range 1-20). 
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From the data collected from the ePJS (electronic patient journey system) clinical 
records, more than half of the patients tested negative for HIV (n = 14, 60.9%); the 
remaining nine subjects had no evidence of testing having been carried out. All 
subjects had been tested for hepatitis-C: 10 had tested positive (43.5%), nine tested 
negative (39.1%) and for four subjects the results were unrecorded and thus unknown 
to the researcher (17.4%). All 23 participants had been tested for hepatitis-B. Almost 
half of the subjects were immunised against hepatitis-B (n = 13, 56.5%). Nine 
subjects were negative (39.1%) and only one subject tested positive for hepatitis-B. 
Hepatitis-B vaccination status indicated that only eight subjects were found to have 
completed the vaccination course (34.8%).  
Thirteen subjects (56.5%) reported being prescribed only methadone. Of the ten 
subjects (43.5%) who reported that they were being prescribed another medication 
along with methadone, four (17.4%) were prescribed antidepressants, five (21.7%) 
were prescribed more than two medications, and one was prescribed an antipsychotic. 
4.4.3.3 Methadone treatment  
Participants were asked about the year in which they were first prescribed methadone, 
and responses ranged between 1999 and 2014, indicating that some subjects had first 
been prescribed methadone more than 12 years previously. The mean dose of 
methadone prescribed was 61.3 ± 18.4 mg/day (30 – 100 mg/day). Almost all of the 
subjects collected their methadone prescriptions daily (n = 20, 87%). Only one subject 
collected his dose from the clinic weekly and another subject reported collecting his 
dose from the clinic once every two weeks. More than half of the subjects reported 
missing a dose in the last week (65.2%); four reported never missing doses (17.4%) 
and only three reported missing their methadone dose (earlier) in the past month. 
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Almost all of the subjects reported that they found themselves increasing their alcohol 
intake when they missed their methadone dose (82.6%). Eleven subjects reported 
using illicit methadone (47.8%); however, they also reported this as infrequent.  
4.4.3.4 Alcohol and Illicit Drug Use History  
Table 4-36 summarises the results of a t-test analysis conducted on female and male 
alcohol and illicit drug use history in subjects in the study.  
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Table 4-36 T-test analysis of female and male alcohol and illicit drug use history in 








t df p-value 
Family history       
Alcohol dependence (yes/no) 17/6 11/5 6/1 -0.83 21 0.39 
Received alcohol dependence 
treatment (yes/no) 
6/17 5/11 1/6 0.83 21 0.39 
Drug dependence (yes/no) 13/10 9/7 4/3 -0.38 21 0.96 
Received drug dependence 
treatment (yes/no) 
12/11 8/8 4/3 -0.3 21 0.75 
Mean age of first use (SD*) 21 (5) 20 (5) 23 (20) 1.23 21 0.23 
Problematic Substance  
(N, %) 
   
  
 
Main problematic substance Heroin (19, 
82) 





9 4 1.06 19 0.32 
Third problematic substance Alcohol 
(14, 60.9) 
11 3 1.24 20 0.17 
Route of Administration  
(N, %)    
  
 
Smoking  (6, 26.1) 5 1    
Injecting (15, 65.2) 10 5 0.92 21 0.37 
Oral (2, 8.7) 1 1    
State of Injecting (N, %)       
Currently injecting (12, 52.2) 9 3 -0.91 21 0.92 
Not injecting (9, 39.1) 6 3    
Never injected (2, 8.7) 1 1    
Injecting in the past 28 
days N (%)  
   
  
 
Yes 11 (47.8) 8 3 0.32 21 0.77 
*SD = Standard Deviation 
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The analysis found no significant differences between female and male participants 
with respect to alcohol consumption.  
4.4.3.5 Illicit drug use  
Table 4-37 summarises self-reported information on participants’ illicit drug use.  
Table 4-37 Self reported data on illicit drug use 
Demographic Sample (n= 23) 
Heroin use in the past 24 hours (yes/no) 17 (73.9%) / 6 (26.1%) 
           Amount in grams in the past 24 hours (g) 0.37 ± 0.27 (0.5 – 1.2) 
           Average amount per day in pounds (£) 18 ± 12 (5 – 60) 
           Use in the past month (yes/no) 19 (82.6 %) / 4 (17.4 %) 
           Number of days used 18 12 (2- 28) 
Crack use in the past 24 hours (yes/no) 12 (52.2%) / 11 (47.8%) 
           Amount in grams in the past 24 hours (g) 8.4 ± 28 (0.03 – 100) 
           Average amount per day in pounds (£) 18.8 ± 22.9 (5 – 100) 
           Use in the past month (yes/no) 16 (69.6%) / 7 (30.4%) 
            Number of days used 9.6 ± 9.4 (28 – 9.6) 
Cannabis use in the past month (yes/no) 5 (21.7 %) / 18 (78.3%) 
Benzodiazepine use in the past month (yes/no) 7 (30.4 %) /16 (69.6%) 
 
Seventeen subjects (73.9 %) reported using heroin in the past 24 hours, while 12 
(52.2%) reported using crack cocaine. The use of heroin and other illicit drugs 
indicated a high level of treatment non-compliance. Seven subjects (30.4%) reported 
using benzodiazepine, and one subject reported using up to seven 10 mg diazepam 
pills per day.  
4.4.3.6 Alcohol consumption behaviour and related data  
All participants reported drinking alcohol regularly, and all except one reported 
drinking in the past month (95.7%). Nineteen participants (82.6%) reported drinking 
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strong beer, with 14 (60.9%) reporting drinking alcoholic beverages with ABV of 9%.  
Of the subjects who reported drinking, the mean number of alcohol units consumed in 
the past month was 627 ± 377.2 units of alcohol (4 – 1260) units of alcohol. All 
except two of the subjects reported drinking in the previous 72 hours. The mean 
number of units of alcohol consumed in the previous 24 hours was 35.4 ± 53.6 units 
of alcohol (range 4.2 – 270 units). Some subjects reported that their last drink had 
been taken in  the late evening (between 9pm and 12am), while 12 participants 
(52.1%) reported that their last drink had been taken during the early hours of the 
morning. Thirteen participants reported drinking before consuming their daily dose of 
methadone (56.5%), while nine (39.1%) reported drinking after receiving their 
methadone dose. The mean score for the Alcohol Use Disorders Identification Test 
(AUDIT) was 25.1 ± 9.8 out of a possible 40 points (range 1 – 40 points). 
 
4.4.3.7 Breathalyser Data 
All participants reported being breathalysed when they attended the clinic to receive 
their methadone treatment. Nineteen participants (82.6%) reported being breathalysed 
at each attendance, two (8.7%) reported being breathalysed at about one-half of their 
attendances while another two reported that they were rarely breathalysed. 
Participants were asked to recall their most recent ‘failed’ breathalyser reading 
(according to the guidelines in the Blackfriars clinic, > 0.39 g alcohol/l is considered 
failing), and the mean score was 0.51 ± 0.14 g alcohol/l (0.34 – 0.89 g alcohol/l). 
Three subjects reported blowing over the cut-off limit on the day of the interview 
(13%). Four participants reported failing the breathalyser test the day before the 
interview (17.4%) and four reported failing the test in the previous week. Four 
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reported failing the breathalyser test in the last year, and six participants (26.1%) 
reported never failing their breathalyser test. Only one reported failing it (earlier) in 
the same week of the interview and one reported failing the test in the last month.  
Fifteen of the participants (65.2%) reported changing their alcohol consumption 
behaviour to avoid failing the breathalyser test. Of these, eight participants (34.8%) 
did not drink alcohol in the morning before visiting the clinic. Four participants 
(17.4%) reported that they tried to stop drinking early the previous evening in order to 
avoid failing the breathalyser test, and two (8.7%) reported having chosen drinks of 
lower ABV than they typically consumed.  
4.4.3.8 Withdrawal Symptoms  
Participants were also asked to complete the Subjective Opiate Withdrawal Scale 
(SOWS) and Subjective Alcohol Withdrawal Scale (SAWS). The SOWS measures 
the presence and intensity of symptoms of opiate/opioid withdrawal and the SAWS 
measures symptoms of alcohol withdrawal. Both are self-administered ten-item 
questionnaires for which each item is rated on a four-point scale  (0 = none, 1 = mild,  
2 = moderate,  3 = severe) (see Table 4-38).  
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Table 4-38 Results of SOWS and SAWS scores 
Subject number SOWS score SAWS score 
1 0 0 
2 30 0 
3 3 6 
4 30 30 
5 30 30 
6 0 0 
7 13 29 
8 0 0 
9 5 8 
10 2 6 
11 16 21 
12 0 23 
13 12 15 
14 0 2 
15 27 16 
16 0 0 
17 22 18 
18 0 15 
19 14 9 
20 0 9 
21 9 13 
22 3 11 
23 0 1 
Mean ± SD 11.3 ± 10.1 9.3 ± 11.2 
 
The mean SOWS score was 11.3 ± 10.1 (0-30), slightly higher than the mean SAWS 
score of 9.3 ± 11.2 (0-30). A one-sample test analysis indicated that there was 
significant difference between SOWS mean scores and the SAWS mean scores (t= 
4.5, df = 21, p = 0.01). Pearson Correlation analysis indicated a weak correlation 
    203 
between these scores (r = 0.56, df = 21, p = 0.01). Table 8-5 summarises the results of 
each participant’s score for SOWS and SAWS. 
4.4.4 Urinary Biological Analysis of EtG and EtS 
Twenty of the participants provided urine samples that were analysed for EtG and EtS 
using LC/MS. The samples were collected at the end of the interview and were stored 
at a -20 C freezer in the laboratory until analysis. The mean EtG urine concentration 
was 30 ± 39.8 (0 –133) and the mean EtS urine concentration was 12.8 ± 15.8 (0 –
60.7). Of the 20 samples analysed, 17 (73.9%) tested positive for EtG and EtS. The 
mean EtG:EtS ratio was 2.2 ± (0 – 4.8). The ratios were highly correlated (r = 0.94, df 
= 18, p < 0.001) with a significantly linear relationship, as can be seen in the Figure 4-
19 below. 
 
Figure 4-19 Scatter plot of EtG and EtS urinary concentration (mg/L) in the study 
subjects (n= 20) with hollow circles presenting the relationship between EtG 
concentration and EtS concentration in urine. The line indicates a strong linear 
relationship (R2= 0.88) 
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4.4.4.1 Correlation between objective measures and subjective 
measures of alcohol use EtG and EtS concentration  
The 17 samples that tested positive for EtG and EtS represent 85% of the 20 urine 
samples analysed. Given these data, Cohen’s Kappa indicated a strong agreement 
between self-report regarding alcohol consumption in the past 24 hours and positive 
EtG and EtS analyses (Cohen’s Kappa 0.61).  
4.4.4.2 Breathalyser test  
Eleven of the participants reported their breathalyser reading on the day of the 
interview, and a urine sample was collected and analysed for EtG and EtS. Table 8-6 
summarises the descriptive statistics for these participants. Results indicate that only 
two participants (18.2%) tested positive for alcohol using the breathalyser (cut off 
above 0.39), as a result of which they were not prescribed their daily methadone dose. 
Compared with EtG EtS positive results, breathalyser positive results indicated a very 
weak agreement with self-report regarding alcohol use in the past 24 hours (Cohen’s 
Kappa 0.10). 
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Table 4-39 Descriptive Statistics for Hepatitis, Self- Reported Alcohol Intake, Alcohol 
Use Identification Test, and Biomarkers for Subjects Participating (mean, SD) 
summarises the descriptive statistics of the 11 subjects 
 
 Female (n = 4) Male (n = 7) 
Age Mean (SD) 40 (2.98) 41 (3.28) 
Medications other than methadone (n)   
Yes 2 4 
No 2 3 
Name of other meds (n)   
Antidepressant 2 1 
Mixed 0 3 
Alcohol Percentage (%) 9 8.1 
Units of Alcohol per Day  27 21.1 
Units of Alcohol consumed in past month 683 600 
AUDIT Score Mean (SD) 29.5 (5.19) 25.14 (12.4) 
Breathalyser Reading  0.14 (0.1) 0.16 (0.2) 
aEpisodic heavy Drinking (n) 4 5 
SOWS Score Mean (SD) 7.7 (10.4) 10.5 (5.2) 
SAWS Score Mean (SD) 8.2 (8.6) 10.8 (10.1) 
Hepatitis C (n)   
Positive 0 3 
Negative 3 3 
Not known 1 1 
Hepatitis B (n)   
Positive 0 1 
Negative 1 4 
Immunised  3 2 
HIV (n)    
Positive 0 0 
Negative 2 4 
EtG Concentration (mg/L) Mean (SD) 24.68 (23.37) 27.56 (48.09) 
EtS Concentration (mg/L) Mean (SD) 9.53 (8.38) 13.38 (22.04) 
EtG:EtS ratio Mean (SD) 2.61 (1.6) 1.5 (1.14) 
EtG Positive (>0.05) (n) 4 5 
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AUDIT, Alcohol Use Disorders Identification Test; SOWS, Short Opioid Withdrawl 
Symptoms; SAWS, Short Alcohol Withdrawal Symptoms; EtG, ethyl glucoronide; EtS, ethyl 
sulphate. 
aDefined as six or more drinks of alcohol on one occasion. 
Unit consumed was corrected according to the time of last consumption in the past 24 
hours according to the following equation: Units consumed x (24- time) / 24  
Further analysis using breathalyser values indicated a good linear relationship (after 
time correction) between breathalyser scores and self-reported consumption in the 
past 24 hours, as shown in 4-20. 
 
 
Figure 4-20 Scatter plot with fitting line indicating a good linear relationship 
(R2=0.72) with each hollow circle representing a subject’s breathalyser reading 
against time corrected units  
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4.4.4.3 EtG Concentration Cut-off Limit  
Figure 4-21 presents the relationship between brethalyser test results and EtG 
concentration. Positive breathalyser results using 0.39 as a cut-off point are plotted 
against EtG concentration values after removing two outliers (two subjects with high 
levels of EtG concentrations and negative breathalysers). The cut-off point for EtG, 




Figure 4-21 Scatter plot of breathalyser test (alcohol positive or negative) against 
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4.4.5 Discussion  
The aim of this study was to examine the effectiveness of using alcohol breathalyser 
to monitor patients’ compliance (which includes not presenting intoxicated) during 
methadone substitution treatment. Alcohol use among patients receiving methadone 
substitution is a form of non-compliance to treatment, as the patient is not taking the 
medication as instructed. Although, ‘adherence’ has replaced ‘compliance’ as a term 
to describe a broad range of behaviours that may affect how the patient takes his or 
her medication as recommended, compliance is the term that will be used in 
describing such behaviour in this thesis.  
In this study, 23 of the 32 patients who were approached by the researcher 
participated. The patients were interviewed, data pertaining to demographics and 
alcohol consumption collected. Twenty participants provided urine samples, which 
were analysed for the recent alcohol use biomarkers EtG and EtS using LC/MS. 
Routine clinical monitoring for recent alcohol use is not well established in terms of 
guidelines or policy as part of methadone substitution treatment; the clinic from which 
the patients were recruited monitored patients presenting with problematic alcohol 
consumption using a breath alcohol test (breathalyser).  
Breathlysers have been commonly used to measure recent alcohol consumption in 
clinical settings; more recently EtG has been approved as a marker for recent alcohol 
consumption. The main findings indicated that the breathalyser was sensitive in 
detecting the units consumed when corrected against time. 
Hazardous or harmful alcohol use (as defined by AUDIT score) during methadone 
substitution treatment is difficult to establish because data are frequently collected 
using self-reported instruments. The use of more objective measures for recent 
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alcohol consumption has mainly been achieved using breathalysers, which were 
suggested as form of contingency management in the early days of developing 
methadone maintenance programs (Kreek et al., 1973). The use of biological tools to 
monitor recent alcohol consumption routinely in this cohort of patients has only relied 
on breathalysers. In this study, participants recruited from an outpatient facility 
(Blackfriars Road Clinic) were required to be breathalysed by the clinical nurse or the 
keyworker who was dispensing at the time. Patients were aware of the clinic’s 
protocol and that methadone would not be dispensed if the breathalyser reading was 
0.39 or over, as failing the breathalyser test is a sign of non-compliance. Other clinics 
use a breathalyser cut-off score of 0.35 or above (there is no scientific justification for 
these cut-off scores; they are just set slightly above the drink-driving limit). Positive 
EtG and EtS urine concentrations were determined using the King’s College 
Biochemistry Laboratory cut-off levels, which were above 0.05 mg/L for both EtG 
and EtS. 
Characteristics of the 23 participants suggested that they were typical of the total 
treatment population in South London. For instance, the mean age of the subjects was 
41 years (29-57), 69.6% male and 73.9% self-described as White British. This is 
consistent with current studies investigating opiate dependents in South London 
(Alves & Winstock., 2012). The majority of participants in the nationwide sample for 
the National Treatment Outcome Study also described themselves as White (Gossop 
et al., 1997). The mean age of the group, moreover, is representative of patients 
presenting with severe problematic alcohol use while on methadone substitution, 
although compared to earlier studies the mean age reported is slightly higher. Best et 
al. (2000), for example, report a mean age of 36.4. Previous studies have established 
that patients’ characteristics such as employment, education, psychological health and 
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history of criminal activity are linked to positive treatment outcomes and patients with 
good psychological support are more likely to benefit from methadone substitution 
treatment (Farrell et al., 1994).  
The study participants all presented with problematic alcohol consumption, a factor 
that is frequently present in patients receiving methadone substitution treatment (Hunt 
et al., 1986). However, 82.4% of the patients in the study scored > 20 on the self-
reported AUDIT instrument, which indicates a likelihood of alcohol dependence. It is 
important to distinguish between harmful drinking and alcohol dependence, which is 
in line with the ICD-10 (WHO 1992) definition of alcohol depdence. The use of 
AUDIT was able to help identify the severity of alcohol use problems among the 
population studied; however, it is apparent that the choice of diagnostic instrument 
and cut-off scores can contribute to differences in the rates of prevalence reported 
because it relies on self report and although there is a chance of underreporting, 
studies have indicated that drug and alcohol dependent patients have shown reliability 
in reporting their information (Del Boca & Noll, 2000). Patients were also reassured 
that the data collected would be anonymised in the study and that the researcher 
would not report back to the clinic. 
Almost all participants reported drinking in the past 24 hours. Based on their reports, 
the amounts frequently exceeded the levels recommended by the UK Department of 
Health for any 24-hr. period, which are 16-24 g for females and 24 - 47 g for males. 
Moreover, all but three of the participants revealed that they had previously failed a 
breathalyser test. Although almost half of the patients revealed that they would start 
drinking alcohol after they had consumed their daily dose of methadone; they also 
reported the introduction of habits to avoid breathalysing positive for alcohol. Some 
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patients reported stopping drinking earlier than usual in the evening on the previous 
day, while others reported switching their drinking to alcohol of lesser strength. These 
reports of changing alcohol habits indicated that the use of breathalysers to monitor 
alcohol consumption was having an impact as a means of contingency management 
which involves a systematic application of positive reinforcement, and in this case the 
positive reinforcement would be receiving the methadone dose (Weaver et al., 2014), 
The use of breathalysers as a means of contingency management was suggested in 
earlier studies (e.g., Kellogg et al., 2005). This indicates that although the patients 
were compliant in one sense by not presenting to the clinic with intoxicating levels of 
alcohol (defined >0.39 using alcohol brethalyser), patients did consume high levels of 
alcohol soon after they received their methadone dose and were not compliant in that 
way. Therefore problematic alcohol use, along with non-compliance in the form of 
patients mixing alcohol with methadone, does not seem to be eliminated using 
breathalyser monitoring, instead patients consume alcohol at a time which correlates 
when methadone starts reaching its peak level in blood which is between 2.5-4 hours 
(Eap et al., 2002). 
From the results (65.2%) of patients reported that they regulate their alcohol 
consumption habits to avoid positive breathalyser readings. Some revealed they 
would stop drinking alcohol earlier in the evening or choose a less strength alcohol 
enable to pass their daily alcohol breathalyser test.  This can be explained as alcohol is 
eliminated by a rate of 0.1/g/kg per hour (Jachau et al., 2004). Therefore even an 
intake of an 8.7 units of alcohol will not be detected in breath after 9 – 10 hours.  
This has been consistent with the results indicating that patients breathalyser score 
was highly correlated with the units of alcohol consumed when corrected to time.  
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Previous studies have investigated other biological markers for alcohol consumption 
compared with breathalyser results. Wurst et al. (2008b) conducted a study to 
compare several alcohol biomakers including recent direct ethanol biomarkers EtG 
with ethanol breath. The study results indicated that out of 146 urine samples, 14 
samples were EtG positive while only one participant yielded a positive alcohol 
breath test. Findings from the Wurst study were consistent with our findings, 
indicating that the number of positive results with recent alcohol consumption using 
biomarkers such as EtG is higher than when using breathalysers. 
Previous studies have compared breathalysers with other biological indicators 
including 5HTOL/5HIAA (Helander et al., 1999, Helander et al. 1996, Bendtsen et 
al., 1998). A study by Lahmek et al. (2012) found that 22 patients tested positive for 
EtG whereas only five (22%) tested positive with a breath alcohol test; however, 10 
(45.5%) reported recent alcohol consumption. This high level of agreement between 
self-report and objective measures has also been supported by our study. Self-report 
agreement with positive objective measures was found higher in EtG and EtS 
concentration than breathalyser testing in our study. There was no significant 
difference between the breathalyser’s measurements and the EtG and EtS 
concentration’s results, but Cohen’s kappa was lower when self-report agreement 
with an alcohol breathlyser test was compared to an EtG and EtS test, yielding a better 
agreement with the self report and EtG and EtS results (Cohen’s kappa 0.3). This is 
due to a considerable number of positive EtG and EtS cases with positive self-reports 
of drinking. The results are not consistent with the study conducted by Wetterling et 
al. (2014), which indicated that the self-report agreed more with breathalyser data 
(Cohen’s kappa 0.79). However, this difference could be due to the nature of the 
study, which intended to investigate abstinence in a group of alcohol dependent 
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patients after a weekend. Our study was investigating the ability of breathalysers to 
detect alcohol use when coming to the clinic to collect methadone maintenance. We 
found that urine tests to detect EtG and EtS biomarkers are more sensitive and more 
accurate than breathalysers in detecting alcohol use in the past 24 hours. Although the 
breathalyser was successful in detecting alcohol consumption in the past 24 hours, 
EtG and EtS urine concentration were more able to detect reported drinking. These 
findings are consistent with previous research by Dhal et al. (2011), who measured 
urinary EtG in outpatient treatment programmes for alcohol and drug dependence (n = 
24). In 87% of the cases, the self-report information agreed with the EtG results (i.e. 
true positives and true negatives). 
In another study by Wurst et al. (2008a), samples, collected from patients receiving 
methadone maintenance and alcohol consumption, were evaluated by measuring 
direct ethanol and self-report. Of the 14 subjects reporting use in the past week, 
(28.5%) were EtG positive. 
Another factor in the importance of monitoring alcohol was the presence of patients 
presenting with Hepatitis C. Alcohol consumption may accelerate the progression of 
Hepatitis C and may result in incomplete treatment adherence and non-compliance 
due to other medical conditions (Peters & Terrault, 2002). 
The presence of Hepatitis C, combined with chronic alcohol consumption, may lead 
to the increase of the progression of fibrosis (Wiley et al., 1998, Pessione et al., 1998) 
This was reflected in two patients who presented with severe liver problems and, due 
to accumulation of ethanol, they were considered an exception and the breathalyser 
cut off limit was increased to 0.60 for them. 
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The high number of negative breathalyser results maybe influenced by the cut-off 
limits implemented by the clinic. Other than contingency management or a purpose 
for controlling alcohol use among patients in the study, the use of a breathalyser cut 
off limit, which is slightly higher than the drink-driving limit, has no scientific basis. 
0.35 is utilised in drink driving in the UK due to concerns about someone driving a 
vehicle with a level of intoxication above that limit. But these concerns do not 
necessarily apply in the clinical setting. Previous studies (Morrison et al., 1997) have 
investigated if MMT patients report to the DVLA regarding their methadone 
prescription. Morrison et al.’s study found that more patients had provisional licences 
than patients in our study, perhaps due to geographical considerations. In this study 
the cohort was taken from the inner city where there is less of a need to drive. Of the 
23 patients in our study, none of them drove to the clinic; only one had a valid driving 
licence and five reported having an invalid licence. Therefore the link between the 
drink driving limit and the breathalyser test to monitor alcohol consumption is not 
necessarily a one with a pharmacokinetic basis. 
The implication of this study is that breathlaysers are an effective biological tool for 
contingency management in patients presenting with alcohol problems (patients 
refrain from using alcohol, or change their behaviour so that they get their methadone 
dose). However, breathalysers are not necessarily suitable for monitoring compliance 
as they cannot necessarily detect drinking 24 hours before the breathalyser test 
because of the speed with which alcohol is excreted. The newly applied biomarkers 
EtG and EtS were more sensitive than the breathalyser: they would be able to detect 
alcohol use in the past 48 hours and even longer in chronic drinkers. In an attempt to 
indicate a relationship between the cut-off reading of the breathalyser and the EtG 
urinary levels, the study compared the EtG concentration when breathalysers were 
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positive and indicated that a cut-off level between 25 and 28 mg/L would be 
equivalent to 0.39. However, indicating a cut-off limit for EtG is beyoned the scope of 
this study. Further controlled studies are needed to establish the relationship between 
recent alcohol consumption biomarkers and breathalyser limits in relation to levels of 
low-risk, hazardous, harmful, or dependent consumption of alcohol. 
The study had further implications as regards patients’ alcohol consumption. The 
results also indicated that most patients (82.6%) found themselves increasing their 
alcohol intake when they missed their methadone dose. This phenomenon could be 
explained by the growing evidence of the link between the endogenous opioid system 
and the ability of alcohol release opioid peptides in regions associated with reward in 
the brain (Gianoulakis et al., 2001). This might also explain cases where patients who 
are under-medicated increase their alcohol intake. Interestingly, the mean dose of 
methadone prescribed was 61.3 r 18.4 mg/day (30 – 100 mg/day). Eleven subjects 
reported using illicit methadone (47.8%); however, they also reported this as 
infrequent. 
The presence of all these combinations is a clear indication of non-adherence to 
treatment. Although patients are coming to collect their daily methadone, they are not 
consuming it as instructed, which includes both refraining from alcohol consumption 
and not using on top. Although the breathalyser has been utilised as a useful means of 
contingency management, the addition of a more specific biomarker for periodical 
testing may in itself increase compliance. 
4.4.6 Implications 
The study’s findings should encourage clinicans to consider more objective biological 
tools to assess recent alcohol consumption. While breathalysers a recurrently used to 
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monitor compliance, establishing a better understanding of what cut-off values should 
be implemented is important. Furthermore, the study indicated the importance of 
identifying patients who are presenting with dual dependence and the need to 
establish dual treatment management guidelines to address co-dependencies of 
alcohol and heroin. 
The limitations of this study included the lack of distinction between gender in the 
scores collected, including the subjective measure using the AUDIT. However, it is 
important to note that breathalyser scores and EtG and EtS scores do not have gender 
specific cut-off values. The number of patients recruited in the study was small due to 
physical and time limitations. A wider study addressing these problems in more depth 
and scope could have a clearer sense of the issues involved. 
4.4.7 Conclusion  
As discussed, the problematic use of alcohol among patients receiving methadone 
treatment is well established. However, it is important for clinicians to identify 
instances of harmful, hazardous, and dependent consumption of alcohol in patients 
receiving methadone, and to be able to distinguish between different patterns of 
consumption based on biological tools. This study aimed to investigate whether 
breathalysers were useful in detecting compliance to treatment regarding avoiding the 
problematic consumption of alcohol. 
 
Evidence from this study, through the comparison of objective biological tools, 
indicates that breathalysers are time dependent and, while useful in contingency 
management, are not as effective as biomarkers like EtG and EtS in identifying 
patterns of alcohol consumption outside of a 24-hour period.  
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Chapter 5 OVERALL DISCUSSION AND CONCLUSION  
 
The aim of this thesis was to determine the usefulness of utilising biological markers 
to monitor patients’ compliance during methadone maintenance treatment. The study 
investigated the metabolic ratio EDDP:methadone for monitoring compliance with 
methadone daily dose, EtG and EtS to monitor recent alcohol consumption, and 
alcohol breathalyser to determine its usefulness to monitor alcohol use during 
methadone maitenance treatment.  
5.1 Main findings of this thesis 
Methadone concentration and its inactive metabolite (EDDP) in urine have been 
studied previously (Kreek et al., 1973; Kell et al., 1994; Preston et al., 2004). The 
current study investigated urinary EDDP:methadone ratio in 60 patients after 
collecting a weekly sample for four weeks during methadone maintenance treatment. 
In total (n=138) urine samples were analysed and indicated EDDP:methadone 
exhibited inter-individual and intra-individual variability. This is consistent with 
previous studies, which explained that the reason for this variability could be owed to 
methadone metabolism where genetic variability in P-glycoprotein can exhibit up to 
11-fold variations (Li et al., 2008). 
The study has also investigated the relationship between EDDP and methadone and 
found they exhibit a positively correlative relationship, which supports the fact that 
methadone is metabolised to EDDP via N-demethylation (Eap et al., 2003). These 
findings highlighted the potential advantage of investigating EDDP in urine as a 
means of monitoring compliance. Because urine samples were collected from patients 
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receiving methadone maintenance treatment it was unlikely to find a negative 
methadone concentration unless a patient had an opportunity to adulterate the sample.   
Furthermore, to control the variation observed in the ratio, the study investigated the 
ratio of EDDP:methadone in urine samples where several participants had the same 
dose: in some cases 40mg and in some cases 50mg. These ratios exhibited less 
variability between subjects; however, this drop in variability was more prevalent in 
patients with a 50mg daily dose than in patients with a 40mg daily dose. This could 
indicate that monitoring the ratio is better at high doses due to a more stable ratio 
between EDDP and methadone. However, of the patients who were noted as outliers, 
it was later found that they had been receiving methadone for less than three weeks, 
and because ratios are more variable during induction, this could establish the reason 
for this high ratio.  
In a further attempt to control variability, the samples were investigated depending on 
alcohol consumption. Findings indicated that the EDDP:methadone ratio was 
significantly different between the two groups. This finding is consistent with 
previous studies indicating that chronic alcohol consumption has a direct effect on 
methadone concentration, a phenomenon that has been investigated by Clark et al. 
(2005). However the study failed to indicate a specific range that would help 
clinicians to indicate the relation to alcohol consumption. 
Due to the high levels of variability observed in the study, it was not possible to 
establish the usefulness of the EDDP:methadone ratio; however, it will be useful for 
clinicians to measure EDDP as a mean of ensuring that the patients have taken their 
daily dose, as EDDP cannot be present in the urine unless methadone has been 
metabolised.  
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The study investigated the usefulness of measuring EtG and EtS to monitor 
compliance in 60 patients receiving methadone maintenance. From the 138 samples 
collected it was indicated that a few patients had reported not to have consumed 
alcohol but had positive EtG and EtS concentrations in their urine. This would 
indicate that EtG and EtS was successful in detecting recent alcohol consumption 
among this population. To our knowledge, only one other study has investigated the 
use of EtG and EtS in this population (Wurst et al., 2008). The findings indicated only 
a small number of patients presented with a low risk pattern of drinking. Both studies 
indicated that biological tools are more objective than self-report (AUDIT) as a means 
of monitoring compliance. However, EtG and EtS can be more relevant to be utilised 
as a clinical tool in alcohol dependence treatment compared to methadone 
maintenance treatment setting when abstinence is a required outcome. Both 
biomarkers can be used as an objective measure of relapse and can be considered to 
be more efficient than self-report, however they can also be used in combination 
which can have promising results.  Furthermore, EtG and EtS can be more useful 
compared to breathalysers in detecting relapse in an alcohol dependence treatment 
setting. For example patients can go drinking for few days before coming reporting 
negative reading for alcohol consumption using the breathalysers leading to a 
negative outcome in long-term abstinence module.  
The final study attempted to investigate the usefulness of the current practice of using 
breathalysers as a mean of objective measurement of recent alcohol consumption. The 
findings indicated that although the breathalyser was successful in managing the 
patients’ recent alcohol consumption before attending the clinic, it was less specific 
than EtG and EtS in monitoring patients’ compliance. This is consistent with studies 
that have investigated the breathalyser as a tool for monitoring alcohol consumption 
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in comparison with EtG and EtS, and found that in detecting alcohol consumptiom, 
breathalysers were less accurate as they depended on time, units consumed, and liver 
fucntioning (Wetterling et al., 2013).  
The study indicated the importance of the use of breathalyser as a means of 
contingency management rather than an objective monitoring tool for recent alcohol 
consumption, and indicated that the biomarkers EtG and EtS would be more sensitive 
and specific tools in a clinical setting. The study has also highlighted the 
shortcomings of the use of breathalyser to detect intoxication in this population. For 
example participants presented with signs of intoxication including an odour of 
alcohol sometimes scores lower than the cut off limit and vice versa, where 
participants did not present with any signs of intoxication however did report drinking 
would score higher than the cut off limit.  Furthermore, some participants reported the 
illicit use of benzodiazepine, which could lead to signs of intoxication. However, the 
use of breathalyser would have not been successful in detecting these sings which is 
an indication of the limitations of the use of the breathalysers in detecting intoxication 
signs which could lead to a fatal methadone, alcohol, and benzodiazepine interaction. 
Findings investigating withdrawal symptoms indicated that the short withdrawal scale 
is not highly specific and when SOWS scale is compared with the SAWS scale few 
items were overlapping including insomnia and heart pounding. Some of the 
symptoms from both scales were also very similar in meaning such as feeling sick and 
nausea. Therefore, this research incorporated using more objective measures and 
biological indicators such as EDDP and Methadone urine levels to monitor clinical 
symptoms including withdrawal symptoms. The use of more ojective measures has 
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been previously suggested e.g. plasma cortical level (Bearn et al., 2001) or methadone 
plasma level (Wolff et al., 1990).   
5.2 Limitations 
The recruitment of the participants to the three studies required engaging with them 
during their daily visits to collect their methadone dose. The researcher had to be 
careful not to discrupt the participants’ treatment due to the demands of the study. 
Collecting urine at trough, right before a patient takes his or her daily dose of 
methadone, can in some cases be difficult, due to a patient’s agitation with withdrawal 
symptoms. Furthermore, participants were required to see the researcher three more 
times once a week after the initial interview. Owing to the sometimes chaotic nature 
of the participants’ lives, it was difficult to obtain full commitment to the study in 
some cases and therefore not all participants provided a full set of urine samples. 
Some participants were also not able to void enough urine, which hindered the 
analysis of their samples.  
Participants presenting with difficult behaviour were managed by the researcher in 
collaboration with their assigned keyworker. They were not recruited without 
consulting with their keyworkers to prevent any potential danger to the researcher as 
well as the participants. This can interpreted as a bias in the process of recruitment.  
As discussed above, the questionnaire part of the study depended on self-report, 
including reporting illicit drug use and alcohol consumption. Two concerns were 
highlighted: the first was the potential for underreporting if the patient felt that the 
information divulged might affect his or her methadone script. Patients were reassured 
that the information collected was confidential, research-related, and would not be 
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shared with the staff at the clinic. The second concern was that some of the questions 
were related to drug use in the past month, which might have been affected by recall 
bias. 
Although Study 1 and Study 2 aimed to collect patients at different stages of time, 
Study 3 collected data at one point of collection and there was no follow up to see 
whether drinking pattern were affected by time.  
As with most qualitative research, the results generalisability and statistical 
significance are difficult to implement fully, due to the small sample size, especially 
in Study 3. Only patients who were breathalysed and who were on methadone were 
recruited, which proved diffiult ecause patients were only recruited from one site and 
only during the daily methadone collection hours of 10am and 12pm. The majority of 
participants in all studies were  from a White British background, which makes it 
difficult to generalise the result with regard to the population as a whole. However, 
the results of this study are consistent with other research on methadone maintenance 
from Britain and America, which lends external validity to its findings.  
Regarding urine analysis, adjustment to urine creatinine when measuring 
EDDP:methadone could have improved the variability; however, the method 
developed did not include creatinine measurement.   
5.3 Future research 
Since the introduction of methadone in the 1960’s, it has remained the gold standard 
for heroin dependence treatment. Attempts to improve the current methadone 
maintenance services using objective biomarkers has been researched but not 
implemented as part of a clear management plan.   This research attempted to identify 
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objective biological tools to assess patients’ compliance during methadone 
maintenance treatment.  
Although EDDP:methadone has presented with both inter-individual and intra-
individual variability, it was observed that this variability reduced when analysed 
according to samples collected from patients receiving the same dose. Further 
research investigating the ratio in samples from patients with the same dose, and the 
addition of creatinine to adjust the ratio, could help reduce the variability and increase 
the potential of using the EDDP:methadone ratio as a specific biological tool to 
identify compliance.  
Incorporating the use of biological tools in combination with self-report seems 
promising. However, this needs to be in line with clear guidelines and implementation 
of new policies for management of patients presenting with co-dependence that could 
be identified early on in the treatment. However, further research in cut-off values to 
identify low-risk, harmful, hazardous and dependent patterns of alcohol consumption, 
using EtG and EtS, in the context of patients presenting to methadone treatment, 
would be valuable in identifying patients with alcohol problems and therefore 
providing them with the most appropriate treatment modality. 
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Patient’s Information Sheet. V2.0, 27-6-2012 
 
Patient’s Information Sheet Title of Research: Methadone and EDDP ratio in urine 
in patients receiving methadone treatment and its effect on treatment outcome 
Name of Researcher: Basma Alharthy 
Center No: 
You are being invited to take part in a study, which is a part of a research project on 
methadone treatment for a PhD at King’s College London. Before deciding to take part, 
you need to find out more about the reasons behind the project and what it will involve. If 
you have any questions, please ask them, and please feel free to take your time to decide 
whether you want to take part in the study. 
What is the purpose of the study? 
The most important aim of the study is to find out more about what happens to 
methadone in the body. We are going to do this by measuring the concentration of 
methadone and a metabolite of methadone (a break down product of methadone) called 
EDDP. By measuring the level of methadone and EDDP together we can find out how 
the drug behaves in your body and this will give us some information about treatment 
compliance. 
Who can take part? 
Anyone who is prescribed methadone or about to be prescribed methadone can take part. 
We are particularly interested in your help if you are: 
1. About to start methadone treatment  
2. Stabilized on methadone on a fixed daily dose  
3. About to begin a programme of dosage reduction  
It does not matter if you are taking other medication because we are also interested in the 
way in which different drugs change the way that methadone works. If you are also using 
other non-prescribed drugs, you can still participate in the study. You will need to sign a 
consent form saying that you agree to take part. 
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What are the benefits of taking part in the study? 
You will be helping us to understand better the way in which methadone works in the 
body and help create better knowledge for clinicians about methadone treatment. 
Everyone who takes part in the research will be given a £10 phone card voucher after the 
first interview and urine sample collection. After that you will get a £5 phone card 
voucher for every further urine sample that you give. 
Patient’s Information Sheet. V2.0, 27-6-2012 
Who will see my information? 
Personal information will be stored confidentially on a computer. All information will be 
confidential, anonymously and in a secure office at King’s College London. The project 
supervisor will ensure patient confidentiality. 
The information collected will be given a code linking it to the collected urine sample but 
will be anonymised and will not be able to be linked to the participant. The information 
that you provide during the study will only be used by research purposes, for example (if 
you were reported using extra methadone on top of your prescription we would not feed 
this information back to the clinic. Any meetings with the consultant on charge will 
involve discussions about recruitment. 
Who has reviewed the study? 
Before the research starts it will have been approved by a Research Ethics Committee. In 
this case the review was carried out by the London-Fullham NHS Research Ethics 
Committee. 
Name and contact details: 
If you have any general questions about the study you can contact me using the details 
below 
Chief Investigator: Miss Basma Alharthy Email: Basma.alharthy@kcl.ac.uk  
If you require further details or if you feel that the study has been harmful to you in any 
way you can contact the Project Supervisor at King's College London using the details 
below for further advice and information: 
Supervisor: 
Dr Kim Wolff, Reader in Addiction Science, Institute of Pharmaceutical Science King's 
College London  
Thank you for your time reading this information sheet. !
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You cannot take part in the study if you are pregnant or breastfeeding. 
What will I have to do? 
You will be asked to complete a self-report questionnaire asking questions about: 
Your methadone treatment programme 
Any withdrawal symptoms you may experience using a standard questionnaire called The 
Opiate Withdrawal Scale (SOWS) 
Questions about other drug use, smoking and alcohol use 
These questions will only take approx 10-15 minutes to complete. There will also be 
some more general questions about you and your current prescribed medications and non-
prescribed drug use. You will be asked to provide one or more urine samples (20 ml of 
urine) before you receive your daily methadone dose depending upon the treatment 
programme that you are receiving. 
How the study will work 
We would like to recruit people on different methadone programmes so that we can find 
out as much as possible about the working of methadone. The groups below are the 
different types of treatment that we are interested in. You will need to tell us which one 
best describes your treatment. 
Group A Group B Group C or non-prescribed drugs Group D Methadone reduction 
treatment (detoxification) 
About to begin methadone treatment (dosage induction) Methadone maintenance 
treatment Methadone treatment but also prescribed other medication 
The only difference between the groups is the number of times your will be required to 
give a urine sample. If you belong to group A, C or D we would like to see you only a 
daily basis and would like you to provide a urine sample before your usual daily dose for 
14 days. If you are in group D we would like to meet you once a week for 4 weeks to 
collect a urine sample. 
The urine samples will always be collected at the clinic just before you receive your daily 
dose of methadone. The urine samples will be stored in the secure laboratory at King’s 
College London at -20oC until required for analysis. Once analysis has taken place the 
urine sample will be destroyed in accordance with the Human Tissue Act. 
Can I pull out from the study? 
Yes. If you feel unwell, uncomfortable, or unable to continue for whatever reason you are 
free to pull out of the study at any time. You do not have to explain the reason why you 
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Appendix C 
  Consent Form v1.0, 24-4-2012 
    
Consent Form 
 
Title of Research: Methadone and EDDP ratio in urine in patients receiving 
methadone treatment and its effect on treatment outcome 
Name of Researcher: Basma Alharthy 
Participants Identification No. for the study 
Center No: 
 
1. I confirm that I have read and understand the information sheet date ________ 
for the above study. I have had the opportunity to ask questions and I am 
happy with the responses given. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason and it will not affect the service of care 
I receive now or in the future. 
3. I understand and give permission for the researcher to have access to my 
records at ______________clinic to collect demographic information for the 
purpose of study. 
4. I understand that my data will be anonymous and my identity will not be 
revealed. I am aware that the data will be stored in security and destroyed after 
6 months. 
5. I am aware that if I become distressed, I can stop the study and would be 
encouraged to speak about it to my key worker. 
6. I agree to take part in the above study. 
 




Name of person taking 




Chief investigator:                                           
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Appendix D 





Title of Research: Methadone and EDDP ratio in urine in patients receiving 
methadone treatment and its effect on treatment outcome 
 
Name of Researcher: Basma Alharthy 
 




Please tick the stage of methadone treatment you are at: 
 
I just started receiving methadone  
I have been receiving methadone   
I will start methadone detoxification  
I will start alcohol detoxification  
 
 The following information is gathered for research purposes only and will not be 
used to identify you in any way.  Please be as honest as possible in your answers and 
where more than one option is given, tick the appropriate box.   
 
1. REFERRAL ROUTE: 
 
Came by self      Sent by family 
 
Transfer from hospital         Transfer from prison 
 
Referred by GP     Referred by a consultant 
 
Ordered by Court 
 






White British   White Caribbean         Indian 
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Other Asian   Other Black      Irish 
 
White & African  Pakistani      Caribbean 
 
Chinese    Other White      Other Mixed 
 
Bangladeshi   African      Other 
 




Full-time employed   Part-time employed  
 
Unemployed    Other 
 
 
4. LEVEL OF EDUCATION REACHED: 
 
No formal qualifications  GCSE / O-Level    
 
A-Level    Vocational qualifications (e.g. HND, NVQ) 
 
Undergraduate Degree  Postgraduate Degree 
 
Higher     Other 
 
 
Do you hold a current driving license?  Yes  No   
 
Do you usually drive to the clinic to collect your methadone? 
 
Yes  No   
SMOKING BEHAVIOUR 
 
5.1 Do you smoke cigarettes or tobacco? 
 
Yes  No  Please specify which…………………………. 
 
(if the answer is no, disregard the remaining questions) 
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ALCOHOL USE BEHAVIOUR 
 
6.1 Do you DRINK alcohol? 
 
Yes  No  Please specify which…………………………. 
 
 
(if the answer is no, disregard the remaining questions) 
 
6.2. How many units of alcohol do you drink per day (1 unit = 1 small glass of 
wine; half a pint of beer; 1 can strong lager or Cider = 3 unit) 
 
……………………………………………………………………………   
6.3.  When was the last time that you drank alcohol? 
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This questionnaire The Alcohol Use Disorders Identification Test (AUDIT) 
Is about your use of alcohol. Your answers will remain confidential so please be 







Questions 0 1 2 3 4  
1. How often do you have 
a drink containing 
alcohol? 
Never Monthly or 
less 
2-4 times a 
month 
2-3 times a 
week 




2. How many drinks 
containing alcohol do you 
have on a typical day 
when you are drinking? 
1 or 2 3 or 4 5 or 6 7 to 9 10 or 
more 
 
3. How often do you have 
six or more drinks on one 
occasion? 
Never Less than 
monthly 




4. How often during the 
last year have you found 
that you were not able to 
stop drinking once you 
had started? 
Never Less than 
monthly 




5. How often during the 
last year have you failed 
to do what was normally 
expected of you because 
of drinking? 
Never Less than 
monthly 




6. How often during the 
last year have you needed 
a first drink in the 
morning to get yourself 
going after a heavy 
drinking session? 
Never Less than 
monthly 




7.How often during the 
last year have you had a 
feeling of guilt or remorse 
after drinking? 
Never Less than 
monthly 




8. How often during the 
last year have you been 
unable to remember what 
happened the night before 
because of your drinking? 
Never Less than 
monthly 




9. Have you or someone 
else been injured because 
of your drinking? 
No  Yes, but 






10.Has a relative, friend, 
doctor, or other health 
care worker been 
concerned about your 
drinking or suggested you 
cut down? 
No  Yes, but 










    235 
 






7.1 Are you currently receiving methadone? 
 
Yes                             N o   
 
7.2 What is the dose of methadone you are receiving? 
.................................................... ..............................................................................  
7.3 How long have you receiving methadone maintenance treatment? 
More than a month                   Less than a month 
7.4 Have you ever taken extra methadone on top of your prescription? 
Yes                             N o   
If yes what is the usual amount that you take on top     .............amou nt in mg 
 
How often to do consume extra methadone? 
Every day  most days  Once a week  less frequently  
 
When was the last time that you missed a normal daily dose of prescribed 
methadone? 




8.1 Are you currently prescribed medications other than your methadone? 
Yes                                            N o   
 
8.2 What is the medication prescribed for? 
..................................................................................................................................  
 
8.3 What is the dose of the medication prescribed? 
……………………………………………………………………………………  
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The following questionnaire is concerned with any withdrawal symptoms that you 
may experience in the last 24 hours 
 
The Short Opiate withdrawal Scale (SOWS) 
 
Please put a check mark in the appropriate box if you have suffered from any of the 
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